진료일정
진료가능
클리닉센터
휴진-진료없음
정원초과
클리닉정원초과
클리닉정원초과
| 월 | 화 | 수 | 목 | 금 | 토 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 오전 | 오후 | 오전 | 오후 | 오전 | 오후 | 오전 | 오후 | 오전 | 오후 | 오전 | 오후 |
※ 병원 방문 전 진료시간표를 정확히 확인하여 주시기 바랍니다.
- 1985 한양대학교 의과대학
- 1991 한양대학교 의과대학
- 1988 한양대학교 의과대학
- 1988 ~ 1989 내과 전문의 자격 취득
- 1985 ~ 의사 면허 취득
- ICH/GCP 임상시험 및 IRB 관련 교육 이수
- 1997 ~ 혈액종양 분과전문의 자격 취득
- 1985 ~ 1986 한양대학교병원 인턴
- 1986 ~ 1989 한양대학교병원 내과 전공의
- 1991 ~ 1993 울산대학교 의과대학 서울아산병원 혈액종양내과 전임의
- 1995 ~ 1999 한양대학교 구리병원 혈액종양내과 조교수
- 2000 ~ 2004 한양대학교병원 혈액종양내과 부교수
- 2005 ~ 2006 한양대학교병원 혈액종양내과 교수
- 2006 ~ 2026 성균관대학교 의과대학 삼성서울병원 혈액종양내과 교수
- 2026 ~ 한양대학교 의과대학 내과학 교실, 혈액종양내과 진료석좌교수
- 2006 ~ 2011 대한항암요법연구회(KCSG) 교육위원장
- 2026 ~ (현) 세계폐암학회(World Conference on Lung Cancer) 조직위원장
- 2015 ~ 2025 대한항암요법연구회(KCSG) 폐암분과위원장
- 2017 ~ 2018 대한종양내과학회(KSMO) 이사장
- 2012 ~ 2018 대한종양내과학회(KSMO) 교육위원장
- 대한폐암학회 17-18대 이사장
- 2016 ~ (현) 대한폐암학회 이사
- 2016 ~ 2018 대한폐암학회 산하 다학제면역요법연구회 회장
- 2008 ~ (현) 대한암학회 이사
- 2008 ~ (현) 대한종양내과학회 이사
- 2011 ~ (현) 세계폐암학회(IASLC) 교육위원
- 2013 ~ (현) Journal of Thoracic Oncology 편집위원
- 대한의사협회 회원
- 대한내과학회 회원
- 대한암학회 회원
- 대한종양내과학회 회원
- 대한혈액학회 회원
- 대한조혈모세포이식학회 회원
- 미국암학회(AACR) 회원
- 미국임상종양학회(ASCO) 회원
- 세계폐암학회(IASLC) 회원
- 유럽종양내과학회(ESMO) 회원
- 2003 한국여자의사회 최우수 연구자상
- 1994 Outstanding Poster in 86th AACR meeting
- 1985 한양대학교 의과대학 우등 졸업 (CUM LAUDE)
- 2019 Highly Cited Researchers from Clarivate Analytics
- 2020 Highly Cited Researchers from Clarivate Analytics
- 2025 제18회 아산의학상
- 2016 대한종양내과학회 최우수 연구자상
- 2014 성균관대학교 SKKU Fellow 수상
- 2011 대한임상종양학회 우수구연상
- 2010 대한임상종양학회 우수구연상
- 2021 Highly Cited Researchers from Clarivate Analytics
- 2021 제20회 보건의료기술진흥 유공자 정부포상 우수연구부문 보건복지부장관상
- 2022 Highly Cited Researchers from Clarivate Analytics
- 2023 WCLC 2023, Adi F. Gazdar IASLC Merit Award
- 2023 Highly Cited Researchers from Clarivate Analytics
- 2024 ESMO Women for Oncology Award
- 2024 Highly Cited Researchers from Clarivate Analytics
- 2025 Highly Cited Researchers from Clarivate Analytics
- 2018 제17회 보령암학술상
- 2020 제30회 분쉬의학상
- 2018 성균관대학교 의과대학 최우수 연구자상
-
Han B, Sun JM, Ahn JS, Park K, Ahn MJ.
Clinical outcomes of atypical carcinoid tumors of the lung and thymus: 7-year experience of a rare malignancy at single institute. 2013
Med Oncol. -
Hirsch FR, Jänne PA, Eberhardt WE, Cappuzzo F, Thatcher N, Pirker R, Choy H, Kim ES, Paz-Ares L, Gandara DR, Wu YL, Ahn MJ, Mitsudomi T, Shepherd FA, Mok TS.
Epidermal Growth Factor Receptor Inhibition in Lung Cancer: Status 2012. 2013
J Thorac Oncol. -
Ahn HK, Jeon K, Yoo H, Han B, Lee SJ, Park H, Lee MJ, Ha SY, Han JH, Sun JM, Ahn JS, Ahn MJ, Park K.
Successful Treatment with Crizotinib in Mechanically Ventilated Patients with ALK Positive Non-Small-Cell Lung Cancer. 2013
J Thorac Oncol. -
Lee SJ, Lee JI, Nam DH, Ahn YC, Han JH, Sun JM, Ahn JS, Park K, Ahn MJ.
Leptomeningeal carcinomatosis in non-small-cell lung cancer patients: impact on survival and correlated prognostic factors. 2013
J Thorac Oncol. -
Park SY, Lim SY, Um SW, Koh WJ, Chung MP, Kim H, Kwon OJ, Park HK, Kim SJ, Im YH, Ahn MJ, Suh GY.
Outcome and predictors of mortality in patients requiring invasive mechanical ventilation due to acute respiratory failure while undergoing ambulatory chemotherapy for solid cancers. 2013
Support Care Cancer. -
Ahn HK, Choi YL, Han JH, Ahn YC, Kim K, Kim J, Shim YM, Um SW, Kim H, Kwon OJ, Sun JM, Ahn JS, Park K, Ahn MJ.
Epidermal growth factor receptor mutation and treatment outcome of mediastinoscopic N2 positive non-small cell lung cancer patients treated with neoadjuvant chemoradiotherapy followed by surgery. 2013
Lung Cancer. -
Lira ME, Kim TM, Huang D, Deng S, Koh Y, Jang B, Go H, Lee SH, Chung DH, Kim WH, Schoenmakers EF, Choi YL, Park K, Ahn JS, Sun JM, Ahn MJ, Kim DW, Mao M.
Multiplexed gene expression and fusion transcript analysis to detect ALK fusions in lung cancer. 2013
J Mol Diagn. -
Kim YN, Lee HY, Lee KS, Seo JB, Chung MJ, Ahn MJ, Park K, Kim TS, Yi CA.
Dual-energy CT in patients treated with anti-angiogenic agents for non-small cell lung cancer: new method of monitoring tumor response? 2012
Korean J Radiol. -
Lee HY, Ahn HK, Jeong JY, Kwon MJ, Han JH, Sun JM, Ahn JS, Park K, Choi YL, Ahn MJ.
Favorable clinical outcomes of pemetrexed treatment in anaplastic lymphoma kinase positive non-small-cell lung cancer. 2013
Lung Cancer. -
Bae SH, Ahn YC, Nam H, Park HC, Pyo HR, Shim YM, Kim J, Kim K, Ahn JS, Ahn MJ, Park K.
High dose involved field radiation therapy as salvage for loco-regional recurrence of non-small cell lung cancer. 2012
Yonsei Med J. -
Yoon HJ, Lee HY, Lee KS, Choi YL, Ahn MJ, Park K, Ahn JS, Sun JM, Kim J, Kim TS, Chung MJ, Yi CA.
Repeat biopsy for mutational analysis of non-small cell lung cancers resistant to previous chemotherapy: adequacy and complications. 2012
Radiology. -
Ji JH; Korean Cancer Study Group (KCSG), Yun T, Kim SB, Kang JH, Park JC, Cho IS, Sohn CH, Heo DS, Jang JS, Shin SW, Hwang DW, Sun JM, Park K, Ahn MJ.
A prospective multicentre phase II study of cisplatin and weekly docetaxel as first-line treatment for recurrent or metastatic nasopharyngeal cancer (KCSG HN07-01). 2012
Eur J Cancer. -
Cho SH, Park LC, Ji JH, Park S, Hwang DW, Lee JY, Choi YL, Han JH, Sun JM, Ahn JS, Park K, Ahn MJ.
Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation. 2012
Cancer Chemother Pharmacol. -
Ahn MJ, Sun JM, Ahn JS, Park K.
The effectiveness of maintenance pharmacotherapies for non-small cell lung cancer. 2012
Clin Med Insights Oncol. -
Sun JM, Lee KH, Kim SW, Lee DH, Min YJ, Yun HJ, Kim HK, Song HS, Kim YH, Kim BS, Hwang IG, Lee K, Jo SJ, Lee JW, Ahn JS, Park K, Ahn MJ; Korean Cancer Study Group.
Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trial. 2012
Cancer. -
Sun JM, Ahn MJ, Ahn JS, Um SW, Kim H, Kim HK, Choi YS, Han J, Kim J, Kwon OJ, Shim YM, Park K.
Chemotherapy for pulmonary large cell neuroendocrine carcinoma: similar to that for small cell lung cancer or non-small cell lung cancer? 2012
Lung Cancer. -
Ahn MJ, Yang JC, Liang J, Kang JH, Xiu Q, Chen YM, Blair JM, Peng G, Linn C, Orlando M.
Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced non-small cell lung cancer. 2012
Lung Cancer. -
Ahn HK, Han B, Lee SJ, Lim T, Sun JM, Ahn JS, Ahn MJ, Park K.
ALK inhibitor crizotinib combined with intrathecal methotrexate treatment for non-small cell lung cancer with leptomeningeal carcinomatosis. 2012
Lung Cancer. -
Han JY, Park K, Kim SW, Lee DH, Kim HY, Kim HT, Ahn MJ, Yun T, Ahn JS, Suh C, Lee JS, Yoon SJ, Han JH, Lee JW, Jo SJ, Lee JS.
First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. 2012
J Clin Oncol. -
Lee HY, Lee KS, Park J, Han J, Kim BT, Kwon OJ, Ahn YC, Ahn MJ, Park K, Kim J, Shim YM.
Baseline SUVmax at PET-CT in stage IIIA non-small-cell lung cancer patients undergoing surgery after neoadjuvant therapy: prognostic implication focused on histopathologic subtypes. 2012
Acad Radiol. -
Park S, Choi YL, Sung CO, An J, Seo J, Ahn MJ, Ahn JS, Park K, Shin YK, Erkin OC, Song K, Kim J, Shim YM, Han J.
High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients. 2012
Histol Histopathol. -
Sung JY, Ahn HK, Kwon JE, Jeong H, Baek CH, Son YI, Ahn YC, Park K, Ahn MJ, Ko YH.
Reappraisal of KIT mutation in adenoid cystic carcinomas of the salivary gland. 2012
J Oral Pathol Med. -
Myung-Ju Ahn, Shin-Young Park, Won Kyu Kim, Ju Hwan Cho, Brian Junho Chang, Dong Jo Kim, Jin Seok Ahn, Keunchil Park, Joong-Soo Han.
A single nucleotide polymorphism in the phospholipase D1 gene is associated with risk of non-small cell lung cancer. 2012
Int J Biomed Sci -
Youngwook Kim, Jeonghun Ko, ZhengYun Cui, Amir Abolhoda, Jin Seok Ahn, Sai-Hong Ou, Myung-Ju Ahn, and Keunchil Park
The EGFR T790M Mutation in Acquired Resistance to an Irreversible Second-Generation EGFR Inhibitor. 2012
Molecular Cancer Thera -
Kyoo Hyung Lee, Jung Shin Lee, Cheolwon Suh, Myung Ju Ahn, Sang We Kim, Byung Soon Doh, Young Il Min, Byung Sik Kim, Kun Choon Park, In Cheol Lee, Young Joo Cho, Mi Gyung Choi, Sang-Hee Kim.
DNA Flow Cytometry of Stomach Cancer. 1993
Cancer 1993;72:1819-1826 -
Kyoo Hyung Lee, Jung Shin Lee, Cheolwon Suh, Myung Ju Ahn, Sang We Kim, Byung Soon Doh, Young Il Min, Byung Sik Kim, Kun Choon Park, In Cheol Lee, Young Joo Cho, Mi Gyung Choi, Sang-Hee Kim.
A complete remission can be achieved despite persistence of abnormal bone marrow promyelocytes in acute promyelocytic leukemia- experience in 2 patients. 1993
J Korean Med Sci 1993:8:246-50. -
Myung Ju Ahn, Jung Shin Lee, Kyoo Hyung Lee, Cheolwon Suh, Sun Sook Choi, Sang-Hee B. Kim.
A Randomized Double-Blind Trial of Ondansetron Alone Versus in Combination with Dexamethasone Versus in Combination with Dexamethasone and Lorazepam in the Prevention of Emesis Due to Cisplatin-Based Chemotherapy. 1994
Am J Clin Oncol 1994;17:150-156 -
Myung-Ju Ahn, Kathryn Nason-Burchenal, Mark M Moasser and Ehtan Dmitrovsky.
Growth suppression of acute promyelocytic leukemia cells having increased expression of the non-rearranged alleles: RAR or PML. 1995
Oncogene 1995;10:2307-2314 -
Myung-Ju AHN, Yun-Hee NOH and Yong-Sung LEE.
Telomease Activity in Head and Neck Cancer 1995
The Korean Jorunal of Biochemistry 1995;27:219-223 -
Myung-Ju Ahn, John Langenfeld, Mark M Moasser, Vlerie Rusch, Ethan Dmitrovsky.
Growth suppression of transformed human bronchial epithelial cells by all-trans retinoic acid occurs through specific reitnoid receptors. 1995
Oncogene 1995:11:2357-2364. -
John Langenfeld, Fulvio Lonardo, Hiroaki Kiyokawa, Tina Passalaris, Myung-Ju Ahn Valerie Rusch, Ethan Dmitrovsky.
Inhibited transformation of immortalized human bronchial epithelial cells by retinoic acid is linked to cyclin E down-regulation. 1996
Oncogene 1996;13:1983-1990 -
M.-J. Ahn, Y.H. Noh, Y.S. Lee, J.H. Lee, T.J. Chung, I.S. Kim, I.Y. Choi, S.H. Kim, J.S. Lee and K.H. Lee.
Telomerase activity in gastric cancer and its clinicopathologic significance. 1997
European Journal of Cancer. 1997;33:1309-1313 -
Jong Soo Choi, Kyoo Hyung Lee, Myung Ju Ahn, Jung shin Lee, Je Han Lee, Dae Young Zang, Chel Won Suh, Sang We Kim, Woo Gun Kim, Jin Cheon Kim, Suk koo Kim, Kun Choon Park, Moo Song Lee, Sang-Hee Kim.
A Randomized Trial Comparing Cisplatin Plus 5-fluorouracil With or Without Levamisole in Operable Gastric Cancer. 1997
The Korean Jorunal of Internal Medicine : 1997;12:155-162 -
Myung-Ju Ahn, Hong-Hee Won, Jeeyun Lee, Seung-Tae Lee, Jong-Mu Sun, Yeon Hee Park, Jin Seok Ahn, O Jung Kwon, Hojoong Kim, Young Mog Shim, Jhingook Kim, Kwhanmien Kim,Yeul Hong Kim, Jae Yong Park, Jong-Won Kim, Keunchil Park.
The 18p11.22 locus is associated with never smoker non-small cell lung cancer susceptibility in Korean populations. 2012
Hum Genet -
Seung Tae Kim, Ji Eun Uhma, Jeeyun Lee, Jong-mu Sun, Insuk Sohn, Seon Woo Kim, Sin-Ho Jung, Yeon Hee Park, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn.
Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy. 2012
Lung Cancer -
JONG-MU SUN, MYUNG-JU AHN, MIN JAE PARK, HUI-YOUNG LEE, JIN SEOK AHN, SEUNGKOO LEE, GU KANG, JOUNGHO HAN, YOUNG-IK SON, CHUNG-HWAN BAEK, YONG CHAN AHN, AND KEUNCHIL PARK.
EXPRESSION OF EXCISION REPAIR CROSS-COMPLEMENTATION GROUP 1 AS PREDICTIVE MARKER FOR NASOPHARYNGEAL CANCER TREATED WITH CONCURRENT CHEMORADIOTHERAPY. 2011
Int. J. Radiation Oncology Biol. Phys., -
Myung-Ju Ahn, Kyung Tae, Yong-Soo park, In-Soon Kim, II-Young Choi, Hyung-Seok Lee, Sun-Kon Kim and Yong-Sung Lee .
Telomerase activity in benign and malignant human thyroid nodules 1997
Korean Society of Medical Biochemistry and Molecular Biology -
In Soon Kim, Chan Kum Park, Hawk Kim, Young Yul Lee, Myung Ju Ahn,Woong Soo Lee.
Epstein Barr Virus Associated Hemophagocytic Syndrome -A Case Report. 1997
Jorunal of Korean Medical Science 1997;12:447-451 -
Myung-Ju Ahn, Suck-Jung Oh, Young-Youl Lee, Tae-Jung, In-Soon Kim, II-Yong Choi, Se-Jin Jang, Yong-Wook Park, Ki-Yong Shin, Yong-Soo Kim
A Case of Prostate Cancer in 34 year old man Presenting with Generalized Lymphadenopathy mimicking Malignant Lymphoma. 1997
Journal of Korean Medical Science 1997;12:262-265 -
Myung-Ju Ahn, Byoung-Hun Kim, Se-Jin Jang, Eun-Kyung Hong, Won-Mi Lee, Hong-Kyu Baik, Hwon-Kyum Park, Chul Burm Lee, Moran Ki.
Expression of Cyclin D1 and Cyclin E in Human Gastric Carcinoma and its Clinicopathologic Significance. 1998
Jorunal of Korean Medical Science 1998;13:513-518 -
Se Jin Jang, Myung Ju Ahn, Seung Sam Paik, Gu Kong,. Joo Seob Keum, Yong Wook Park, Jung Dal Lee.
Expression of Cyclin Dependent Kinase Inhibitor p21WAF1 alone and in Combination With p27KIP1 shows Prognostic Value in Gastric Carinoma. 1998
Journal of Korean Medical Science 1998;13:369-376 -
Seok Chol Jeon, Heung Suk Seo, Chang Kok Hahm, Myung Ju Ahn.
Treatment of Invasive Pulmonary Aspergillosis by Combined Intravenous and Transthoracic Injection of Amphotericin B in a Patients with Acute Leukemia: A Case Report 1998
J Korean Radiol Soc 1998;39:705-708 -
Myung-Ju Ahn, Dong-Su Han, Joo Hyun Sohn, Yong-Cheol Jeon, Dae-Won Jun, Nak-Won Choi,, Hwon-Kyum Park, Hong-Kyu Baik, Hong-Gi Lee, Young-Soo Nam, II-Young Choi.
Combination Chemotherapy of oral 5’-deoxy-5-fluorouridine and Cisplatin in Advanced Gastric Cancer: A Phase II Study. 1998
Jorunal of Korean Medical Science 1998;13:612-616 -
Hee-Joon Yu, Yun-Suck Kim, Hong-Yoon Yang, Sang-Jin Kwon, Myung-Ju Ahn, Chan-Kum Park.
A Case of Leukemia Cutis. 1998
Journal of Korean Medical Science 1998;13:686-692 -
Myung-Ju Ahn, Il-Young Choi, In-Soon Kim.
A Case of Successful Engraftment with Uncontrolled Rate Cryopreserved Stem Cells at -80. 1999
대한조혈모세포이식학회지 1999;4:91-95 -
Myung-Ju Ahn, Yun-Hee Noh, Wo-Chul Kim, Hyun-Soo Kim, Young-Yul Lee, Tae-June Jung, Il-Young Choi, In-Soon Kim, Young-Sung Lee.
Detection of Tumor Cell Contamination in Peripheral Blood Stem Cells by RT-PCR in High risk or Metastatic Breast Cancer Patients and its Clincal Implications. 1999
대한조혈모세포이식학회지 1999;4:1-11 -
S.-J. Jang, Y,-W. Park, M.-H. Park, J.-D. Lee, Y.-Y. Lee, T.-J. Jung, I.-S Kim, I.-Y. Choi, M.Ki, B.-Y. Choi and M.-J. Ahn.
Expression of Cell-cycle regulators, cyclin E and p21WAF1/CIPI, potential prognostic markers for gastric cancer. 1999
European Journal of Surgical Oncology 1999;25:157-163 -
YunHee Noh, Griwou Im, Ja-Hyun ku, Yong-Sung Lee, Myung-Ju Ahn.
Detection of tumor cell contamination in peripheral blood by RT-PCR in gastrointestinal tract cancer patients. 1999
J Korean Med Sci 1999:14:623-628 -
Myung-Ju Ahn, Hawk Kim, In Soon Kim, Jin Kyung Park, Moran Ki, Chan Kem Park.
P53 protein expression and its prognositc importance in patients with nodal non-Hodgkin’s lymphoma. 2000
J Korean Med Sci 2000:15: 59-64 -
Myung-Ju Ahn, In-hong Lee, Ja-HunJung, Jung-Hye Choi, Kyung-Ran Cho, Seoung-Yun Kim.
A case of immunoablative high-dose cyclophosphamide therapy without stem cell rescue in the treatment of refractory rheumatoic arthritis patient. 2000
대한조혈모세포학회지 2000;5:129-133. -
Hawk Kim, Mi-Ok Kim, Myung-Ju Ahn, Young-Yeul Lee, Tae-June Jung, Il-Young Choi, In-Soon Kim, Chan-Kum Park.
Eosinophilic fascitis preceding relapse of peripheral T-cell lymphoma. 2000
Journal of Korean Medical Science. 2000:15:346-350. -
Myung-ju Ahn, Yong-Wook Park, Dong-soo Han, Jung-Hae Choi, Sung-Jun Shin, Byung-Chul Yoon, In-Soon Kim.
A case of primary intestinal T-cell lymphoma involving entire gastrointestinal tract: esophagus to rectum. 2000
Korean Journal of Internal Medicine. 2000; 15: 245-249. -
Myung-Ju Ahn, Yun-Hee Noh, Ho-Ju Yoon, Chan-Kum Park.
Detection of malignant cells in pleural fluid or ascites by CD44v8-10/CD44v10 competitive RT-PCR. 2001
Korean Journal of Internal Medicine. 2001;16:30-36. -
Yun-Hee Noh, Jung-Ah Kim, G-Rewo Lim, Yong-Sung Lee, Myung-Ju Ahn.
Detection of circulating tumor cells in patients with gastrointestinal tract cancer using RT-PCR and its clinical implications. 2001
Experimental and Molecular Medicine. 2001;33:8-14. -
Myung-Ju Ahn, Yun-Hee Noh, Yong-Sung Lee,, Il-Young Choi, In-Soon Kim, Eun-Kyung Joh, Dong-Bock Shin, Si-Young Kim, Kyung-Sam Cho, Hyo-Cheul Kim, Kyun-Soo Kim, Cheolwon Suh, Sang-Hee Kim, Jung-Ae Lee, Young-Suck Park.
Clinical impacts of tumor cell contamination of hematopoietic stem cell products in metastatic breast cancer patients undergoing autologous peripheral stem cell transplantation; multicenter trial. 2001
Journal of Korean Medical Science. 2001;16:175-182. -
Hang-Lak Lee, Myung-Ju Ahn, Jung-Hye Choi, Woon Hyun Lun, Young-Ueul Lee, In-Soon Kim, Il Young Choi, Se-Jin Jang, Young-Wook Park.
A case of NK/T-cell lymphoma complicated by a squamous cell carcinoma of hard palate during combination chemotherapy and radiation therapy. 2001
Korean Journal of Internal Medicine. 2001;16:255-258. -
Myung-Ju Ahn, Chan-Kum Park, Jung-Hye Choi,. Won-Mee Lee, Moran Ki.
Clinical significance of microvessel density in multiple myeloma patients. 2001
Journal of Korean Medical Science. 2001;16:45-50. -
Jung-Hye Choi, Myung-Ju Ahn, Joon-Sung Park, In-Soon Kim, Woong-Soo Lee.
A case of successful engraftement of high-dose melphalan and peripheral blood stem cell transplantation in multiple myeloma with renal insufficiency. 2001
한양의대학술지 2001;21:127-130. -
Jung-Hye Choi, Myung-Ju Ahn, Mo-ran Ki, Ho-Suk Oh, Young-Yeul Lee, In-Soon Kim.
Clinical prognostic factors and treatment outcome of aggressive non-Hodgkin’s lymphoma in elderly patients. 2001
대한암학회지 2001;33:324-328. -
Myung-Ju Ahn, Yong-Wook Park, Jung-Hye Choi, Ho-Suk Oh, Chul-Bum Lee, Hong-Kyu Paik, Chan-Kum Park.
Clinical prognostic values of vascular endothelial growth factor, microvessel density, and p53 expression in esophageal carcinomas. 2002
Journal of Korean Medical Science. 2002:17:201-207. -
Myung-Ju Ahn, Tae-June Jung, Jung-Hye Choi, Mi-Ran Oh, Hwi-Joong Yoon, Jun-Suk Kim, Chul-Won Choi, Kyung-Wook Hur, Dae-Sik Hong, Hee-Sook Park, Sung-Kyu Pare, Jung-Ae Lee, Young-Suk Park, Honggi Jung.
Randomized controlled open labelled, phase III trials, comparing the efficacy between Fentas and Durogesic patches in controlling cancer pain: multicenter trial. 2002
Cancer Research and Treatment 2002:34:165-169. -
Ho-Suk Oh, Myung-Ju Ahn, Jung-Hye Choi, Yong-Wook Pare, Byung-Joo Song, Young-Yeul Lee, In-Soon Kim, Il-Young Choi, Jun-Goo Kang, Sung-Joon Shin.
A case of bilateral primary orbital MALT lymphoma. 2002
Hanyang Journal of Medicine. 2002:22:119-123. -
Ki-Hwan Lee, Mi-Yoon Chang, Joon-Ik Ahn, Dong-Hyun Yu, Sung-Soo Jung, Jung-Hye Choi, Yun-Hee Noh, Yong-Sung Lee, Myung-Ju Ahn.
Differential gene expression in retinoic acid induced differentiation of acute promyelocytic leukemia cells, NB4 and HL-60 cells. 2002
Biochemical and Biophysical Research Communications 2002:296:1125-1133. -
Ki Chan Kim, In Hong Lee, Jung Hye Choi, Mee Ran Oh, Myung-Ju Ahn, Seong Yoon Kim.
Autologous stem cell transplantation in the treatment of refractory rheumatoid arthritis. 2002
Journal of Korean Medical Science. 2002 17:129-132. -
Myung-Ju Ahn, Jung-Hae Choi, Sung-Gon Shim, Kyoung-Sun Na, Think-You Kim, Sang-Cheol Bae.
Autologous peripheral blood stem cell transplantation in rapidly progressive systemic sclerosis: case report. 2002
Korean Journal of Hematopoietic Stem Cell Transplantation. 2002 7(2) :161-166. -
Oh HS, Choi JH, Park CK, Jung CW, Lee SI, Park Q, Suh C, Kim SB, Chi HS, Lee JH, Bang SM, Ahn MJ.
Comparison of microvessel density before and after peripheral blood stem cell transplantation in multiple myeloma patients and its clinical implications: multicenter trial. 2002
International Journal of Hematology. 2002:76:465-470 -
Choi JH, Ahn MJ, Jang SJ, Park CK, Park YW, Oh HS, Lee YY, Choi IY, Kim IS.
Absence of clinical prognostic value of vascular endothelial growth factor and microvessel denstiy in multiple myeloma. 2002
International Journal of Hematology 2002:76:460-464 -
Lee, Hye-Sook, Mi-Yune Jang, Jung-Hye Choi, Young-Yeul Lee, Hyung-Bae Park, Yong-Sung Lee, Seung-Wrong Kim, Myung-Ju Ahn.
Comparison of cell proliferation, apoptosis, and telomerase activity in human cord blood CD34+ cells cultured with various cytokine combinations. 2003
J Microbiol Biotechol 2003;13(3):422-428. -
Myung-Ju Ahn, Jung-Hye Choi, Young-Yeul Lee, Il-Young Choi, In-Soon Kim, Sung-Soo Yoon, Sun-Yang Park, Byung-Kook Kim, Cheolwon Suh, Hee Jeong Son, Cheol-Won Jung, Jae Hoon Lee, Ju-Myung Sung, Suck-Ah Im, Doyeun Oh, So-Young Jung, Hwi-Joong Yoon, Kyung-Sam Cho, Jung-Ae Lee, Young-Jin Yuh, Sung-Rok K
Outcome of Adult Severe or Very Severe Aplastic Anemia Treated With Immunosuppressive Therapy Compared to Bone Marrow Transplantation: Multicenter Trial. 2003
International Journal of Hematology 2003;78:133-138. -
Jung-Hye Choi, Myung-Ju Ahn, Seock-Ah Im, Bong-Seog Kim, Ho-Suk Oh, Heung Woo Lee, Yeung Chul Mun, Chu-Myung Seong, Soon Nam Lee, Young-Yeul Lee, Il-Young Choi, In-Soon Kim.
Gemcitabine and infusional 5-fluororuacil in advanced pancreatic cancer: A clinical benefit response-oriented phase II study. 2003
Cancer Research and Treatment 2003;35(3) 213-217. -
Soo-Mee Bang, Eun Kyung Cho, Cheolwon Suh, Sung-Soo Yoon, Chu Myung Seong, Kyung Sam Cho, Yoon Goo Kang, Seonyang Park, Myung-Ju Ahn, Young Suk Park, Hugh C. Kim, Chul Won Jung, Samuong Kim, Jae Hoon Lee.
High dose therapy followed by autologous peripheral blood stem cell transplantation as a first line treatment for multiple myeloma: a Korean Multicenter Study. 2003
Journal of Korean Medical Science 2003;18(5):673-678. -
Myung-Ju Ahn, Ho-Scuk Oh, Jung-Hye Choi, Young-Yeul Lee, In-Soon Kim, Il-Young Choi, Oh Young Lee, Heung-Woo Lee.
Combination chemotherapy of oxaliplatin and capecitabine in patients with metastatic colorectal cancer: a pilot study. 2003
Cancer Resarch and Treatment 2003: 35(5),407-410. -
Hee Young Cho, Mi Kyung Kim, Young Do Yoo, Myung Ju Ahn, Joung Soon.Jang.
Proteomic profiling of human small cell lung cancer cell line NCI-H211. 2003
Cancer Research and Treatment 2003:35(6), 489-496. -
Myung-Ju Ahn, Ki-Hwan Lee, Joon-Ik Ahn, Dong-Hyun Yu, Hye-Sook Lee, Jung-Hye Choi, Houng Soon Jang, Jong Min Bae, Yong-Sung Lee.
The differential gene expression profiles between sensitive and resistant breast cancer cells to adriamycin by cDNA microarray. 2004
Cancer Research and Treatment. 2004:36(1), 43-49. -
Jung-Hye Choi, Myung-Ju Ahn, Hyunchul Rhim, Heung Woo Lee, Ho-Suk Oh, Young-Yeul Lee, Il-Young, Choi, In-Soon Kim.
Radiofrequency ablation for metastatic hepatic tumor in colorectal carcinoma. 2004
Cancer Research and Treatment 2004:36(2) 128-131. -
Hyun-Seok Cho, In-Soon Kim, Hwan Cheol Park, Myung-Ju Ahn, Young-Yil Lee, Chan Kum Park.
A case of severe chronic active Epstein-Barr Virus infection with T-cell lymphoproliferative disorder. 2004
The Koran Journal of Internal Medicine 2004, 19(2), 124-127. -
JM Kim, YK Oh, YJ Kim, J Youn, MJ Ahn.
Escherichia coli up-regulates proinflammatory cytokine expression in granulocyte/macrophage lineages of CD34+ stem cells via p50 homodimeric NF-Kb. 2004
Clin Exp Immunol 2004:137:341-350. -
Myung-Ju Ahn , Ho-Suk Oh , Jung-Hye Choi, Young-Yeul Lee, Il-Young, Choi, In-Soon Kim, Oh Young Lee, Ho-Soon Choi, Sung-Joon Kwon.
Combination chemotherapy of heptaplatin, paclitaxel, and 5-fluorouracil in patients with advanced gastric cancer: a pilot study. 2004
Cancer Research and Treatment. 2004, 36(3), 182-186. -
Young-Woong Won, Young-Hyo Lim, Ho-Yong Park, Ho-Suk Oh, Jung-Hye Choi, Young-Yeul Lee, In-Soon Kim, Il-Young Choi, Myung-Ju Ahn.
Phase II study of irinotecan, 5-fluorouracil, and leucovorin in relapsed or metastatic colorectal cancer as first-line therapy. 2004
Cancer Research and Treatment 2004, 36(4), 235-239. -
Jin-Hyun Woo, Sung-Hyun Park, Yoon-Kyung Park, Chan-Bum Choi, Yun-Young Choi, Myung-Ju Ahn, In-Soon Kim.
Postsplenectomy recurrence of thrombocytopenia with an accessory spleen. 2004
The Korean Journal of Internal Medicine. 2004, 19(3), 199-201. -
Myung-Ju Ahn, Young-Do Yoo, Ki-Hwan Lee, Joon-Ik Ahn, Dong-Hyun Yu, Hye-Sook Lee, Ho-Suck Oh, Jung-Hye Choi, Yong-Sung Lee.
cDNA microarray analysis of differential gene expression in gastric cancer cells sensitive and resistance to 5-fluorouracil and cisplatin. 2005
Cancer Research and Treatment 2005 37(1) 54-62. -
Young-Hyo Lim, Su-Kyoung Park, Ho-Suk Oh, Jung-Hye Choi, Myung-Ju Ahn, Young-Yul Lee, In-Soon Kim.
A case of primary plasmacytoma of lymph nodes. 2005
The Korean Journal of Internal Medicine 2005, 20(2), 183-186. -
Byung-Ryul Choi, Myung-Ju Ahn, Woong-Soo Lee, Tae-Hwan Kim, Sang-Cheol Bae, Jae-Bum Jun.
Actue erythroleukemia in a rheumatoid arthritis patient during low-dose methotrexate therapy. 2005
Rheumatol Int 2005, 25, 311-313. -
Young-Woong Won, Won Moon, Yeong-Seop Yun, Ho-Suk Oh, Jung-Hye Choi, Young-Yeul Lee, In-Soon Kim, Il-Young Choi, Myung-Ju Ahn.
Clinical aspects of pregnancy and delivery in patients with chronic idiopathic thrombocytopenic purpura (ITP). 2005
The Korean Journal of Internal Medicine. 2005,20(2) 129-134. -
Junh-Hye Choi, Myunh-Ju Ahn, Yong-Wook Park, Ho-Suk Oh, Young-Yeul Lee, In-Soon Kim.
A case of erythema nodosum and serositis associated with myelodysplastic syndrome. 2005
The Korean Journal of Internal Medicine 2005, 20(2), 177-179. -
Myung-Ju Ahn, Jung-Hye Choi, Ho-Suk Oh, Young-Yeul Lee, In-Soon Kim, Il-Young CHoi, Kang-Hong Lee, Kang-Won Song, Chan-Kum Park.
Thymidylate synthase, thymidine phosphorylase, VEGF, and p53 protein expression in primary colorectal cancer for predicting response to 5-fluororuacil-based chemotherapy. 2005
Cancer Research and Treatment. 2005, 37(4), 216-222. -
Ji-Young Moon, Byung-Su Kim, Hye-Ryeon Yun, Jug-Hye Choi, Yong-Yeul Lee, In-Soon Kim, Myung-Ju Ahn.
A case of avascular necrosis of the femoral head as initial presentation of chronic myelogenous leukemia. 2005
The Korean Journal of Internal Medicine 2005, 20(3), 255-259. -
Jung Mogg Kim, Nam In Kim, Yu-Kyoung Oh, Young-Jeon Kim, Jeehee Youn, Myung-Ju Ahn.
CpG oligodeoxynucleotides induce IL-8 expression in CD34+ cells via mitogen-activated protein kinase-dependent and NF-kB-independent pathways. 2005
International Inumology 2005, 17(12), 1525-1531. -
Jung-Hye Choi, Myung-Ju Ahn, Hyan-Chul Rhim, Jin-Woon Kim, Gang-Hong Lee, Young-Yeul Lee, In-Soon Kim.
Comparison of WHO and RECIST criteria for response in metastatic colorectal carcinoma. 2005
Cancer. Cancer Res Treat.2005 37(5), 290-293. -
Nam Su Lee, Hee Sook Park, Jong Ho Won, Dae Sik Hong, Su Taek Uh, Sang Jae Lee, Joo Hang Kim, Se Kyu Kim, Myung Ju Ahn, Jung Hye Choi, Suk Chul Yang, Jung Ae Lee, Keun Seok Lee, Chang Yeol Yim, Yong Chul Lee, Chul Soo Kim, Moon Hee Lee, Kab Do Jung, Hanlim Moon, Yl Sub Lee.
Randomized, Multi-center Phase II Trial of Docetaxel Plus Cisplatin Versus Etoposide Plus Cisplatin as the First-line Therapy for Patients with Advanced Non-Small Cell Lung Cancer. 2005
Cancer Res Treat. 2005 ; 037 : 332~338. -
Jong-Mu Sun, Joungho Han, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn,
Significance of Thymidylate Synthase and Thyroid Transcription Factor 1 Expression in Patients with Nonsquamous Non-small Cell Lung Cancer Treated with Pemetrexed-Based Chemotherapy. 2011
J Thorac Oncol. -
Jung-Hye Choi, Myung-Ju Ahn, Chan-Kum Park, Hong-xiu Han, Sung-Joon Kwon, Youg-Yuel Lee, In-Soon Kim.
Phospho-stat3 expression and correlation with VEGF, p53, and b cl –2 in gastric carcinoma using tissue microarray. 2006
APMIS 114:, 619-625, 2006 -
Nam Keun Kim, So Young Chong, Moon Ju Jang, Seoung Ho Hong, Heung Sik Kim, Eun Kyung Cho, Jung Ae Lee, Myung Ju Ahn, Chul Soo Kim, Do Yeun Oh.
Association of the methyenetetrahydrofolate reductase polymorphism in Korean patients with childhood acute lymphoblastic leukemia. 2006
Anticancer Research 26: 2879-2882, 2006 -
YS Hong, HR Lee, S Park, IG Hwang, B-B Park, J Lee, JS Ahn, M-J Ahn, HY Lim, K Park.
Three-week schedule of irinotecan plus cisplatin in patients with previously untreated extensive small cell lung cancer. 2006
Br J Cancer 95:1648-1652, 2006 -
Duk-Joo Lee, Ho-Suk Oh, Jung-Hye Choi, Young-Yeul Lee, In-Soon Kim, Myung-Ju Ahn.
Phase II study of oxaliplatin, 5-fluorouracil, and leucovorin in relapsed or metastatic colorectal cancer as second line therapy. 2006
Cancer. Cancer Res Treat.2006 38(4), 201-205. -
Sarah Park, Myung-Ju Ahn, Jin Seok Ahn, Jeeyun Lee, Yong Sang Hong, Byeong-Bae Park, Sang Chul Lee, In Gyun Hwang, Joon Oh Park, Hoyeong Lim, Won Ki Kang, Keunchil Park.
Combination chemotherapy with paclitaxel and ifofamide as the third-line rgimen in patients with heavily pretreated small cell lung cancer. 2007
Lung Cancer 58:116-122, 2007 -
H-S Lee, ST Kim, J Lee, YS Choi, J-H Han, Y-C Ahn, K-S Lee, JS Ahn, MJ Ahn, K Kim, YM Shim, J Kim, K Park.
Single institutional experience of thymic epithelial tumours over 11 years: clinical features and outcome and implications for future management. 2007
British Journal of Cancer 97, 22 – 28, 2007 -
Doyeun Oh, Nam Keun Kim, Moon Ju Jang, Hugh Chul Kim, Jae Hoon Lee, Jung Ae Lee, Myung-Ju Ahn,, Chul Soo Kim, Heung Sik Kim, Seonyang Park, Hyun Sook Chi, Yoo Hong Min, HOGS Investigators.
Association of the 5,10-Methylenetetrahydrofolate Reductase (MTHFR C677T and A1298C) Polymorphisms in Korean Patients with Adult Acute Lymphoblastic Leukemia. 2007
Anticancer Research 27: 3419-3424, 2007 -
Joon Oh Park, Sang-We Kim, Jin Seok Ahn, Cheolwon Suh, Jung Shin Lee, Joung Soon Jang, Eun Kyung Cho, Sung Hyun Yang, Jin-Hyuk Choi, Dae Seog Heo, Suk Young Park, Sang Won Shin, Myung Ju Ahn, Jong Seok Lee, Young Ho Yun, Jae-Won Lee, Keunchil Park.
Phase III Trial of Two Versus Four Additional Cycles in Patients Who Are Nonprogressive After Two Cycles of Platinum-Based Chemotherapy in Non–Small-Cell Lung Cancer. 2007
Journal of Clinical Oncology, Vol 25, No 33 (November 20), 2007: pp. 5233-5239 -
Jeeyun Lee, Tae-You Kim, Myung Ah Lee, Myung-Ju Ahn, Hoon-Kyo Kim, Ho-Young Lim, Nam Su Lee, Byung Joo Park, Jun Suk Kim, (Korean Cancer Study Group).
Phase II trial of gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinoma. 2008
Cancer Chemother Pharmacol 2008 61:47-52. -
Park BB, Im YH, Hwang IG, Lee SC, Ahn JS, Ahn MJ, Lim HY, Kang WK, Park K.
Salvage chemotherapy with mitomycin C, ifosfamide, and cisplatin (MIC) for previously treated metastatic or recurrent esophageal squamous cell carcinoma. 2008
Invest New Drugs. 2008 Aug;26(4):387-92. Epub 2008 Mar 27. -
Ahn MJ, Park BB, Ahn JS, Kim SW, Kim HT, Lee JS, Kang JH, Cho JY, Song HS, Park SH, Sohn CH, Shin SW, Choi JH, Ki CS, Park CK, Holmes AJ, Jänne PA, Park K.
Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced non-small cell lung cancer? 2008
Clin Cancer Res. 2008 Jun 15;14(12):3860-6 -
Jun HJ, Ahn MJ, Kim HS, Yi SY, Han J, Lee SK, Ahn YC, Jeong HS, Son YI, Baek JH, Park K.
ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation. 2008
Br J Cancer. 2008 Jul 8;99(1):167-72. -
Hwang IG, Ahn MJ, Park BB, Ahn YC, Han J, Lee S, Kim J, Shim YM, Ahn JS, Park K.
ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy. 2008
Cancer. 2008 Sep 15;113(6):1379-86. -
Hong JY, Choi MK, Uhm JE, Park MJ, Lee J, Park YH, Ahn JS, Park K, Han JH, Ahn MJ.
The role of palliative chemotherapy for advanced pulmonary pleomorphic carcinoma. 2009
Med Oncol. 2009:26:287-291 -
Chang MH, Kim KH, Jun HJ, Kim HS, Yi SY, Uhm JE, Park MJ, Lim DH, Ji SH, Hwang IG, Lee J, Park YH, Ahn JS, Ahn MJ, Park K.
Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced non-small cell lung cancer. 2009
Cancer Chemother Pharmacol. 2009 64:917-924 -
Kim HS, Yi SY, Jun HJ, Ahn JS, Ahn MJ, Lee J, Kim Y, Cui ZY, Hong HJ, Kim JM, Li S, Hwang IG, Park K.
L1 cell adhesion molecule as a predictor for recurrence in pulmonary carcinoids and large-cell neuroendocrine tumors. 2009
APMIS. 2009 Feb;117(2):140-6. -
Kim HS, Park K, Jun HJ, Yi SY, Lee J, Ahn JS, Park YH, Kim S, Lee S, Ahn MJ.
Comparison of survival in advanced non-small cell lung cancer patients in the pre- and post-gefitinib eras. 2009
Oncology. 2009;76(4):239-46. -
Oh YH, Kim Y, Kim YP, Seo SW, Mitsudomi T, Ahn MJ, Park K, Kim HS.
Rapid detection of the epidermal growth factor receptor mutation in non-small-cell lung cancer for analysis of acquired resistance using molecular beacons. 2010
J Mol Diagn. 2010 Sep;12(5):644-52. -
Lee HY, Ahn MJ, Park YH, Ahn JS, Kim BS, Kim HK, Kim HT, Ryoo HM, Bae SH, Lee SS, Choi K, Hong DS, Lee KH, Kwon JH, Choi IS, Kim BS, Lee NS, Gong SJ, Park K.
Adenocarcinoma has an excellent outcome with pemetrexed treatment in Korean patients: A prospective, multicenter trial. 2009
Lung Cancer. 2009 Dec;66(3):338-43. -
Kim Y, Kim HS, Cui ZY, Lee HS, Ahn JS, Park CK, Park K, Ahn MJ.
Clinicopathological implications of EpCAM expression in adenocarcinoma of the lung. 2009
Anticancer Res. 2009 May;29(5):1817-22. -
Park S, Holmes-Tisch AJ, Cho EY, Shim YM, Kim J, Kim HS, Lee J, Park YH, Ahn JS, Park K, Jänne PA, Ahn MJ.
Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer. 2009
J Thorac Oncol. 2009 Jul;4(7):809-15. -
Kim KH, Lee J, Lee JI, Nam DH, Kong DS, Ahn YC, Park HC, Jung Kwon O, Kim H, Chang MH, Yi SY, Ji SH, Park YH, Ahn JS, Park K, Ahn MJ.
Can upfront systemic chemotherapy replace stereotactic radiosurgery or whole brain radiotherapy in the treatment of non-small cell lung cancer patients with asymptomatic brain metastases? 2010
Lung Cancer. 2010 68(2):258-63. -
Uhm JE, Park BB, Ahn MJ, Lee J, Ahn JS, Kim SW, Kim HT, Lee JS,_Kang JH, Cho JY, Song HS, Park SH, Sohn CH, Shin SW, Choi JH, Park K.
Erlotinib monotherapy for stage IIIB/IV non-small cell lung cancer. A multicenter trial by the Korean Cancer Study Group. 2009
J Thorac Oncol 2009; 4:1136-1143. -
Chang MH, Lee J, Han J, Park YH, Ahn JS, Park K, Ahn MJ.
Prognostic role of insulin-like growth factor-1 expression in small cell lung cancer. 2009
APMIS 2009;117;861-869. -
Sun JM, Ahn MJ, Park MJ, Yi JH, Kim TS, Chung MJ, Park YH, Ahn JS, Park K.
Accuracy of RECIST 1.1 for non-small cell lung cancer treated with EGFR tyrosine kiniase inhibitors. 2010
Lung Cancer 2010:69:105-109 -
Chung MK. Jeong H, Park SG, Ahn MJ, Baek C.
Metabolic tumor volume of F18-fluorodeoxyglucose postiron emission tomography/computed tomography predicts short-term outcome to radiotherapy with or without chemotherapy in pharyngeal cancer. 2009
Clin Cancer Res 2009;15:5861-8. -
Kim HS, Park YH, Lee J, Ahn JS, Park K, Han J, Ahn MJ.
Clinical impact of phosphorylated signal transducer and activator of treanscription 3, epidermal growth factor receptor, p53 and vascular endothelial growth factor receptor 1 expression in resected adenocarcinoma of lung by using tissue microarray. 2010
Cancer 2010;116:676-85. -
Lee DH, Park K, Kim JH, Lee J, Shin SW, Ahn MJ, Kim SW.
Randomized phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy. 2010
Clin Cancer Res 2010;16:1307-14. -
Lee DH, Kim SW, Suh C, Lee JS, Ahn JS, Ahn MJ, Park K, Yang SY.
Multicenter phase II study of belotecan, a new camptothecin analog, and cisplatin for chemotherapy-naïve patients with extensive –disease small cell lung cancer. 2010
Cancer 2010;116:132-136. -
Sun JM, Park JO, Won YW, Kim JH, Yun J, Lee J, Park YH, Ahn JS, Ahn MJ, Park K.
Who are less likely to receive subsequent chemotherapy beyond first-line therapy for advanced non-small cell lung cancer? 2010
J J Thorac Oncol 2010; 5:540-545. -
Kim ST, Lee J, Kim JH, Won YW, Sun JM, Yun J, Park YH, Ahn JS, Park K, Ahn MJ.
Comparison of gefitnib versus erlotinib in patients with non-small cell lung cancer who failed previous chemotherapy. 2010
Cancer 2010:116;3025-3033. -
Ho Yun Lee, Seung Hyup Hyun, Kyung Soo Lee, Byung-Tae Kim, Jhingook Kim, Young Mog Shim, Myung-Ju Ahn, Tae Sung Kim, Chin A Yi, Myung Jin Chung.
Volume-Based Parameter of 18F-FDG PET/CT in Malignant Pleural Mesothelioma: Prediction of Therapeutic Response and Prognostic Implications. 2010
Ann Surg Oncol 17:2787-2794, 2010 -
Myung-Ju Ahn, Jeeyun Lee, Yun-Hee Park, Jin-Seok Ahn, Argyrios Ziogas, Jason A. Zell, Keunchil Park, Sai-Hong Ignatius Ou,
Korean Ethnicity as Compared with White Ethnicity Is an Independent Favorable Prognostic Factor for Overall Survival in Non-small Cell Lung Cancer before and after the Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Era. 2010
J Thora Oncol 8:1185-1196, 2010 -
Jong-Mu Sun, Tae Sung Kim, Jeeyun Lee, Yeon Hee Park, Jin Seok Ahn, Hojoong Kim, O. Jung Kwon, Kyung Soo Lee, Keunchil Park, Myung-Ju Ahn.
Unsuspected pulmonary emboli in lung cancer patients: The impact on survival and the significance of anticoagulation therapy 2010
Lung Cancer 69 :330–336, 2010 -
Chang MH, Ahn JS, Lee J, Kim KH, Park YH, Han J, Ahn MJ, Park K.
The efficacy of pemetrexed as a third- or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer. 2010
Lung Cancer. 2010 Sep;69(3):323-9. -
Min JH, Lee HY, Lee KS, Han J, Park K, Ahn MJ, Lee SJ.
Stepwise evolution from a focal pure pulmonary ground-glass opacity nodule into an invasive lung adenocarcinoma: an observation for more than 10 years. 2010
Lung Cancer. 2010 Jul;69(1):123-6 -
Sun JM, Choi YL, Won JK, Hirsch FR, Ahn JS, Ahn MJ, Park K.
A dramatic response to crizotinib in a non-small-cell lung cancer patient with IHC-positive and FISH-negative ALK. 2012
J Thorac Oncol. -
Lee HY, Lee KS, Hwang HS, Lee JW, Ahn MJ, Park K, Kim TS, Yi CA, Chung MJ.
Molecularly targeted therapy using bevacizumab for non-small cell lung cancer: a pilot study for the new CT response criteria. 2010
Korean J Radiol. 2010 Nov-Dec;11(6):618-26. -
Kim ST, Lee J, Sun JM, Park YH, Ahn JS, Park K, Ahn MJ.
Prognostic Model to Predict Outcomes in Non-Small Cell Lung Cancer Patients with Erlotinib as Salvage Treatment. 2010
Oncology. -
Sun JM, Won YW, Kim ST, Kim JH, Choi YL, Lee J, Park YH, Ahn JS, Park K, Ahn MJ.
The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patients. 2011
J Cancer Res Clin Oncol. -
Sun JM, Ahn JS, Lee S, Kim JA, Lee J, Park YH, Park HC, Ahn MJ, Ahn YC, Park K.
Predictors of skeletal-related events in non-small cell lung cancer patients with bone metastases. 2011
Lung Cancer. -
Won YW, Park YH, Ahn MJ, Do IG, Ko YH, Park K.
A phase II study of combination chemotherapy with capecitabine and cisplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck. 2011
Ann Oncol. -
Chang MH, Ahn HK, Lee J, Jung CK, Choi YL, Park YH, Ahn JS, Park K, Ahn MJ.
Clinical impact of amphiregulin expression in patients with epidermal growth factor receptor (EGFR) wild-type nonsmall cell lung cancer treated with EGFR-tyrosine kinase inhibitors. 2011
Cancer. -
Lee HY, Lee KS, Ahn MJ, Hwang HS, Lee JW, Park K, Ahn JS, Kim TS, Yi CA, Chung MJ.
New CT response criteria in non-small cell lung cancer: Proposal and application in EGFR tyrosine kinase inhibitor therapy. 2011
Lung Cancer. -
Seung-Tae Lee, Ji-Youn Kim, Min-Jung Kown, Sun Wook Kim, Jae Hoon Chung, Myung-Ju Ahn,Young Lyun Oh, Jong-Won Kim, and Chang-Seok Ki.
Mutant Enrichment with 3=-Modified Oligonucleotides A Practical PCR Method for Detecting Trace Mutant DNAs 2011
The Journal of Molecular Diagnostics -
Seung Tae Kim, Ji Eun Uhma, Jeeyun Lee, Jong-mu Sun, Insuk Sohn, Seon Woo Kim, Sin-Ho Jung, Yeon Hee Park, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn.
Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy. 2012
Lung Cancer -
Sun JM, Nam MH, Chung JY, Im B, Lee SY, Suh YL, Ahn JS, Park K, Ahn MJ.
Safety and pharmacokinetics of intrathecal administration of pemetrexed in rats. 2011
Cancer Chemother Pharmacol. -
Soohyeon Lee, Youngwook Kim, Jong-Mu Sun, Yoon La Choi,Jhin Gook Kim, Young-Mog Shim, Yeon Hee Park, Jin Seok Ahn, Keunchil Park, Jung Ho Han, Myung-Ju Ahn.
Molecular profiles of EGFR, K-ras, c-met, and FGFR in pulmonary pleomorphic carcinoma, a rare lung malignancy. 2011
J Cancer Res Clin Oncol -
Myung-Ju AHN, Chun-Ming TSAI, Te-Chun HSIA, Elaine WRIGHT, John Wen-Cheng CHANG, Heung Tae KIM, Joo-Hang KIM, Jin Hyoung KANG, Sang-We KIM, Eun-Jin BAE, Mijeong KANG, Johanna LISTER and Stefan WALZER.
Cost-effectiveness of bevacizumab-based therapy versus cisplatin plus pemetrexed for the first-line treatment of advanced non-squamous NSCLC in Korea and Taiwan. 2011
Asia–Pacific Journal of Clinical Oncology -
Gee-Chen CHANG, Myung-Ju AHN, Elaine WRIGHT, Heung Tae KIM, Joo-Hang KIM, Jin Hyoung KANG, Sang-We KIM, Steven SHERMAN and Stefan WALZER.
Comparative effectiveness of bevacizumab plus cisplatin-based chemotherapy versus pemetrexed plus cisplatin treatment in East Asian non-squamous non-smal cell lung cancer patients applying real-life outcomes. 2011
Asia–Pacific Journal of Clinical Oncology -
John Wen-Cheng CHANG, Sumitra THONGPRASERT, Elaine WRIGHT, Kenneth TSANG, Heung Tae KIM, Myung-Ju AHN, Joo-Hang KIM, Jin Hyoung KANG, Sang-We KIM and Stefan WALZER.
An indirect comparison of bevacizumab plus cisplatin-gemcitabine and cisplatin plus pemetrexed treatment for patients with advanced first-line non-squamous non-small cell lung cancer in East Asia. 2011
Asia–Pacific Journal of Clinical Oncology -
Yi Kyung Kim , Ho Yun Lee, Kyung Soo Lee, Joungho Han, Myung-Ju Ahn, Keunchil Park, Young Mog Shim, Jhingook Kim.
Dry Pleural Dissemination in Non–Small Cell Lung Cancer: Prognostic and Diagnostic Implications. 2011
Radiology -
Jong-Mu Sun a,e, Hyun Jung Jun a,e, Young Hyeh Ko b, Yeon Hee Park a, Yong Chan Ahn c, Young-Ik Son d, Jeong-Hwan Baek d, Keunchil Park a, Myung-Ju Ahn.
Insulin-like growth factor binding protein-3, in association with IGF-1 receptor, can predict prognosis in squamous cell carcinoma of the head and neck. 2011
Oral Oncology -
Shim BY, Park SH, Lee S, Kim JS, Lee KE, Kang YK, Ahn MJ.
Current Status and Challenges of Cancer Clinical Trials in Korea. 2015
Cancer Res Treat. -
Blumenschein GR Jr, Smit EF, Planchard D, Kim DW, Cadranel J, De Pas T, Dunphy F, Udud K, Ahn MJ, Hanna NH, Kim JH, Mazieres J, Kim SW, Baas P, Rappold E, Redhu S, Puski A, Wu FS, Jänne PA.
A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†. 2015
Ann Oncol. -
Noh JM, Ahn YC, Lee H, Pyo H, Kim B, Oh D, Park H, Lee E, Park K, Ahn JS, Ahn MJ, Sun JM.
Definitive Bimodality Concurrent Chemoradiotherapy in Patients with Inoperable N2-positive Stage IIIA Non-small Cell Lung Cancer. 2015
Cancer Res Treat. -
Costa DB, Shaw AT, Ou SH, Solomon BJ, Riely GJ, Ahn MJ, Zhou C, Shreeve SM, Selaru P, Polli A, Schnell P, Wilner KD, Wiltshire R, Camidge DR, Crinò L.
Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases. 2015
J Clin Oncol. -
Um SW, Kim HK, Jung SH, Han J, Lee KJ, Park HY, Choi YS, Shim YM, Ahn MJ, Park K, Ahn YC, Choi JY, Lee KS, Suh GY, Chung MP, Kwon OJ, Kim J, Kim H.
Endobronchial ultrasound versus mediastinoscopy for mediastinal nodal staging of non-small-cell lung cancer. 2015
J Thorac Oncol. -
Park SB, Choi JY, Moon SH, Yoo J, Kim H, Ahn YC, Ahn MJ, Park K, Kim BT.
Prognostic value of volumetric metabolic parameters measured by [18F]fluorodeoxyglucose-positron emission tomography/computed tomography in patients with small cell lung cancer. 2014
Cancer Imaging. -
Chang JH, Ahn YC, Park H, Oh D, Noh JM, Sun JM, Ahn MJ, Park K.
Fate of patients with nasopharyngeal cancer who developed distant metastasis as first failure after definitive radiation therapy. 2014
Head Neck. -
Lim SH, Lee JY, Lee MY, Kim HS, Lee J, Sun JM, Ahn JS, Um SW, Kim H, Kim BS, Kim ST, Na DL, Sun JY, Jung SH, Park K, Kwon OJ, Lee JI, Ahn MJ.
A randomized phase III trial of stereotactic radiosurgery (SRS) versus observation for patients with asymptomatic cerebral oligo-metastases in non-small-cell lung cancer. 2015
Ann Oncol. -
Cha YK, Lee HY, Ahn MJ, Choi YL, Lee JH, Park K, Lee KS.
Survival outcome assessed according to tumor burden and progression patterns in patients with epidermal growth factor receptor mutant lung adenocarcinoma undergoing epidermal growth factor receptor tyrosine kinase inhibitor therapy. 2015
Clin Lung Cancer. -
Baek JH, Sun JM, Min YJ, Cho EK, Cho BC, Kim JH, Ahn MJ, Park K.
Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell lung cancer except both exon 19 deletion and exon 21 L858R: a retrospective analysis in Korea. 2015
Lung Cancer. -
Ku BM, Jho EH, Bae YH, Sun JM, Ahn JS, Park K, Ahn MJ.
BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer. 2015
Invest New Drugs. -
Kim SM, Kim MJ, Jung HA, Sun JM, Choi YL, Ko YH, Park K, Baek CH, Son YI, Ahn MJ.
The presence of ALK Translocation in Sarcomatoid Carcinoma of Head and Neck and Treatment effect of crizotinib: A Case series. 2015
Head Neck. -
Sun JM, Choi YL, Ji JH, Ahn JS, Kim KM, Han J, Ahn MJ, Park K.
Small cell lung cancer detection in never-smokers: clinical characteristics and multigene mutation profiling using targeted next-generation sequencing. 2015
Ann Oncol. -
Ahn MJ, Kim SW, Cho BC, Ahn JS, Lee DH, Sun JM, Massey D, Kim M, Shi Y, Park K.
Phase II Study of Afatinib as Third-Line Treatment for Patients in Korea With Stage IIIB/IV Non-Small Cell Lung Cancer Harboring Wild-Type EGFR. 2015
Oncologist. -
Jänne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, Ahn MJ, Kim SW, Su WC, Horn L, Haggstrom D, Felip E, Kim JH, Frewer P, Cantarini M, Brown KH, Dickinson PA, Ghiorghiu S, Ranson M.
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. 2015
N Engl J Med. -
Kim HS, Kwon HJ, Jung I, Yun MR, Ahn MJ, Kang BW, Sun JM, Kim SB, Yoon DH, Park KU, Lee SH, Koh YW, Kim SH, Choi EC, Koo DH, Sohn JH, Kim B, Kwon NJ, Yun HJ, Lee MG, Lee JH, Kim TM, Kim HR, Kim JH, Paik S, Cho BC.
Phase II Clinical and Exploratory Biomarker Study of Dacomitinib in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck. 2015
Clin Cancer Res. -
Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, Wu YL, Thomas M, O'Byrne KJ, Moro-Sibilot D, Camidge DR, Mok T, Hirsh V, Riely GJ, Iyer S, Tassell V, Polli A, Wilner KD, Jänne PA.
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer. 2013
N Engl J Med. -
Yang JC, Ahn MJ, Nakagawa K, Tamura T, Barraclough H, Enatsu S, Cheng R, Orlando M.
Pemetrexed Continuation Maintenance in Patients with Nonsquamous Non-small Cell Lung Cancer: Review of Two East Asian Trials in Reference to PARAMOUNT. 2014
Cancer Res Treat. -
Ku B, Jung H, Sun JM, Ko Y, Jeong HS, Son YI, Baek CH, Park K, Ahn MJ.
High-throughput profiling identifies clinically actionable mutations in salivary duct carcinoma. 2014
J Transl Med. -
Yang JC, Kang JH, Mok T, Ahn MJ, Srimuninnimit V, Lin CC, Kim DW, Tsai CM, Barraclough H, Altug S, Orlando M, Park K.
First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: a randomised, phase 3 trial. 2014
Eur J Cancer. -
Park K, Cho BC, Kim DW, Ahn MJ, Lee SY, Gernhardt D, Taylor I, Campbell AK, Zhang H, Giri N, Letrent SP, O'Connell J, Heo DS.
Safety and efficacy of dacomitinib in korean patients with KRAS wild-type advanced non-small-cell lung cancer refractory to chemotherapy and erlotinib or gefitinib: a phase I/II trial. 2014
J Thorac Oncol. -
Choi MK, Hong JY, Chang WJ, Kim MJ, Kim SM, Jung HA, Do IG, Choi YL, Sun JM, Ahn JS, Park K, Ahn MJ.
A phase II trial of gefitinib monotherapy in pretreated patients with advanced non-small cell lung cancer not harboring activating EGFR mutations: implications of sensitive EGFR mutation test. 2015
Cancer Chemother Pharmacol. -
Lee MY, Jung KS, Kim HS, Lee JY, Lim SH, Kim M, Jung HA, Kim SM, Sun JM, Ahn MJ, Lee J, Park SH, Yi SY, Hwang IG, Lee SC, Ahn HK, Lim do H, Lee SI, Park KW.
Weekly docetaxel and gemcitabine in previously treated metastatic esophageal squamous cell carcinoma. 2015
World J Gastroenterol. -
Ahn S, Choi IH, Han J, Kim J, Ahn MJ.
Pleural mesothelioma: an institutional experience of 66 cases. 2014
Korean J Pathol. -
Ou SH, Soo RA, Kubo A, Kawaguchi T, Ahn MJ.
Will the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) Non-Small Cell Lung Cancer Globally? 2014
Front Oncol. -
Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, Hamid O, Goldman JW, Soria JC, Dolled-Filhart M, Rutledge RZ, Zhang J, Lunceford JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K, Gandhi L;
Pembrolizumab for the treatment of non-small-cell lung cancer. 2015
N Engl J Med. -
Lim SH, Lee JY, Sun JM, Ahn JS, Park K, Ahn MJ.
Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21. 2014
J Thorac Oncol. -
Choi MK, Hong JY, Chang W, Kim M, Kim S, Jung HA, Lee SJ, Park S, Chung MP, Sun JM, Park K, Ahn MJ, Ahn JS.
Safety and efficacy of gemcitabine or pemetrexed in combination with a platinum in patients with non-small-cell lung cancer and prior interstitial lung disease. 2014
Cancer Chemother Pharmacol. -
Lee JY, Lim SH, Kim M, Kim S, Jung HA, Chang WJ, Choi MK, Hong JY, Lee SJ, Sun JM, Ahn JS, Park K, Ahn MJ.
Is there any predictor for clinical outcome in EGFR mutant NSCLC patients treated with EGFR TKIs? 2014
Cancer Chemother Pharmacol. -
Chong Y, Kim JH, Lee HY, Ahn YC, Lee KS, Ahn MJ, Kim J, Shim YM, Han J, Choi YL.
Quantitative CT variables enabling response prediction in neoadjuvant therapy with EGFR-TKIs: are they different from those in neoadjuvant concurrent chemoradiotherapy? 2014
PLoS One. -
Barlesi F, Scherpereel A, Gorbunova V, Gervais R, Vikström A, Chouaid C, Chella A, Kim JH, Ahn MJ, Reck M, Pazzola A, Kim HT, Aerts JG, Morando C, Loundou A, Groen HJ, Rittmeyer A.
Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial. 2014
Ann Oncol. -
Lee H, Ahn YC, Pyo H, Kim B, Oh D, Nam H, Lee E, Sun JM, Ahn JS, Ahn MJ, Park K, Choi YS, Kim J, Zo JI, Shim YM.
Pretreatment clinical mediastinal nodal bulk and extent do not influence survival in N2-positive stage IIIA non-small cell lung cancer patients treated with trimodality therapy. 2014
Ann Surg Oncol. -
Chang WJ, Sun JM, Lee JY, Ahn JS, Ahn MJ, Park K.
A retrospective comparison of adjuvant chemotherapeutic regimens for non-small cell lung cancer (NSCLC): paclitaxel plus carboplatin versus vinorelbine plus cisplatin. 2014
Lung Cancer. -
Lira ME, Choi YL, Lim SM, Deng S, Huang D, Ozeck M, Han J, Jeong JY, Shim HS, Cho BC, Kim J, Ahn MJ, Mao M.
A Single-Tube Multiplexed Assay for Detecting ALK, ROS1, and RET Fusions in Lung Cancer. 2014
J Mol Diagn. -
Sun JM, Lira M, Pandya K, Choi YL, Ahn JS, Mao M, Han J, Park K, Ahn MJ, Kim J.
Clinical characteristics associated with ALK rearrangements in never-smokers with pulmonary adenocarcinoma. 2014
Lung Cancer. -
Hyun SH, Ahn HK, Kim H, Ahn MJ, Park K, Ahn YC, Kim J, Shim YM, Choi JY.
Volume-based assessment by (18)F-FDG PET/CT predicts survival in patients with stage III non-small-cell lung cancer. 2014
Eur J Nucl Med Mol Imaging. -
Kim Y, Hammerman PS, Kim J, Yoon JA, Lee Y, Sun JM, Wilkerson MD, Pedamallu CS, Cibulskis K, Yoo YK, Lawrence MS, Stojanov P, Carter SL, McKenna A, Stewart C, Sivachenko AY, Oh IJ, Kim HK, Choi YS, Kim K, Shim YM, Kim KS, Song SY, Na KJ, Choi YL, Hayes DN, Kim J, Cho S, Kim YC, Ahn JS, Ahn MJ, Getz
Integrative and comparative genomic analysis of lung squamous cell carcinomas in East asian patients. 2014
J Clin Oncol. -
Barlesi F, Scherpereel A, Rittmeyer A, Pazzola A, Ferrer Tur N, Kim JH, Ahn MJ, Aerts JG, Gorbunova V, Vikström A, Wong EK, Perez-Moreno P, Mitchell L, Groen HJ.
Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). 2013
J Clin Oncol. -
Sun JM, Kim JR, Do IG, Lee SY, Lee J, Choi YL, Ahn JS, Ahn MJ, Park K.
A phase-1b study of everolimus plus paclitaxel in patients with small-cell lung cancer. 2013
Br J Cancer. -
Sun JM, Ahn MJ, Choi YL, Ahn JS, Park K.
Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors. 2013
Lung Cancer. -
Ahn JS, Lee KH, Sun JM, Park K, Kang ES, Cho EK, Lee DH, Kim SW, Lee GW, Kang JH, Lee JS, Lee JW, Ahn MJ.
A randomized, phase II study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer following first-line platinum-doublet chemotherapy. 2013
Lung Cancer. -
Rittmeyer A, Gorbunova V, Vikström A, Scherpereel A, Kim JH, Ahn MJ, Chella A, Chouaid C, Campbell AK, Barlesi F.
Health-related quality of life in patients with advanced nonsquamous non-small-cell lung cancer receiving bevacizumab or bevacizumab-plus-pemetrexed maintenance therapy in AVAPERL (MO22089). 2013
J Thorac Oncol. -
Maeng CH, Lee HY, Kim YW, Choi MK, Hong JY, Jung HA, Lee KS, Kim H, Kwon OJ, Sun JM, Ahn JS, Park K, Um SW, Ahn MJ.
High-throughput molecular genotyping for small biopsy samples in advanced non-small cell lung cancer patients. 2013
Anticancer Res. -
Sun JM, Hwang DW, Ahn JS, Ahn MJ, Park K.
Prognostic and Predictive Value of KRAS Mutations in Advanced Non-Small Cell Lung Cancer. 2013
PLoS One. -
Lee JY, Lim SH, Lee JY, Kim JH, Choi KH, Park K, Sun JM, Ahn JS, Ahn MJ.
Tumor lysis syndrome in a solid tumor: a case report of a patient with invasive thymoma. 2013
Cancer Res Treat. -
Woo HI, Kim JA, Jung HA, Kim KK, Lee JY, Sun JM, Ahn JS, Park K, Lee SY, Ahn MJ.
Correlation of genetic polymorphisms with clinical outcomes in pemetrexed-treated advanced lung adenocarcinoma patients. 2015
Pharmacogenomics. -
Kim HK, Lee HY, Choi YL, Choi SJ, Choi H, Lee J, Han J, Ahn MJ, Lee KS, Kim J.
Assessment of intratumoral heterogeneity of oncogenic driver mutations in surgically-resected lung adenocarcinoma: implications of percutaneous biopsy-based molecular assay for target-directed therapy. 2014
Anticancer Res. -
Lim SH, Lee JY, Sun JM, Kim KM, Ahn JS, Ahn MJ, Park K.
A new KIT gene mutation in thymic cancer and a promising response to imatinib. 2013
J Thorac Oncol. -
Park S, Ahn MJ, Ahn JS, Sun JM, Shim YM, Kim J, Choi YS, Kim K, Shin S, Ahn Y, Kwon OJ, Kim H, Lee SJ, Chang WJ, Park K.
A Prospective Phase II Trial of Induction Chemotherapy with Docetaxel/Cisplatin for Masaoka Stage III/IV thymic Epithelial Tumors. 2013
J Thorac Oncol. -
Kim YS, Sun JM, Ahn JS, Ahn MJ, Park K.
The optimal duration of vitamin supplementation prior to the first dose of pemetrexed in patients with non-small-cell lung cancer. 2013
Lung Cancer. -
Ahn MJ, Park SY, Kim WK, Cho JH, Chang BJ, Kim DJ, Ahn JS, Park K, Han JS.
A Single Nucleotide Polymorphism in the Phospholipase D1 Gene is Associated with Risk of Non-Small Cell Lung Cancer. 2012
Int J Biomed Sci. -
Moon SH, Cho SH, Park LC, Ji JH, Sun JM, Ahn JS, Park K, Choi JY, Ahn MJ.
Metabolic response evaluated by (18)F-FDG PET/CT as a potential screening tool in identifying a subgroup of patients with advanced non-small cell lung cancer for immediate maintenance therapy after first-line chemotherapy. 2013
Eur J Nucl Med Mol Imaging. -
Sun JM, Ahn YC, Choi EK, Ahn MJ, Ahn JS, Lee SH, Lee DH, Pyo H, Song SY, Jung SH, Jo JS, Jo J, Sohn HJ, Suh C, Lee JS, Kim SW, Park K.
Phase III trial of concurrent thoracic radiotherapy with either first- or third-cycle chemotherapy for limited-disease small-cell lung cancer. 2013
Ann Oncol. -
Jhun BW, Lee KJ, Jeon K, Suh GY, Chung MP, Kim H, Kwon OJ, Sun JM, Ahn JS, Ahn MJ, Park K, Choi JY, Lee KS, Han J, Um SW.
Clinical applicability of staging small cell lung cancer according to the seventh edition of the TNM staging system. 2013
Lung Cancer. -
Huang D, Kim DW, Kotsakis A, Deng S, Lira P, Ho SN, Lee NV, Vizcarra P, Cao JQ, Christensen JG, Kim TM, Sun JM, Ahn JS, Ahn MJ, Park K, Mao M.
Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment. 2013
Genomics. -
Park S, Kim IR, Baek KK, Lee SJ, Chang WJ, Maeng CH, Hong JY, Choi MK, Kim YS, Sun JM, Ahn JS, Park K, Jo J, Jung SH, Ahn MJ.
Prospective analysis of quality of life in elderly patients treated with adjuvant chemotherapy for non-small-cell lung cancer. 2013
Ann Oncol. -
Ahn MJ, Kim DW, Cho BC, Kim SW, Lee JS, Ahn JS, Kim TM, Lin CC, Kim HR, John T, Kao S, Goldman JW, Su WC, Natale R, Rabbie S, Harrop B, Overend P, Yang Z, Yang JC.
Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study. 2017
Lancet Respir Med. -
Kim H, Chan Ahn Y, Pyo H, Oh D, Noh JM, Sun JM, Ahn JS, Ahn MJ, Park K, Choi YS, Kim J, Zo JI, Shim YM, Lee M, Han J.
Do new pN sub-classifications, proposed by IASLC's lung cancer staging project, agree with ypN categories following tri-modality therapy for initial N2 disease? 2016
J Thorac Oncol. -
Cho M, Ahn S, Hong M, Bang H, Van Vrancken M, Kim S, Lee J, Park SH, Park JO, Park YS, Lim HY, Kang WK, Sun JM, Lee SH, Ahn MJ, Park K, Kim DH, Lee S, Park W, Kim KM.
Tissue recommendations for precision cancer therapy using next generation sequencing: a comprehensive single cancer center's experiences. 2017
Oncotarget. -
Ahn MJ, D'Cruz A, Vermorken JB, Chen JP, Chitapanarux I, Dang HQ, Guminski A, Kannarunimit D, Lin TY, Ng WT, Park KU, Chan AT.
Clinical recommendations for defining platinum unsuitable head and neck cancer patient populations on chemoradiotherapy: A literature review. 2016
Oral Oncol. -
Govindan R, Szczesna A, Ahn MJ, Schneider CP, Gonzalez Mella PF, Barlesi F, Han B, Ganea DE, Von Pawel J, Vladimirov V, Fadeeva N, Lee KH, Kurata T, Zhang L, Tamura T, Postmus PE, Jassem J, O'Byrne K, Kopit J, Li M, Tschaika M, Reck M.
Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer. 2017
J Clin Oncol. -
Guo Y, Ahn MJ, Chan A, Wang CH, Kang JH, Kim SB, Bello M, Arora RS, Zhang Q, He X, Li P, Dechaphunkul A, Kumar V, Kamble K, Li W, Kandil A, Cohen EEW, Geng Y, Zografos E, Tang PZ.
Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic amous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial. 2019
Ann Oncol. -
Grünwald V, Chirovsky D, Cheung WY, Bertolini F, Ahn MJ, Yang MH, Castro G, Berrocal A, Sjoquist K, Kuyas H, Auclair V, Guillaume X, Joo S, Shah R, Harrington K; GLANCE H&N STUDY Investigators.
Global treatment patterns and outcomes among patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results of the GLANCE H&N study. 2020
Oral Oncol. -
Lee JY, Ku BM, Lim SH, Lee MY, Kim H, Kim M, Kim S, Jung HA, Sun JM, Ahn JS, Park K, Ahn MJ.
The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors. 2015
J Thorac Oncol. -
Moon SH, Choi JY, Lee HJ, Son YI, Baek CH, Ahn YC, Ahn MJ, Park K, Kim BT.
Prognostic value of volume-based positron emission tomography/computed tomography in patients with nasopharyngeal carcinoma treated with concurrent chemoradiotherapy. 2015
Clin Exp Otorhinolaryngol. -
Sun JM, Ahn JS, Jung SH, Sun J, Ha SY, Han J, Park K, Ahn MJ.
Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin According to Thymidylated Synthase Expression in Nonsquamous Non-Small-Cell Lung Cancer: A Biomarker-Stratified Randomized Phase II Trial. 2015
J Clin Oncol. -
Ahn JS, Ahn YC, Kim JH, Lee CG, Cho EK, Lee KC, Chen M, Kim DW, Kim HK, Min YJ, Kang JH, Choi JH, Kim SW, Zhu G, Wu YL, Kim SR, Lee KH, Song HS, Choi YL, Sun JM, Jung SH, Ahn MJ, Park K.
Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04. 2015
J Clin Oncol. -
Yoshioka H, Azuma K, Yamamoto N, Takahashi T, Nishio M, Katakami N, Ahn MJ, Hirashima T, Maemondo M, Kim SW, Kurosaki M, Akinaga S, Park K, Tsai CM, Tamura T, Mitsudomi T, Nakagawa K.
A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study). 2015
Ann Oncol. -
Soria JC, Wu YL, Nakagawa K, Kim SW, Yang JJ, Ahn MJ, Wang J, Yang JC, Lu Y, Atagi S, Ponce S, Lee DH, Liu Y, Yoh K, Zhou JY, Shi X, Webster A, Jiang H, Mok TS.
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. 2015
Lancet Oncol. -
Hyun SH, Ahn HK, Ahn MJ, Ahn YC, Kim J, Shim YM, Choi JY.
Volume-Based Assessment With 18F-FDG PET/CT Improves Outcome Prediction for Patients With Stage IIIA-N2 Non-Small Cell Lung Cancer. 2015
AJR Am J Roentgenol. -
Ji JH, Oh YL, Hong M, Yun JW, Lee HW, Kim D, Ji Y, Kim DH, Park WY, Shin HT, Kim KM, Ahn MJ, Park K, Sun JM.
Identification of Driving ALK Fusion Genes and Genomic Landscape of Medullary Thyroid Cancer. 2015
PLoS Genet. -
Lee SJ, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ.
Pemetrexed plus platinum versus pemetrexed alone in non-small cell lung cancer patients who have progressed after first-line EGFR TKIs. 2015
Lung Cancer. -
Cho KR, Lee MH, Kong DS, Seol HJ, Nam DH, Sun JM, Ahn JS, Ahn MJ, Park K, Kim ST, Lim do H, Lee JI.
Outcome of gamma knife radiosurgery for metastatic brain tumors derived from non-small cell lung cancer. 2015
J Neurooncol. -
Kim ST, Lee J, Hong M, Park K, Park JO, Ahn T, Park SH, Park YS, Lim HY, Sun JM, Ahn JS, Ahn MJ, Kim HC, Sohn TS, Choi DI, Cho JH, Heo JS, Kwon W, Uhm SW, Lee H, Min BH, Hong SN, Kim DH, Jung SH, Park W, Kim KM, Kang WK, Park K.
The NEXT-1 (Next generation pErsonalized tX with mulTi-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysis. 2015
Oncotarget. -
Park S, Langley E, Sun JM, Lockton S, Ahn JS, Jain A, Park K, Singh S, Kim P, Ahn MJ.
Low EGFR/MET ratio is associated with resistance to EGFR inhibitors in non-small cell lung cancer. 2015
Oncotarget. -
Cho JH, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ.
Late-Onset Cholecystitis with Cholangitis after Avelumab Treatment in Non-Small Cell Lung Cancer. 2018
J Thorac Oncol. -
Kim HS, Kim SM, Kim H, Pyo KH, Sun JM, Ahn MJ, Park K, Keam B, Kwon NJ, Yun HJ, Kim HG, Chung IJ, Lee JS, Lee KH, Kim DJ, Lee CG, Hur J, Chung H, Park JC, Shin SK, Lee SK, Kim HR, Moon YW, Lee YC, Kim JH, Paik S, Cho BC.
7.Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma. 2015
Oncotarget. -
Kim HS, Lee JY, Lim SH, Sun JM, Lee SH, Ahn JS, Park K, Moon SH, Ahn MJ.
A Prospective Phase II Study of Cisplatin and Cremophor EL-Free Paclitaxel (Genexol-PM) in Patients with Unresectable Thymic Epithelial Tumors. 2015
J Thorac Oncol. -
Kang JH, Ahn MJ, Kim DW, Cho EK, Kim JH, Shin SW, Wang X, Kim JS, Orlando M, Park K.
Tolerability and Outcomes of First-line Pemetrexed+Cisplatin Followed by Gefitinib Maintenance Therapy versus Gefitinib Monotherapy in Korean Patients with Advanced Nonsquamous Non-small Cell Lung Cancer: A Post Hoc Descriptive Subgroup Analysis of a Randomized, Phase 3 Trial. 2015
Cancer Res Treat. -
Kim HS, Lee JY, Lim SH, Park K, Sun JM, Ko YH, Baek CH, Son YI, Jeong HS, Ahn YC, Lee MY, Hong M, Ahn MJ.
Association Between PD-L1 and HPV Status and the Prognostic Value of PD-L1 in Oropharyngeal Squamous Cell Carcinoma. 2015
Cancer Res Treat. -
Lim SH, Lee SJ, Ahn MJ, Park K, Sun JM.
Different clinical outcomes between locally advanced hypopharyngeal and oropharyngeal cancer treated with definitive concurrent chemoradiotherapy: implication for subgroup selection for induction chemotherapy. 2015
Jpn J Clin Oncol. -
Lim SH, Hong M, Ahn S, Choi YL, Kim KM, Oh D, Ahn YC, Jung SH, Ahn MJ, Park K, Zo JI, Shim YM, Sun JM.
Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer. 2015
Eur J Cancer. -
Lee JY, Sun JM, Lim SH, Kim H, Yoo KH, Jung KS, Song HN, Ku BM, Koh J, Bae YH, Lee SH, Ahn JS, Park K, Ahn MJ.
Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non-Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib. 2015
Clin Cancer Res. -
Lee JY, Sun JM, Oh DR, Lim SH, Goo J, Lee SH, Kim SB, Park KU, Kim HK, Hong DS, Kim JS, Kim SG, Yi SY, Yun HJ, Hyun MS, Kim HJ, Jung SH, Park K, Ahn YC, Ahn MJ.
Comparison of weekly versus triweekly cisplatin delivered concurrently with radiation therapy in patients with locally advanced nasopharyngeal cancer: A multicenter randomized phase II trial (KCSG-HN10-02). 2016
Radiother Oncol. -
Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, de Castro G Jr, Garrido M, Lubiniecki GM, Shentu Y, Im E, Dolled-Filhart M, Garon EB.
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. 2015
Lancet. -
Park K, Yu CJ, Kim SW, Lin MC, Sriuranpong V, Tsai CM, Lee JS, Kang JH, Chan KC, Perez-Moreno P, Button P, Ahn MJ, Mok T.
First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer: The ASPIRATION Study. 2016
JAMA Oncol. -
Yang JC, Srimuninnimit V, Ahn MJ, Lin CC, Kim SW, Tsai CM, Mok T, Orlando M, Puri T, Wang X, Park K.
First-Line Pemetrexed plus Cisplatin followed by Gefitinib Maintenance Therapy versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer: Final Overall Survival Results from a Randomized Phase 3 Study. 2016
J Thorac Oncol. -
Song HN, Jung KS, Yoo KH, Cho J, Lee JY, Lim SH, Kim HS, Sun JM, Lee SH, Ahn JS, Park K, Choi YL, Park W, Ahn MJ.
Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non-Small Cell Lung Cancer. 2015
J Thorac Oncol. -
Lee JY, Qing X, Xiumin W, Yali B, Chi S, Bak SH, Lee HY, Sun JM, Lee SH, Ahn JS, Cho EK, Kim DW, Kim HR, Min YJ, Jung SH, Park K, Mao M, Ahn MJ.
Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02). 2016
Oncotarget. -
Ham JS, Kim S, Kim HK, Byeon S, Sun JM, Lee SH, Ahn JS, Park K, Choi YL, Han J, Park W, Ahn MJ.
Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment. 2016
J Thorac Oncol. -
Huang KK, Jang KW, Kim S, Kim HS, Kim SM, Kwon HJ, Kim HR, Yun HJ, Ahn MJ, Park KU, Ramnarayanan K, McPherson JR, Zhang S, Rhee JK, Vettore AL, Das K, Ishimoto T, Kim JH, Koh YW, Kim SH, Choi EC, Teh BT, Rozen SG, Kim TM, Tan P, Cho BC.
Exome sequencing reveals recurrent REV3L mutations in cisplatin-resistant squamous cell carcinoma of head and neck. 2016
Sci Rep. -
Lim SH, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ.
Pembrolizumab for the treatment of non-small cell lung cancer. 2016
Expert Opin Biol Ther. -
Kim N, Cho A, Watanabe H, Choi YL, Aziz M, Kassner M, Joung JG, Park AK, Francis JM, Bae JS, Ahn SM, Kim KM, Park JO, Park WY, Ahn MJ, Park K, Koo J, Yin HH, Cho J.
Integrated genomic approaches identify upregulation of SCRN1 as a novel mechanism associated with acquired resistance to erlotinib in PC9 cells harboring oncogenic EGFR mutation. 2016
Oncotarget. -
Ku BM, Yi SY, Koh J, Bae YH, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ.
The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma. 2016
Oncotarget. -
Lee JH, Lee HY, Ahn MJ, Park K, Ahn JS, Sun JM, Lee KS.
Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control study. 2016
Cancer Imaging. -
Ku BM, Bae YH, Koh J, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ.
AZD9291 overcomes T790M medicated resistance through degradation of EGFR (L858R/T790M) in non-small cell lung cancer cells. 2016
Invest New Drugs -
Lee T, Lee B, Choi YL, Han J, Ahn MJ, Um SW.
Non-small cell lung cancer with concomitant EGFR, KRAS, and ALK mutation: Clinicopathologic features of 12 cases. 2016
J Pathol Transl Medi -
Lim SM, Kim HR, Cho EK, Min YJ, Ahn JS, Ahn MJ, Park K, Cho BC, Lee JH, Jeong HC, Kim EK, Kim JH.
Targeted sequencing identifies genetic alterations that confer Primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium). 2016
Oncotarget. -
Kim HS, Lee JY, Lim SH, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ.
Assessment of objective responses in thymic epithelial tumors using ITMIG modified criteria. 2016
Lung Cancer. -
Kim HK, Cho JH, Choi YS, Zo JI, Shim YM, Park K, Ahn MJ, Ahn YC, Kim K, Kim J.
Outcomes of neoadjuvant concurrent chemoradiotherapy followed by surgery for non-small-cell lung cancer with N2 disease. 2016
Lung Cancer. -
Ahn S, Hwang SH, Han J, Choi YL, Lee SH, Ahn JS, Park K, Ahn MJ, Park W.
Transformation to Small Cell Lung Cancer of Pulmonary Adenocarcinoma: Clinicopathologic Analysis of Six Cases. 2016
J Pathol Transl Med. -
Wang L, Wu YL, Lu S, Deng L, Ahn MJ, Hsu FM, Iscoe N, Hossain A, Puri T, Zhang P, Orlando M.
An East Asian subgroup analysis of PROCLAIM, a phase III trial of pemetrexed and cisplatin or etoposide and cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small cell lung cancer. 2016
Asia Pac J Clin Oncol. -
Lim SH, Sun JM, Choi YL, Kim HR, Ahn S, Lee JY, Lee SH, Ahn JS, Park K, Kim JH, Cho BC, Ahn MJ.
Efficacy and safety of dovitinib in pretreated patients with advanced squamous non-small cell lung cancer with FGFR1 amplification: A single-arm, phase 2 study. 2016
Cancer. -
Bang OY, Chung JW, Lee MJ, Kim SJ, Cho YH, Kim GM, Chung CS, Lee KH, Ahn MJ, Moon GJ.
Cancer Cell-Derived Extracellular Vesicles Are Associated with Coagulopathy Causing Ischemic Stroke via Tissue Factor-Independent Way: The OASIS-CANCER Study. 2016
PLoS One. -
Crinò L, Ahn MJ, De Marinis F, Groen HJ, Wakelee H, Hida T, Mok T, Spigel D, Felip E, Nishio M, Scagliotti G, Branle F, Emeremni C, Quadrigli M, Zhang J, Shaw AT.
Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2. 2016
J Clin Oncol. -
Byeon S, Ham JS, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ.
Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis. 2016
Med Oncol. -
Choi JW, Kong DS, Seol HJ, Nam DH, Yoo KH, Sun JM, Ahn JS, Ahn MJ, Park K, Lee JI.
Outcomes of Gamma Knife Radiosurgery in Combination with Crizotinib for Patients with Brain Metastasis from Non-Small Cell Lung Cancer. 2016
World Neurosurg. -
Moon SH, Kim HS, Cho YS, Sun JM, Ahn JS, Park K, Kim BT, Ahn MJ, Lee KH.
Value of volume-based early metabolic response in patients with unresectable thymic epithelial tumor. 2016
Lung Cancer. -
Moon SH, Cho YS, Son YI, Ahn YC, Ahn MJ, Choi JY, Kim BT, Lee KH.
Value of 18F-FDG heterogeneity for discerning metastatic from benign lymph nodes in nasopharyngeal carcinoma patients with suspected recurrence. 2016
Br J Radiol. -
Cho WK, Oh D, Ahn YC, Shim YM, Zo JI, Sun JM, Ahn MJ, Park K.
Supraclavicular and/or celiac lymph node metastases from thoracic esophageal squamous cell carcinoma did not compromise survival following neoadjuvant chemoradiotherapy and surgery. 2017
Oncotarget. -
Lee K, Jung HA, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ.
Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in Korea. 2019
Cancer Res Treat. -
Leighl NB, Rizvi NA, de Lima LG Jr, Arpornwirat W, Rudin CM, Chiappori AA, Ahn MJ, Chow LQ, Bazhenova L, Dechaphunkul A, Sunpaweravong P, Eaton K, Chen J, Medley S, Poondru S, Singh M, Steinberg J, Juergens RA, Gadgeel SM.
Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations. 2017
Clin Lung Cancer. -
Hwang S, Han J, Choi M, Ahn MJ, Choi YS.
Size of Non-lepidic Invasive Pattern Predicts Recurrence in Pulmonary Mucinous Adenocarcinoma: Morphologic Analysis of 188 Resected Cases with Reappraisal of Invasion Criteria. 2017
J Pathol Transl Med. -
Lee SH, Lee JK, Ahn MJ, Kim DW, Sun JM, Keam B, Kim TM, Heo DS, Ahn JS, Choi YL, Min HS, Jeon YK, Park K.
Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial. 2016
Ann Oncol. -
Kim HR, Jang JS, Sun JM, Ahn MJ, Kim DW, Jung I, Lee KH, Kim JH, Lee DH, Kim SW, Cho BC.
A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01). 2016
Oncotarget. -
Kim JE, Jang JS, Kim JW, Sung YL, Cho CH, Lee MA, Kim DJ, Ahn MJ, Lee KY, Sym SJ, Lim MC, Jung H, Cho EK, Min KW.
Efficacy and safety of aprepitant for the prevention of chemotherapy-induced nausea and vomiting during the first cycle of moderately emetogenic chemotherapy in Korean patients with a broad range of tumor types. 2017
Support Care Cancer. -
Lim SH, Shim YM, Park SH, Kim HK, Choi YS, Ahn MJ, Park K, Zo JI, Sun JM.
A Randomized Phase II Study of Leucovorin/5-Fluorouracil with or Without Oxaliplatin (LV5FU2 vs. FOLFOX) for Curatively-Resected, Node-Positive Esophageal Squamous Cell Carcinoma. 2016
Cancer Res Treat. -
Ahn MJ, Sun JM, Lee SH, Ahn JS, Park K.
Transient Asymptomatic Pulmonary Opacities during Osimertinib Treatment: "Stop or Go" Decision. 2016
J Thorac Oncol. -
Yang Z, Guo Q, Wang Y, Chen K, Zhang L, Cheng Z, Xu Y, Yin X, Bai Y, Rabbie S, Kim DW, Ahn MJ, Yang JC, Zhang X.
AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases. 2016
Sci Transl Med. -
Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WS, Lee CK, Sebastian M, Templeton A, Mann H, Marotti M, Ghiorghiu S, Papadimitrakopoulou VA; AURA3 Investigators.
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. 2016
N Engl J Med. -
Hanna NH, Kaiser R, Sullivan RN, Aren OR, Ahn MJ, Tiangco B, Voccia I, Pawel JV, Kovcin V, Agulnik J, Gaschler-Markefski B, Barrueco J, Sikken P, Schloss C, Kim JH; LUME-Lung 2 Study group.
Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial. 2016
Lung Cancer. -
Lee MJ, Chung JW, Ahn MJ, Kim S, Seok JM, Jang HM, Kim GM, Chung CS, Lee KH, Bang OY.
Hypercoagulability and Mortality of Patients with Stroke and Active Cancer: the OASIS-CANCER Study. 2016
J Stroke. -
Kwon AY, Han J, Chu J, Choi YS, Jeong BH, Ahn MJ, Ahn YC.
Histologic characteristics of thymic adenocarcinomas: Clinicopathologic study of a nine-case series and a review of the literature. 2017
Pathol Res Pract. -
Lee MY, Ku BM, Kim HS, Lee JY, Lim SH, Sun JM, Lee SH, Park K, Oh YL, Hong M, Jeong HS, Son YI, Baek CH, Ahn MJ.
Genetic Alterations and Their Clinical Implications in High-Recurrence Risk Papillary Thyroid Cancer. 2016
Cancer Res Treat. -
Park H, Oh D, Ahn YC, Pyo H, Noh JM, Sun JM, Ahn JS, Ahn MJ, Park K, Kim HK, Choi YS, Kim J, Zo JI, Shim YM.
Role of Adjuvant Thoracic Radiation Therapy and Full Dose Chemotherapy in pN2 Non-Small Cell Lung Cancer: Elucidation Based on Single Institute Experience. 2016
Cancer Res Treat. -
Cha YK, Lee HY, Ahn MJ, Park K, Ahn JS, Sun JM, Choi YL, Lee KS.
The impact of smoking status on radiologic tumor progression patterns and response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations. 2016
J Thorac Dis. -
Kim Y, Lee SJ, Lee JY, Lee SH, Sun JM, Park K, An HJ, Cho JY, Kang EJ, Lee HY, Kim J, Keam B, Kim HR, Lee KE, Choi MY, Lee KH, Ahn MJ.
Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01). 2017
Cancer. -
Park K, Cho EK, Bello M, Ahn MJ, Thongprasert S, Song EK, Soldatenkova V, Depenbrock H, Puri T, Orlando M.
Efficacy and Safety of First-Line Necitumumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin In East Asian Patients with Stage IV Squamous Non-Small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-Label, Randomized SQUIRE Study. 2017
Cancer Res Treat. -
Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ.
Osimertinib for the treatment of non-small cell lung cancer. 2017
Expert Opin Pharmacother. -
Hui R, Garon EB, Goldman JW, Leighl NB, Hellmann MD, Patnaik A, Gandhi L, Eder JP, Ahn MJ, Horn L, Felip E, Carcereny E, Rangwala R, Lubiniecki GM, Zhang J, Emancipator K, Roach C, Rizvi NA.
Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial. 2017
Ann Oncol. -
Drilon A, Siena S, Ou SI, Patel M, Ahn MJ, Lee J, Bauer TM, Farago AF, Wheler JJ, Liu SV, Doebele R, Giannetta L, Cerea G, Marrapese G, Schirru M, Amatu A, Bencardino K, Palmeri L, Sartore-Bianchi A, Vanzulli A, Cresta S, Damian S, Duca M, Ardini E, Li G, Christiansen J, Kowalski K, Johnson AD, Pate
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). 2017
Cancer Discov. -
Kim JE, Jang JS, Kim JW, Lee SY, Cho CH, Lee MA, Kim DJ, Ahn MJ, Lee KY, Sym SJ, Lim MC, Jung H, Kim CE, Min KW.
Erratum to: Efficacy and safety of aprepitant for the prevention of chemotherapy-induced nausea and vomiting during the first cycle of moderately emetogenic chemotherapy in Korean patients with a broad range of tumor types. 2017
Support Care Cancer. -
Kim KW, Kim HK, Kim J, Shim YM, Ahn MJ, Choi YL.
Outcomes of Curative-Intent Surgery and Adjuvant Treatment for Pulmonary Large Cell Neuroendocrine Carcinoma. 2017
World J Surg. -
Yang JC, Ahn MJ, Kim DW, Ramalingam SS, Sequist LV, Su WC, Kim SW, Kim JH, Planchard D, Felip E, Blackhall F, Haggstrom D, Yoh K, Novello S, Gold K, Hirashima T, Lin CC, Mann H, Cantarini M, Ghiorghiu S, Jänne PA.
Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component. 2017
J Clin Oncol. -
Ahn MJ, Sun JM, Lee SH, Ahn JS, Park K.
EGFR TKI combination with immunotherapy in non-small cell lung cancer. 2017
Expert Opin Drug Saf. -
Heo MH, Kim HK, Lee H, Ahn MJ.
Antineutrophil Cytoplasmic Antibody-Associated Rapid Progressive Glomerulonephritis after Pembrolizumab Treatment in Thymic Epithelial Tumor: A Case Report. 2017
J Thorac Oncol. -
Park HK, Seo Y, Choi YL, Ahn MJ, Han J.
Metastatic Squamous Cell Carcinoma from Lung Adenocarcinoma after Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy. 2017
J Pathol Transl Med. -
Lee SJ, Lee SY, Lee WS, Yoo JS, Sun JM, Lee J, Park SH, Park JO, Ahn MJ, Lim HY, Kang WK, Park YS.
Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors. 2017
Invest New Drugs. -
Lim SH, Yoh KA, Lee JS, Ahn MJ, Kim YJ, Kim SH, Zhang J, Patel D, Swallow E, Kageleiry A, Galebach P, Lee D, Stein K, Degun R, Park K.
Characteristics and outcomes of ALK+ non-small cell lung cancer patients in Korea. 2017
Asia Pac J Clin Oncol. -
Soo RA, Kubo A, Ando M, Kawaguchi T, Ahn MJ, Ou SI.
Association Between Environmental Tobacco Smoke Exposure and the Occurrence of EGFR Mutations and ALK Rearrangements in Never-smokers With Non-Small-cell Lung Cancer: Analyses From a Prospective Multinational ETS Registry. 2017
Clin Lung Cancer. -
Kim HR, Kang HN, Shim HS, Kim EY, Kim J, Kim DJ, Lee JG, Lee CY, Hong MH, Kim SM, Kim H, Pyo KH, Yun MR, Park HJ, Han JY, Youn HA, Ahn MJ, Paik S, Kim TM, Cho BC.
Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma. 2017
Ann Oncol. -
Soh SX, Siddiqui FJ, Allen JC, Kim GW, Lee JC, Yatabe Y, Soda M, Mano H, Soo RA, Chin TM, Ebi H, Yano S, Matsuo K, Niu X, Lu S, Isobe K, Lee JH, Yang JC, Zhao M, Zhou C, Lee JK, Lee SH, Lee JY, Ahn MJ, Tan TJ, Tan DS, Tan EH, Ong ST, Lim WT.
A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer. 2017
Oncotarget. -
Kim DW, Tiseo M, Ahn MJ, Reckamp KL, Hansen KH, Kim SW, Huber RM, West HL, Groen HJM, Hochmair MJ, Leighl NB, Gettinger SN, Langer CJ, Paz-Ares Rodríguez LG, Smit EF, Kim ES, Reichmann W, Haluska FG, Kerstein D, Camidge DR.
Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial. 2017
J Clin Oncol. -
Lim SM, Kim HR, Lee JS, Lee KH, Lee YG, Min YJ, Cho EK, Lee SS, Kim BS, Choi MY, Shim HS, Chung JH, La Choi Y, Lee MJ, Kim M, Kim JH, Ali SM, Ahn MJ, Cho BC.
Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement. 2017
J Clin Oncol. -
Soo RA, Stone ECA, Cummings KM, Jett JR, Field JK, Groen HJM, Mulshine JL, Yatabe Y, Bubendorf L, Dacic S, Rami-Porta R, Detterbeck FC, Lim E, Asamura H, Donington J, Wakelee HA, Wu YL, Higgins K, Senan S, Solomon B, Kim DW, Johnson M, Yang JCH, Sequist LV, Shaw AT, Ahn MJ, Costa DB, Patel JD, Horn
Scientific Advances in Thoracic Oncology 2016. 2017
J Thorac Oncol. -
Kim HK, Heo MH, Lee HS, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ.
Comparison of RECIST to immune-related response criteria in patients with non-small cell lung cancer treated with immune-checkpoint inhibitors. 2017
Cancer Chemother Pharmacol. -
Ku BM, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ.
An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer. 2017
Expert Rev Mol Diagn. -
Sun JM, Noh JM, Oh D, Kim HK, Lee SH, Choi YS, Pyo H, Ahn JS, Jung SH, Ahn YC, Kim J, Ahn MJ, Zo JI, Shim YM, Park K.
Randomized Phase II Trial Comparing Chemoradiotherapy with Chemotherapy for Completely Resected Unsuspected N2-Positive Non-Small Cell Lung Cancer. 2017
J Thorac Oncol. -
Mok TSK, Kim SW, Wu YL, Nakagawa K, Yang JJ, Ahn MJ, Wang J, Yang JC, Lu Y, Atagi S, Ponce S, Shi X, Rukazenkov Y, Haddad V, Thress KS, Soria JC.
Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses. 2017
J Clin Oncol. -
Ku BM, Bae YH, Koh J, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ.
Mutational status of TP53 defines the efficacy of Wee1 inhibitor AZD1775 in KRAS-mutant non-small cell lung cancer. 2017
Oncotarget. -
Shin SW, Lee BS, Yang K, Amornkitbamrung L, Jang MS, Ku BM, Cho SW, Lee JH, Bae H, Oh BK, Ahn MJ, Lim YT, Um SH.
Fluorescence-coded DNA Nanostructure Probe System to Enable Discrimination of Tumor Heterogeneity via a Screening of Dual Intracellular microRNA Signatures in situ. 2017
Sci Rep. -
Park SE, Lee SH, Ahn JS, Ahn MJ, Park K, Sun JM.
Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer. 2017
J Thorac Oncol. -
Cho JH, Ku BM, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ.
KIF5B-MET Gene Rearrangement with Robust Antitumor Activity in Response to Crizotinib in Lung Adenocarcinoma. 2017
J Thorac Oncol. -
Shin HT, Choi YL, Yun JW, Kim NKD, Kim SY, Jeon HJ, Nam JY, Lee C, Ryu D, Kim SC, Park K, Lee E, Bae JS, Son DS, Joung JG, Lee J, Kim ST, Ahn MJ, Lee SH, Ahn JS, Lee WY, Oh BY, Park YH, Lee JE, Lee KH, Kim HC, Kim KM, Im YH, Park K, Park PJ, Park WY.
Prevalence and detection of low-allele-fraction variants in clinical cancer samples. 2017
Nat Commun. -
Yu HA, Ahn MJ, Cho BC, Gerber DE, Natale RB, Socinski MA, Giri N, Quinn S, Sbar E, Zhang H, Giaccone G.
Phase 2 study of intermittent pulse dacomitinib in patients with advanced non-small cell lung cancers. 2017
Lung Cancer. -
Han KY, Kim KT, Joung JG, Son DS, Kim YJ, Jo A, Jeon HJ, Moon HS, Yoo CE, Chung W, Eum HH, Kim S, Kim HK, Lee JE, Ahn MJ, Lee HO, Park D, Park WY.
SIDR: simultaneous isolation and parallel sequencing of genomic DNA and total RNA from single cells. 2017
Genome Res. -
Ahn MJ.
Cell-free DNA Analysis in SCLC: Ready for Clinical Practice? 2018
J Thorac Oncol. -
Lee J, Kim HK, Park BJ, Cho JH, Choi YS, Zo JI, Shim YM, Pyo H, Ahn YC, Ahn JS, Ahn MJ, Park K, Kim J.
Recurrence dynamics after trimodality therapy (Neoadjuvant concurrent chemoradiotherapy and surgery) in patients with stage IIIA (N2) lung cancer. 2018
Lung Cancer. -
Goss G, Tsai CM, Shepherd FA, Ahn MJ, Bazhenova L, Crinò L, de Marinis F, Felip E, Morabito A, Hodge R, Cantarini M, Johnson M, Mitsudomi T, Jänne PA, Yang JC.
CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials. 2018
Ann Oncol. -
Kim HI, Kim M, Lee SH, Park SY, Kim YN, Kim H, Jeon MJ, Kim TY, Kim SW, Kim WB, Kim SW, Lee DH, Park K, Ahn MJ, Chung JH, Shong YK, Kim WG, Kim TH.
Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer. 2017
Oncoimmunology. -
Tan EH, Lim WT, Ahn MJ, Ng QS, Ahn JS, Shao-Weng Tan D, Sun JM, Han M, Payumo FC, McKee K, Yin W, Credi M, Agarwal S, Jac J, Park K.
Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC. 2018
Clin Pharmacol Drug Dev. -
Sun JM, Lee KH, Kim BS, Kim HG, Min YJ, Yi SY, Yun HJ, Jung SH, Lee SH, Ahn JS, Park K, Ahn MJ.
extensive disease small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase II study (KCSG-LU12-07). 2018
Br J Cancer. -
Park BJ, Cho JH, Lee JH, Shin S, Kim HK, Choi YS, Zo JI, Shim YM, Sun JM, Lee SH, Ahn JS, Ahn MJ, Park K, Kim J.
Temporal and regional distribution of initial recurrence site in completely resected N1-stage II lung adenocarcinoma: The effect of postoperative adjuvant chemotherapy. 2018
Lung Cancer. -
Lee J, Kim ST, Park S, Lee S, Park SH, Park JO, Lim HY, Ahn H, Bok H, Kim KM, Ahn MJ, Kang WK, Park YS.
Phase I Trial of Anti-MET Monoclonal Antibody in MET-Overexpressed Refractory Cancer. 2018
Clin Colorectal Cancer. -
Ku BM, Heo MH, Kim JH, Cho BC, Cho EK, Min YJ, Lee KH, Sun JM, Lee SH, Ahn JS, Park K, Kim TJ, Lee HY, Kim H, Lee KJ, Ahn MJ.
Molecular Screening of Small Biopsy Samples Using Next-Generation Sequencing in Korean Patients with Advanced Non-small Cell Lung Cancer: Korean Lung Cancer Consortium (KLCC-13-01). 2018
J Pathol Transl Med. -
Wu YL, Yang JC, Kim DW, Lu S, Zhou J, Seto T, Yang JJ, Yamamoto N, Ahn MJ, Takahashi T, Yamanaka T, Kemner A, Roychowdhury D, Paolini J, Usari T, Wilner KD, Goto K.
Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer. 2018
J Clin Oncol. -
Chung JW, Cho YH, Ahn MJ, Lee MJ, Kim GM, Chung CS, Bang OY.
Association of Cancer Cell Type and Extracellular Vesicles With Coagulopathy in Patients With Lung Cancer and Stroke. 2018
Stroke. -
Ku BM, Choi MK, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ.
Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical model. 2018
PLoS One. -
Choi MK, Ahn JS, Kim YC, Cho BC, Oh IJ, Kim SW, Lee JS, Kim JH, Ahn MJ, Park K.
Afatinib in heavily pretreated advanced NSCLC patients who progressed following prior gefitinib or erlotinib: Compassionate use program in Korea. 2018
Lung Cancer. -
Ahn MJ.
Consolidation of immunotherapy becomes new standard of care in unresectable stage III non-small cell lung cancer. 2018
J Thorac Dis. -
Lim SM, Cho SH, Hwang IG, Choi JW, Chang H, Ahn MJ, Park KU, Kim JW, Ko YH, Ahn HK, Cho BC, Nam BH, Chun SH, Hong JH, Kwon JH, Choi JG, Kang EJ, Yun T, Lee KW, Kim JH, Kim JS, Lee HW, Kim MK, Jung D, Kim JE, Keam B, Yun HJ, Kim S, Kim HR.
Investigating the Feasibility of Targeted Next-Generation Sequencing to Guide the Treatment of Head and Neck Squamous Cell Carcinoma. 2018
Cancer Res Treat. -
Camidge DR, Kim DW, Tiseo M, Langer CJ, Ahn MJ, Shaw AT, Huber RM, Hochmair MJ, Lee DH, Bazhenova LA, Gold KA, Ou SI, West HL, Reichmann W, Haney J, Clackson T, Kerstein D, Gettinger SN.
Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials. 2018
J Clin Oncol. -
Lee H, Lee HY, Sun JM, Lee SH, Kim Y, Park SE, Ahn JS, Park K, Ahn MJ.
Transient Asymptomatic Pulmonary Opacities During Osimertinib Treatment and its Clinical Implication. 2018
J Thorac Oncol. -
Lee J, Shim JH, Park WY, Kim HK, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ.
Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-mutated Non-small Cell Lung Cancer. 2018
Cancer Res Treat. -
Park S, Ahn BC, Lim SW, Sun JM, Kim HR, Hong MH, Lee SH, Ahn JS, Park K, Choi Y, Cho BC, Ahn MJ.
Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice. 2018
J Thorac Oncol. -
Lee SW, Park H, Lee HY, Sohn I, Lee SH, Kang J, Sun JM, Ahn MJ.
Deciphering Clinicoradiologic Phenotype for Thymidylate Synthase Expression Status in Patients with Advanced Lung Adenocarcinoma Using a Radiomics Approach. 2018
Sci Rep. -
Kim Y, Lee SH, Ahn JS, Ahn MJ, Park K, Sun JM.
Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib. 2018
Cancer Res Treat. -
Cho J, Kim HS, Ku BM, Choi YL, Cristescu R, Han J, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ.
Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial. 2018
J Clin Oncol. -
Kim MJ, Kim SM, Jung HA, Hong JY, Chang WJ, Choi MK, Kim HS, Sun JM, Park K, Ahn MJ.
Efficacy and safety of cisplatin and weekly docetaxel in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. 2018
Korean J Intern Med. -
Park SE, Noh JM, Kim YJ, Lee HS, Cho JH, Lim SW, Ahn YC, Pyo H, Choi YL, Han J, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ.
EGFR Mutation is Associated with Short Progression Free Survival in Patients with Stage III Non-Squamous Cell Lung Cancer Treated with Concurrent Chemoradiotherapy. 2018
Cancer Res Treat. -
Byeon S, Kim Y, Lim SW, Cho JH, Park S, Lee J, Sun JM, Choi YL, Lee SH, Ahn JS, Park K, Ahn MJ.
Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea. 2018
Cancer Res Treat. -
Wu YL, Ahn MJ, Garassino MC, Han JY, Katakami N, Kim HR, Hodge R, Kaur P, Brown AP, Ghiorghiu D, Papadimitrakopoulou VA, Mok TSK.
CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3). 2018
J Clin Oncol. -
Drilon A, Ou SI, Cho BC, Kim DW, Lee J, Lin JJ, Zhu VW, Ahn MJ, Camidge DR, Nguyen J, Zhai D, Deng W, Huang Z, Rogers E, Liu J, Whitten J, Lim JK, Stopatschinskaja S, Hyman DM, Doebele RC, Cui JJ, Shaw AT.
Repotrectinib (TPX-0005) is a next generation ROS1/TRK/ALK inhibitor that potently inhibits ROS1/TRK/ALK solvent front mutations. 2018
Cancer Discov. -
Moon SH, Kim J, Joung JG, Cha H, Park WY, Ahn JS, Ahn MJ, Park K, Choi JY, Lee KH, Kim BT, Lee SH.
Correlations between metabolic texture features, genetic heterogeneity, and mutation burden in patients with lung cancer. 2018
Eur J Nucl Med Mol Imaging. -
Wu YL, Zhang L, Kim DW, Liu X, Lee DH, Yang JC, Ahn MJ, Vansteenkiste JF, Su WC, Felip E, Chia V, Glaser S, Pultar P, Zhao S, Peng B, Akimov M, Tan DSW.
Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer. 2018
J Clin Oncol. -
Yoo KH, Lee SJ, Cho J, Lee KH, Park KU, Kim KH, Cho EK, Choi YH, Kim HR, Kim HG, Ahn HJ, Lee HY, Yun HJ, Kang JH, Jeong J, Choi MY, Jung SH, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ.
A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13. 2018
Cancer Res Treat. -
Lee KH, Ahn YC, Pyo H, Noh JM, Park SG, Kim TG, Lee E, Nam H, Lee H, Sun JM, Ahn JS, Ahn MJ, Park K.
Salvage Concurrent Chemo-radiation Therapy for Loco-regional Recurrence Following Curative Surgery of Non-small Cell Lung Cancer. 2018
Cancer Res Treat. -
Lim SW, Park S, Kim Y, Cho JH, Park SE, Lee H, Kim HK, Kim SM, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ.
Continuation of gefitinib beyond progression in patients with EGFR mutation-positive non-small-cell lung cancer: A phase II single-arm trial. 2018
Lung Cancer. -
Camidge DR, Kim HR, Ahn MJ, Yang JC, Han JY, Lee JS, Hochmair MJ, Li JY, Chang GC, Lee KH, Gridelli C, Delmonte A, Garcia Campelo R, Kim DW, Bearz A, Griesinger F, Morabito A, Felip E, Califano R, Ghosh S, Spira A, Gettinger SN, Tiseo M, Gupta N, Haney J, Kerstein D, Popat S.
Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. 2018
N Engl J Med. -
Kim Y, Lee B, Shim JH, Lee SH, Park WY, Choi YL, Sun JM, Ahn JS, Ahn MJ, Park K.
Concurrent genetic alterations predict the progression to target therapy in EGFR-mutated advanced non-small cell lung cancer. 2018
J Thorac Oncol. -
Drilon A, Fu S, Patel MR, Fakih M, Wang D, Olszanski AJ, Morgensztern D, Liu SV, Cho BC, Bazhenova L, Rodriguez CP, Doebele RC, Wozniak A, Reckamp KL, Seery T, Nikolinakos P, Hu Z, Oliver J, Trone D, McArthur K, Patel R, Multani PS, Ahn MJ.
A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105. 2018
Cancer Discov. -
Cohen EEW, Soulières D, Le Tourneau C, Dinis J, Licitra L, Ahn MJ, Soria A, Machiels JP, Mach N, Mehra R, Burtness B, Zhang P, Cheng J, Swaby RF, Harrington KJ; KEYNOTE-040 investigators.
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. 2019
Lancet. -
Ahn MJ, Tsai CM, Shepherd FA, Bazhenova L, Sequist LV, Hida T, Yang JCH, Ramalingam SS, Mitsudomi T, Jänne PA, Mann H, Cantarini M, Goss G.
Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies. 2019
Cancer. -
Moon SH, Sun JM, Ahn JS, Park K, Ahn MJ, Choi JY.
Pretreatment Tumor 18F-FDG Uptake Improves Risk Stratification Beyond RECIST 1.1 in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer: FDG Uptake and Risk Stratification. 2019
Clin Nucl Med. -
Kim H, Oh D, Ahn YC, Park K, Ahn MJ, Lee SH, Sun JM, Shim YM, Zo JI, Choi YS, Kim HK, Cho JH.
Clinical outcomes of radiation therapy for clinical T4b oesophageal cancer with airway invasion. 2018
Radiat Oncol. -
Lim SW, Ahn MJ.
Current status of immune checkpoint inhibitors in treatment of non-small cell lung cancer. 2019
Korean J Intern Med. -
Kim KH, Cho J, Ku BM, Koh J, Sun JM, Lee SH, Ahn JS, Cheon J, Min YJ, Park SH, Park K, Ahn MJ, Shin EC.
The First-week Proliferative Response of Peripheral Blood PD-1+CD8+ T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors. 2019
Clin Cancer Res. -
Herbst RS, Baas P, Perez-Gracia JL, Felip E, Kim DW, Han JY, Molina JR, Kim JH, Dubos Arvis C, Ahn MJ, Majem M, Fidler MJ, Surmont V, de Castro G, Garrido M, Shentu Y, Emancipator K, Samkari A, Jensen EH, Lubiniecki GM, Garon EB.
Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial. 2019
Ann Oncol. -
Lee J, Sun JM, Lee SH, Ahn JS, Park K, Choi Y, Ahn MJ.
Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor. 2019
Clin Lung Cancer. -
Nam BD, Kim TJ, Park K, Ahn MJ, Choi YL, Chung MJ, Kim TS, Lee KS.
Transthoracic Rebiopsy for Mutation Analysis in Lung Adenocarcinoma: Outcomes and Risk Factors for the Acquisition of Nondiagnostic Specimens in 199 Patients. 2019
Clin Lung Cancer. -
Barlesi F, Garon EB, Kim DW, Felip E, Han JY, Kim JH, Ahn MJ, Fidler MJ, Gubens MA, de Castro G Jr, Surmont V, Li Q, Deitz AC, Lubiniecki GM, Herbst RS.
Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC. 2019
Thorac Oncol. -
Jung KH, LoRusso P, Burris H, Gordon M, Bang YJ, Hellmann MD, Cervantes A, de Olza MO, Marabelle A, Hodi FS, Ahn MJ, Emens LA, Barlesi F, Hamid O, Calvo E, McDermott D, Soliman H, Rhee I, Lin R, Pourmohamad T, Suchomel J, Tsuhako A, Morrissey K, Mahrus S, Morley R, Pirzkall A, Davis SL.
se I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors. 2019
Clin Cancer Res. -
Yang B, Lee H, Um SW, Kim K, Zo JI, Shim YM, Jung Kwon O, Lee KS, Ahn MJ, Kim H.
Incidence of brain metastasis in lung adenocarcinoma at initial diagnosis on the basis of stage and genetic alterations. 2019
Lung Cancer. -
Shin SH, Park HY, Im Y, Jung HA, Sun JM, Ahn JS, Ahn MJ, Park K, Lee HY, Lee SH.
Improved treatment outcome of pembrolizumab in patients with nonsmall cell lung cancer and chronic obstructive pulmonary disease. 2019
Int J Cancer. -
Leighl NB, Hellmann MD, Hui R, Carcereny E, Felip E, Ahn MJ, Eder JP, Balmanoukian AS, Aggarwal C, Horn L, Patnaik A, Gubens M, Ramalingam SS, Lubiniecki GM, Zhang J, Piperdi B, Garon EB.
Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study. 2019
Lancet Respir Med. -
Cho JH, Jung HA, Lee SH, Ahn JS, Ahn MJ, Park K, Sun JM.
act of EGFR mutation on the clinical efficacy of PD-1 inhibitors in patients with pulmonary adenocarcinoma. 2019
J Cancer Res Clin Oncol. -
Cho WK, Oh D, Kim HK, Ahn YC, Noh JM, Shim YM, Zo JI, Choi YS, Sun JM, Lee SH, Ahn MJ, Park K, Nam H.
neoadjuvant chemoradiotherapy and surgery. 2019
Radiother Oncol. -
Remon J, Ahn MJ, Girard N, Johnson M, Kim DW, Lopes G, Pillai RN, Solomon B, Villacampa G, Zhou Q.
Advanced-Stage Non-Small Cell Lung Cancer: Advances in Thoracic Oncology 2018. 2019
J Thorac Oncol. -
Ahn MJ.
Combination of Osimertinib with Durvalumab in Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer: Is There Room for Reinvestigation? 2019
J Thorac Oncol. -
Park E, Choi YL, Ahn MJ, Han J.
Histopathologic characteristics of advanced-stage ROS1-rearranged non-small cell lung cancers. 2019
Pathol Res Pract. -
Park S, Joung JG, Min YW, Nam JY, Ryu D, Oh D, Park WY, Lee SH, Choi Y, Ahn JS, Ahn MJ, Park K, Sun JM.
Paired whole exome and transcriptome analyses for the Immunogenomic changes during concurrent chemoradiotherapy in esophageal squamous cell carcinoma. 2019
J Immunother Cancer. -
Ku BM, Bae YH, Lee KY, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ.
Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer. 2019
Invest New Drugs. -
Park S, Lee H, Lee B, Lee SH, Sun JM, Park WY, Ahn JS, Ahn MJ, Park K.
A Damage Response and Repair Pathway Alteration and Its Association With Tumor Mutation Burden and Platinum-Based Chemotherapy in SCLC. 2019
J Thorac Oncol. -
Garon EB, Hellmann MD, Rizvi NA, Carcereny E, Leighl NB, Ahn MJ, Eder JP, Balmanoukian AS, Aggarwal C, Horn L, Patnaik A, Gubens M, Ramalingam SS, Felip E, Goldman JW, Scalzo C, Jensen E, Kush DA, Hui R.
Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. 2019
J Clin Oncol. -
Kim Y, Kim CH, Lee HY, Lee SH, Kim HS, Lee S, Cha H, Hong S, Kim K, Seo SW, Sun JM, Ahn MJ, Ahn JS, Park K.
Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor. 2019
J Thorac Oncol. -
Bak SH, Park H, Sohn I, Lee SH, Ahn MJ, Lee HY.
Prognostic Impact of Longitudinal Monitoring of Radiomic Features in Patients with Advanced Non-Small Cell Lung Cancer. 2019
Sci Rep. -
Antonia SJ, Balmanoukian A, Brahmer J, Ou SI, Hellmann MD, Kim SW, Ahn MJ, Kim DW, Gutierrez M, Liu SV, Schöffski P, Jäger D, Jamal R, Jerusalem G, Lutzky J, Nemunaitis J, Calabrò L, Weiss J, Gadgeel S, Bhosle J, Ascierto PA, Rebelatto MC, Narwal R, Liang M, Xiao F, Antal J, Abdullah S, Angra N, Gup
Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC. 2019
J Thorac Oncol. -
Park S, Shim JH, Lee B, Cho I, Park WY, Kim Y, Lee SH, Choi Y, Han J, Ahn JS, Ahn MJ, Park K, Sun JM.
Paired genomic analysis of squamous cell carcinoma transformed from EGFR-mutated lung adenocarcinoma. 2019
Lung Cancer. -
Ahn MJ, Han JY, Kim DW, Cho BC, Kang JH, Kim SW, Yang JC, Mitsudomi T, Lee JS.
Osimertinib in Patients with T790M Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies. 2019
Cancer Res Treat. -
Bang OY, Chung JW, Cho YH, Oh MJ, Seo WK, Kim GM, Ahn MJ.
Circulating DNAs, a Marker of Neutrophil Extracellular Traposis and Cancer-Related Stroke: The OASIS-Cancer Study. 2019
Stroke. -
Moon SH, Sun JM, Ahn JS, Park K, Kim BT, Lee KH, Ahn MJ, Choi JY.
Predictive and Prognostic Value of 18F-fluorodeoxyglucose Uptake Combined with Thymidylate Synthase Expression in Patients with Advanced Non-Small Cell Lung Cancer. 2019
Sci Rep. -
Kim HS, Cha H, Kim J, Park WY, Choi YL, Sun JM, Ahn JS, Ahn MJ, Park K, Lee SH.
Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing. 2019
Eur J Cancer. -
Jung H, Kim HS, Kim JY, Sun JM, Ahn JS, Ahn MJ, Park K, Esteller M, Lee SH, Choi JK.
DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load. 2019
Nat Commun. -
Kato K, Cho BC, Takahashi M, Okada M, Lin CY, Chin K, Kadowaki S, Ahn MJ, Hamamoto Y, Doki Y, Yen CC, Kubota Y, Kim SB, Hsu CH, Holtved E, Xynos I, Kodani M, Kitagawa Y.
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. 2019
Lancet Oncol. -
Ahn MJ, Han JY, Lee KH, Kim SW, Kim DW, Lee YG, Cho EK, Kim JH, Lee GW, Lee JS, Min YJ, Kim JS, Lee SS, Kim HR, Hong MH, Ahn JS, Sun JM, Kim HT, Lee DH, Kim S, Cho BC.
Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study. 2019
Lancet Oncol. -
Tan WL, Chua KLM, Lin CC, Lee VHF, Tho LM, Chan AW, Ho GF, Reungwetwattana T, Yang JC, Kim DW, Soo RA, Ahn YC, Onishi H, Ahn MJ, Mok TSK, Tan DSW, Yang F.
Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC. Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC. 2020
J Thorac Oncol. -
Huber RM, Hansen KH, Paz-Ares Rodríguez L, West HL, Reckamp KL, Leighl NB, Tiseo M, Smit EF, Kim DW, Gettinger SN, Hochmair MJ, Kim SW, Langer CJ, Ahn MJ, Kim ES, Kerstein D, Groen HJM, Camidge DR.
Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial. 2020
J Thorac Oncol. -
Papadimitrakopoulou VA, Han JY, Ahn MJ, Ramalingam SS, Delmonte A, Hsia TC, Laskin J, Kim SW, He Y, Tsai CM, Hida T, Maemondo M, Kato T, Jenkins S, Patel S, Huang X, Laus G, Markovets A, Thress KS, Wu YL, Mok T.
Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer. 2020
Cancer. -
Yang JCH, Kim SW, Kim DW, Lee JS, Cho BC, Ahn JS, Lee DH, Kim TM, Goldman JW, Natale RB, Brown AP, Collins B, Chmielecki J, Vishwanathan K, Mendoza-Naranjo A, Ahn MJ.
Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study. 2020
J Clin Oncol. -
Drilon A, Siena S, Dziadziuszko R, Barlesi F, Krebs MG, Shaw AT, de Braud F, Rolfo C, Ahn MJ, Wolf J, Seto T, Cho BC, Patel MR, Chiu CH, John T, Goto K, Karapetis CS, Arkenau HT, Kim SW, Ohe Y, Li YC, Chae YK, Chung CH, Otterson GA, Murakami H, Lin CC, Tan DSW, Prenen H, Riehl T, Chow-Maneval E, Sim
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. 2020
Lancet Oncol. -
Byeon S, Lee B, Park WY, Choi YL, Jung HA, Sun JM, Ahn JS, Ahn MJ, Park K, Lee SH.
Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests. 2020
Clin Lung Cancer. -
Shin HT, Kim NKD, Yun JW, Lee B, Kyung S, Lee KW, Ryu D, Kim J, Bae JS, Park D, Choi YL, Lee SH, Ahn MJ, Park K, Park WY.
Junction Location Identifier (JuLI): Accurate Detection of DNA Fusions in Clinical Sequencing for Precision Oncology. 2020
J Mol Diagn. -
Lee T, Cho J, Baek CH, Son YI, Jeong HS, Chung MK, Hong SD, Ahn YC, Oh DR, Noh JM, Park K, Ahn MJ, Kim HJ, Kim YK, Ko YH.
Prevalence of NUT carcinoma in head and neck: Analysis of 362 cases with literature review. 2020
Head Neck. -
Shin S, Choi YS, Jung JJ, Im Y, Shin SH, Kang D, Cho JH, Kim HK, Kim J, Zo JI, Shim YM, Park K, Ahn MJ, Ahn YC, Lee G, Cho J, Lee HY, Park HY.
Impact of diffusing lung capacity before and after neoadjuvant concurrent chemoradiation on postoperative pulmonary complications among patients with stage IIIA/N2 non-small-cell lung cancer. 2020
Respir Res. -
Sequist LV, Han JY, Ahn MJ, Cho BC, Yu H, Kim SW, Yang JC, Lee JS, Su WC, Kowalski D, Orlov S, Cantarini M, Verheijen RB, Mellemgaard A, Ottesen L, Frewer P, Ou X, Oxnard G.
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. 2020
Lancet Oncol. -
Lim JH, Choi JY, Im Y, Yoo H, Jhun BW, Jeong BH, Park HY, Lee K, Kim H, Kwon OJ, Han J, Ahn MJ, Kim J, Um SW.
Prognostic value of SUVmax on 18F-fluorodeoxyglucose PET/CT scan in patients with malignant pleural mesothelioma. 2020
PLoS One. -
Kim K, Kim HS, Kim JY, Jung H, Sun JM, Ahn JS, Ahn MJ, Park K, Lee SH, Choi JK.
Predicting clinical benefit of immunotherapy by antigenic or functional mutations affecting tumour immunogenicity. 2020
Nat Commun. -
Kim KH, Hur JY, Cho J, Ku BM, Koh J, Koh JY, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ, Shin EC.
Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment. 2020
Oncoimmunology. -
Lee J, Ku BM, Shim JH, La Choi Y, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ.
Characteristics and outcomes of RET-rearranged Korean non-small cell lung cancer patients in real-world practice. 2020
Jpn J Clin Oncol. -
Lee J, Kim HS, Lee B, Kim HK, Sun JM, Ahn JS, Ahn MJ, Park K, Lee SH.
Genomic landscape of acquired resistance to third-generation EGFR tyrosine kinase inhibitors in EGFR T790M-mutant non-small cell lung cancer. 2020
Cancer. -
Lim SH, Sun JM, Hong J, Oh D, Ahn YC, Chung MK, Jeong HS, Son YI, Ahn MJ, Baek CH, Park K.
Induction chemotherapy followed by concurrent chemoradiotherapy versus CCRT for locally advanced hypopharynx and base of tongue cancer. 2020
Korean J Intern Med. -
Rizvi NA, Cho BC, Reinmuth N, Lee KH, Luft A, Ahn MJ, van den Heuvel MM, Cobo M, Vicente D, Smolin A, Moiseyenko V, Antonia SJ, Le Moulec S, Robinet G, Natale R, Schneider J, Shepherd FA, Geater SL, Garon EB, Kim ES, Goldberg SB, Nakagawa K, Raja R, Higgs BW, Boothman AM, Zhao L, Scheuring U, Stockm
Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial. 2020
JAMA Oncol. -
Shim JH, Kim HS, Cha H, Kim S, Kim TM, Anagnostou V, Choi YL, Jung HA, Sun JM, Ahn JS, Ahn MJ, Park K, Park WY, Lee SH.
HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients. 2020
Ann Oncol. -
Kim KH, Kim HK, Kim HD, Kim CG, Lee H, Han JW, Choi SJ, Jeong S, Jeon M, Kim H, Koh J, Ku BM, Park SH, Ahn MJ, Shin EC.
PD-1 blockade-unresponsive human tumor-infiltrating CD8+ T cells are marked by loss of CD28 expression and rescued by IL-15. 2020
Cell Mol Immunol. -
Hur JY, Ku BM, Shim JH, Jung HA, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ.
Characteristics and Clinical Outcomes of Non-small Cell Lung Cancer Patients in Korea With MET Exon 14 Skipping. 2020
In Vivo. -
Byeon S, Cho JH, Jung HA, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ.
PD-1 Inhibitors for Non-Small Cell Lung Cancer Patients With Special Issues: Real-world Evidence. 2020
Cancer Med. -
Kim K, Kim HS, Kim JY, Jung H, Sun JM, Ahn JS, Ahn MJ, Park K, Lee SH, Choi JK.
Predicting Clinical Benefit of Immunotherapy by Antigenic or Functional Mutations Affecting Tumour Immunogenicity. 2020
Nat Commun. -
Lee J, Choi Y, Jung HA, Lee SH, Ahn JS, Ahn MJ, Park K, Sun JM. Lee J, et al.
Outstanding Clinical Efficacy of PD-1/PD-L1 Inhibitors for Pulmonary Pleomorphic Carcinoma. 2020
Eur J Cancer. -
Bang OY, Chung JW, Lee MJ, Seo WK, Kim GM, Ahn MJ; OASIS-Cancer Study Investigators.
Cancer-Related Stroke: An Emerging Subtype of Ischemic Stroke With Unique Pathomechanisms 2020
J Stroke. -
Dingemans AC, Soo RA, Jazieh AR, Rice SJ, Kim YT, Teo LLS, Warren GW, Xiao SY, Smit EF, Aerts JG, Yoon SH, Veronesi G, De Cobelli F, Ramalingam SS, Garassino MC, Wynes MW, Behera M, Haanen J, Lu S, Peters S, Ahn MJ, Scagliotti GV, Adjei AA, Belani CP.
Treatment Guidance for Patients With Lung Cancer During the Coronavirus 2019 Pandemic. 2020
J Thorac Oncol. -
Papadimitrakopoulou VA, Han JY, Ahn MJ, Ramalingam SS, Delmonte A, Hsia TC, Laskin J, Kim SW, He Y, Tsai CM, Hida T, Maemondo M, Kato T, Jenkins S, Patel S, Huang X, Laus G, Markovets A, Thress KS, Wu YL, Mok T. Papadimitrakopoulou VA, et al.
Epidermal Growth Factor Receptor Mutation Analysis in Tissue and Plasma From the AURA3 Trial: Osimertinib Versus Platinum-Pemetrexed for T790M Mutation-Positive Advanced Non-Small Cell Lung Cancer 2020
Cancer. -
Ahn MJ, Chiu CH, Cheng Y, Han JY, Goldberg SB, Greystoke A, Crawford J, Zhao Y, Huang X, Johnson M, Vishwanathan K, Yates JWT, Brown AP, Mendoza-Naranjo A, Mok T.
Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis. 2020
J Thorac Oncol. -
Oxnard GR, Yang JC, Yu H, Kim SW, Saka H, Horn L, Goto K, Ohe Y, Mann H, Thress KS, Frigault MM, Vishwanathan K, Ghiorghiu D, Ramalingam SS, Ahn MJ.
TATTON: A Multi-Arm, Phase Ib Trial of Osimertinib Combined With Selumetinib, Savolitinib, or Durvalumab in EGFR-mutant Lung Cancer 2020
Ann Oncol. -
Kim N, Kim HK, Lee K, Hong Y, Cho JH, Choi JW, Lee JI, Suh YL, Ku BM, Eum HH, Choi S, Choi YL, Joung JG, Park WY, Jung HA, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ, Lee HO.Kim N, et al.
Single-cell RNA Sequencing Demonstrates the Molecular and Cellular Reprogramming of Metastatic Lung Adenocarcinoma. 2020
Nat Commun. -
Tan WL, Chua KLM, Lin CC, Lee VHF, Tho LM, Chan AW, Ho GF, Reungwetwattana T, Yang JC, Kim DW, Soo RA, Ahn YC, Onishi H, Ahn MJ, Mok TSK, Tan DSW, Yang F.Tan WL, et al.
Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC. 2020
J Thorac Oncol. -
Yang JCH, Kim SW, Kim DW, Lee JS, Cho BC, Ahn JS, Lee DH, Kim TM, Goldman JW, Natale RB, Brown AP, Collins B, Chmielecki J, Vishwanathan K, Mendoza-Naranjo A, Ahn MJ.
Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study.. 2020
J Clin Oncol. -
Kim KH, Lim SM, Ahn HK, Lee YG, Lee KW, Ahn MJ, Keam B, Kim HR, Lee HW, An HJ, Kim JS
A Phase II Trial of Nintedanib in Patients with Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC): In-Depth Analysis of Nintendanib Arm from the KCSG HN 15-16 TRIUMPH Trial 2023
Cancer Res Treat. -
Remon J, Passiglia F, Ahn MJ, Barlesi F, Forde PM, Garon EB, Gettinger S, Goldberg SB, Herbst RS, Horn L, Kubota K, Lu S, Mezquita L, Paz-Ares L, Popat S, Schalper KA, Skoulidis F, Reck M, Adjei AA, Scagliotti GV.
Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations. 2020
J Thorac Oncol. -
Huber RM, Hansen KH, Paz-Ares Rodríguez L, West HL, Reckamp KL, Leighl NB, Tiseo M, Smit EF, Kim DW, Gettinger SN, Hochmair MJ, Kim SW, Langer CJ, Ahn MJ, Kim ES, Kerstein D, Groen HJM, Camidge DR.
Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial. 2020
J Thorac Oncol. -
Cho JH, Lim SH, An HJ, Kim KH, Park KU, Kang EJ, Choi YH, Ahn MS, Lee MH, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ.
Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09). 2020
J Clin Oncol. -
Byeon S, Lee B, Park WY, Choi YL, Jung HA, Sun JM, Ahn JS, Ahn MJ, Park K, Lee SH.
Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests. 2020
Clin Lung Cancer. -
Jung H, Kim HS, Kim JY, Sun JM, Ahn JS, Ahn MJ, Park K, Esteller M, Lee SH, Choi JK.
DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load. 2019
Nat Commun. -
Kim K, Kim HS, Kim JY, Jung H, Sun JM, Ahn JS, Ahn MJ, Park K, Lee SH, Choi JK.
Predicting clinical benefit of immunotherapy by antigenic or functional mutations affecting tumour immunogenicity. 2020
Nat Commun. -
Lee J, Kim HS, Lee B, Kim HK, Sun JM, Ahn JS, Ahn MJ, Park K, Lee SH.
Genomic landscape of acquired resistance to third-generation EGFR tyrosine kinase inhibitors in EGFR T790M-mutant non-small cell lung cancer. 2020
Cancer. -
Lim SH, Sun JM, Hong J, Oh D, Ahn YC, Chung MK, Jeong HS, Son YI, Ahn MJ, Baek CH, Park K.
Induction chemotherapy followed by concurrent chemoradiotherapy versus CCRT for locally advanced hypopharynx and base of tongue cancer. 2020
Korean J Intern Med. -
Shim JH, Kim HS, Cha H, Kim S, Kim TM, Anagnostou V, Choi YL, Jung HA, Sun JM, Ahn JS, Ahn MJ, Park K, Park WY, Lee SH.
HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients. 2020
Ann Oncol. -
Kim KH, Kim HK, Kim HD, Kim CG, Lee H, Han JW, Choi SJ, Jeong S, Jeon M, Kim H, Koh J, Ku BM, Park SH, Ahn MJ, Shin EC.
PD-1 blockade-unresponsive human tumor-infiltrating CD8+ T cells are marked by loss of CD28 expression and rescued by IL-15. 2021
Cell Mol Immunol. -
Harrington KJ, Soulières D, Le Tourneau C, Dinis J, Licitra LF, Ahn MJ, Soria A, Machiels JH, Mach N, Mehra R, Burtness B, Ellison MC, Cheng JD, Chirovsky DR, Swaby RF, Cohen EEW.
Quality of Life With Pembrolizumab for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040. 2020
J Natl Cancer Inst. -
Lim SM, Kim SW, Cho BC, Kang JH, Ahn MJ, Kim DW, Kim YC, Lee JS, Lee JS, Lee SY, Park KU, An HJ, Cho EK, Jang TW, Kim BS, Kim JH, Lee SS, Na II, Yoo SS, Lee KH.
Real-World Experience of Nivolumab in Non-small Cell Lung Cancer in Korea. 2020
Cancer Res Treat. -
Jung HA, Noh JM, Sun JM, Lee SH, Ahn JS, Ahn MJ, Pyo H, Ahn YC, Park K.
Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer. 2020
Lung Cancer. -
Jung HA, Sun JM, Lee SH, Ahn JS, Ahn MJ, Park K.
Ten-year patient journey of stage III non-small cell lung cancer patients: A single-center, observational, retrospective study in Korea (Realtime autOmatically updated data warehOuse in healTh care; UNIVERSE-ROOT study). 2020
Lung Cancer. -
Park S, Ku BM, Jung HA, Sun JM, Ahn JS, Lee SH, Park K, Ahn MJ.
EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation. 2020
Cancer Res Treat. -
Park S, Shim J, Mortimer PGS, Smith SA, Godin RE, Hollingsworth SJ, Kim HJ, Jung HA, Sun JM, Park WY, Ahn JS, Ahn MJ, Lee SH, Park K.
Biomarker-driven phase 2 umbrella trial study for patients with recurrent small cell lung cancer failing platinum-based chemotherapy. 2020
Cancer. -
Lee J, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ.
Are there any ethnic differences in the efficacy and safety of immune checkpoint inhibitors for treatment of lung cancer? 2020
J Thorac Dis. -
Park S, Lee MH, Seong M, Kim ST, Kang JH, Cho BC, Lee KH, Cho EK, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ.
A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy. 2020
Ann Oncol. -
Koh J, Kim Y, Lee KY, Hur JY, Kim MS, Kim B, Cho HJ, Lee YC, Bae YH, Ku BM, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ.
MDSC subtypes and CD39 expression on CD8+ T cells predict the efficacy of anti-PD-1 immunotherapy in patients with advanced NSCLC. 2020
Eur J Immunol. -
Lee J, Choi Y, Han J, Park S, Jung HA, Su JM, Lee SH, Ahn JS, Park K, Ahn MJ.
Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status. 2020
J Thorac Oncol. -
Park JH, Chun SH, Lee YG, Chang H, Lee KW, Kim HR, Shin SH, An HJ, Lee KE, Hwang IG, Ahn MJ, Kim SB, Keam B.
Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors: Korean cancer study group HN 18-12. 2020
J Cancer Res Clin Oncol. -
Lee J, Park S, Jung HA, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ.
Evaluating entrectinib as a treatment option for non-small cell lung cancer. 2020
Expert Opin Pharmacother. -
Kim H, Kwon M, Kim B, Jung HA, Sun JM, Lee SH, Park K, Ahn MJ.
Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea. 2020
BMC Cancer. -
Kim G, Kim J, Cha H, Park WY, Ahn JS, Ahn MJ, Park K, Park YJ, Choi JY, Lee KH, Lee SH, Moon SH.
Metabolic radiogenomics in lung cancer: associations between FDG PET image features and oncogenic signaling pathway alterations. 2020
Sci Rep. -
Camidge DR, Kim HR, Ahn MJ, Yang JCH, Han JY, Hochmair MJ, Lee KH, Delmonte A, García Campelo MR, Kim DW, Griesinger F, Felip E, Califano R, Spira A, Gettinger SN, Tiseo M, Lin HM, Gupta N, Hanley MJ, Ni Q, Zhang P, Popat S.
Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial. 2020
J Clin Oncol. -
Papadimitrakopoulou VA, Mok TS, Han JY, Ahn MJ, Delmonte A, Ramalingam SS, Kim SW, Shepherd FA, Laskin J, He Y, Akamatsu H, Theelen WSME, Su WC, John T, Sebastian M, Mann H, Miranda M, Laus G, Rukazenkov Y, Wu YL.
Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis. 2020
Ann Oncol. -
Kim S, Kim S, Park YS, Park JO, Lim HY, Ahn JS, Lee J, Sun JM, Kang WK, Han R, Kim J, Ahn MJ.
Phase I clinical trial of KML001 monotherapy in patients with advanced solid tumors. 2020
Expert Opin Investig Drugs. -
Ahn MJ.
Molecular Testing in Lung Cancer: Still Big Gap in Implementation for Real-World Use. 2020
J Thorac Oncol. -
Seong M, Park S, Kim ST, Park SG, Kim YK, Kim HJ, Ahn MJ.
Diagnostic accuracy of MR imaging of patients with leptomeningeal seeding from lung adenocarcinoma based on 2017 RANO proposal: added value of contrast-enhanced 2D axial T2 FLAIR. 2020
J Neurooncol. -
Park S, Ahn MJ.
Osimertinib in central nervous system progressive EGFR-mutant lung cancer: do we need to detect T790M? 2020
Ann Oncol. -
Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, Goldman JW, Laktionov K, Kim SW, Kato T, Vu HV, Lu S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Zeng L, Hodge R, Atasoy A, Rukazenkov Y, Herbst RS; ADAURA Investigators.
Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. 2020
N Engl J Med. -
Kim HR, Kang HN, Yun MR, Ju KY, Choi JW, Jung DM, Pyo KH, Hong MH, Ahn MJ, Sun JM, Kim HS, Kim J, Yoo J, Kim KR, Koh YW, Kim SH, Choi EC, Yoon SO, Shim HS, Paik S, Kim TM, Cho BC.
Mouse-human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck. 2020
Br J Cancer. -
Hong TH, Cha H, Shim JH, Lee B, Chung J, Lee C, Kim NKD, Choi YL, Hwang S, Lee Y, Park S, Jung HA, Kim JY, Park YH, Sun JM, Ahn JS, Ahn MJ, Park K, Lee SH, Park WY.
Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity. 2020
J Immunother Cancer. -
Jung HA, Woo SY, Lee SH, Ahn JS, Ahn MJ, Park K, Sun JM.
The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer. 2020
Transl Lung Cancer Res. -
Jung HA, Park S, Sun JM, Lee SH, Ahn JS, Ahn MJ, Park K.
Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: Are They Different from Those with Common EGFR Mutations? 2020
Biology (Basel). -
Lee J, Choi JY, Lim SW, Ahn MJ, Park K, Zo JI, Shim YM, Oh D, Sun JM.
Utility of positron emission-computed tomography for predicting pathological response in resectable oesophageal squamous cell carcinoma after neoadjuvant chemoradiation. 2020
Eur J Cardiothorac Surg. -
Koh J, Hur JY, Lee KY, Kim MS, Heo JY, Ku BM, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ.
Regulatory (FoxP3+) T cells and TGF-β predict the response to anti-PD-1 immunotherapy in patients with non-small cell lung cancer. 2020
Sci Rep. -
So YK, Byeon SJ, Ku BM, Ko YH, Ahn MJ, Son YI, Chung MK.
An increase of CD8+ T cell infiltration following recurrence is a good prognosticator in HNSCC. 2020
Sci Rep. -
Kim JH, Lee JW, Park K, Ahn MJ, Moon JW, Ham SY, Yi CA.
Dynamic contrast-enhanced MRI for response evaluation of non-small cell lung cancer in therapy with epidermal growth factor receptor tyrosine kinase inhibitors: a pilot study. 2020
Ann Palliat Med. -
Park JH, Chun SH, Lee YG, Chang H, Lee KW, Kim HR, Shin SH, An HJ, Lee KE, Hwang IG, Ahn MJ, Kim SB, Keam B.
Correction to: Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors: Korean cancer study group HN 18-12. 2020
J Cancer Res Clin Oncol. -
Perets R, Bar J, Rasco DW, Ahn MJ, Yoh K, Kim DW, Nagrial A, Satouchi M, Lee DH, Spigel DR, Kotasek D, Gutierrez M, Niu J, Siddiqi S, Li X, Cyrus J, Chackerian A, Chain A, Altura RA, Cho BC.
Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer. 2020
Ann Oncol. -
Lee MH, Cho KR, Choi JW, Kong DS, Seol HJ, Nam DH, Jung HA, Sun JM, Lee SH, Ahn JS, Ahn MJ, Park K, Lee JI.
Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer with Brain Metastasis : The Role of Gamma Knife Radiosurgery. 2020
J Korean Neurosurg Soc. -
Lee YG, Chang H, Keam B, Chun SH, Park J, Park KU, Shin SH, An HJ, Lee KE, Lee KW, Kim HR, Kim SB, Ahn MJ, Hwang IG.
Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12. 2020
Cancer Res Treat. -
Passaro A, Mok T, Peters S, Popat S, Ahn MJ, de Marinis F.
Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations. 2020
J Thorac Oncol. -
Kim KH, Hur JY, Koh J, Cho J, Ku BM, Koh JY, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ, Shin EC.
Immunological Characteristics of Hyperprogressive Disease in Patients with Non-small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 Abs. 2020
Immune Netw. -
Lee J, Ahn MJ.
Immune checkpoint inhibitors in driver mutation-positive nonsmall cell lung cancer: is there a role? 2021
Curr Opin Oncol. -
Ku BM, Kim Y, Lee KY, Kim SY, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ.
Tumor infiltrated immune cell types support distinct immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer. 2021
Eur J Immunol. -
Park JH, You GL, Ahn MJ, Kim SW, Hong MH, Han JY, Ock CY, Lee JS, Oh IJ, Lee SY, Kim CH, Min YJ, Choi YH, Ryu JS, Park SH, Ahn HK, Shim BY, Lee KH, Lee SY, Kim JS, Yi J, Choi SK, An H, Kang JH.
Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05. 2021
J Cancer Res Clin Oncol. -
Kim ES, Barlesi F, Mok T, Ahn MJ, Shen J, Zhang P, Ou SI.
ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib. 2021
Future Oncol. -
Ahn MJ, Chirovsky D, Kuyas H, Auclair V, Abounit S, Joo S, Shah R, Yang MH.
Global longitudinal assessment of treatment outcomes in recurrent/metastatic nasopharyngeal carcinoma: GLANCE-NPC study. 2021
Future Oncol. -
Dziadziuszko R, Krebs MG, De Braud F, Siena S, Drilon A, Doebele RC, Patel MR, Cho BC, Liu SV, Ahn MJ, Chiu CH, Farago AF, Lin CC, Karapetis CS, Li YC, Day BM, Chen D, Wilson TR, Barlesi F.
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer. 2021
J Clin Oncol. -
Kim H, Jung HA, Lee SH, Ahn JS, Ahn MJ, Park K, Sun JM.
Comprehensive evaluation of the clinical utility of plasma EGFR test in non-small cell lung cancer patients with acquired resistance to first-line EGFR inhibitors. 2021
Transl Lung Cancer Res. -
Ho AL, Brana I, Haddad R, Bauman J, Bible K, Oosting S, Wong DJ, Ahn MJ, Boni V, Even C, Fayette J, Flor MJ, Harrington K, Kim SB, Licitra L, Nixon I, Saba NF, Hackenberg S, Specenier P, Worden F, Balsara B, Leoni M, Martell B, Scholz C, Gualberto A.
Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations. 2021
J Clin Oncol. -
Garon EB, Cho BC, Reinmuth N, Lee KH, Luft A, Ahn MJ, Robinet G, Le Moulec S, Natale R, Schneider J, Shepherd FA, Garassino MC, Geater SL, Szekely ZP, Van Ngoc T, Liu F, Scheuring U, Patel N, Peters S, Rizvi NA.
Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer (MYSTIC). 2021
Clin Lung Cancer. -
Park S, Olsen S, Ku BM, Lee MS, Jung HA, Sun JM, Lee SH, Ahn JS, Park K, Choi YL, Ahn MJ.
High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program. 2021
Cancer. -
Park J, Jung HA, Shim JH, Park WY, Kim TH, Lee SH, Kim SW, Ahn MJ, Park K, Chung JH.
Multimodal treatments and outcomes for anaplastic thyroid cancer before and after tyrosine kinase inhibitor therapy: a real-world experience. 2021
Eur J Endocrinol. -
Paz-Ares L, Barlesi F, Siena S, Ahn MJ, Drilon A, Conley A, Rolfo C, Wolf J, Seto T, Doebele R, Kapre A, Chen D, McCallum S, Osborne S, Demetri G.
Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours. 2021
ESMO Open. -
Kim H, Park S, Jung HA, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ.
Long-Term Survival in Non-Small Cell Lung Cancer Patients with Metachronous Brain-Only Oligorecurrence Who Underwent Definitive Treatment. 2021
Cancer Res Treat. -
Park S, Lee C, Ku BM, Kim M, Park WY, Kim NKD, Ahn MJ.
Paired analysis of tumor mutation burden calculated by targeted deep sequencing panel and whole exome sequencing in non-small cell lung cancer. 2021
BMB Rep. -
Koh J, Kim S, Lee SN, Kim SY, Kim JE, Lee KY, Kim MS, Heo JY, Park YM, Ku BM, Sun JM, Lee SH, Ahn JS, Park K, Yang S, Ha SJ, Lim YT, Ahn MJ.
Therapeutic efficacy of cancer vaccine adjuvanted with nanoemulsion loaded with TLR7/8 agonist in lung cancer model. 2021
Nanomedicine. -
Kang EJ, Ahn MJ, Ock CY, Lee KW, Kwon JH, Yang Y, Choi YH, Kim MK, Ji JH, Yun T, Nam BH, Kim SB, Keam B.
Randomized Phase II Study of Axitinib versus Observation in Patients with Recurred or Metastatic Adenoid Cystic Carcinoma. 2021
Clin Cancer Res. -
Cho BC, Yoh K, Perets R, Nagrial A, Spigel DR, Gutierrez M, Kim DW, Kotasek D, Rasco D, Niu J, Satouchi M, Ahn MJ, Lee DH, Maurice-Dror C, Siddiqi S, Ren Y, Altura RA, Bar J.
Anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody quavonlimab in combination with pembrolizumab: Safety and efficacy from a phase I study in previously treated extensive-stage small cell lung cancer. 2021
Lung Cancer. -
Camidge DR, Kim HR, Ahn MJ, Yang JCH, Han JY, Hochmair MJ, Lee KH, Delmonte A, Garcia Campelo MR, Kim DW, Griesinger F, Felip E, Califano R, Spira AI, Gettinger SN, Tiseo M, Lin HM, Liu Y, Vranceanu F, Niu H, Zhang P, Popat S.
Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial. 2021
J Thorac Oncol. -
Park JE, Lee B, Yoon SJ, Park CM, Jung CW, Ahn MJ, Park HD, Hwang SY, Shin TG, Kang ES.
Complementary Use of Presepsin with the Sepsis-3 Criteria Improved Identification of High-Risk Patients with Suspected Sepsis. 2021
Biomedicines. -
Lee J, Ahn MJ.
Brain metastases in patients with oncogenic-driven non-small cell lung cancer: Pros and cons for early radiotherapy. 2021
Cancer Treat Rev. -
Jang SB, Kim KB, Sim S, Cho BC, Ahn MJ, Han JY, Kim SW, Lee KH, Cho EK, Haddish-Berhane N, Mehta J, Oh SW.
Cardiac Safety Assessment of Lazertinib: Findings From Patients With EGFR Mutation-Positive Advanced NSCLC and Preclinical Studies. 2021
JTO Clin Res Rep. -
Kim H, Kim DW, Kim M, Lee Y, Ahn HK, Cho JH, Kim IH, Lee YG, Shin SH, Park SE, Jung J, Kang EJ, Ahn MJ.
Long-term outcomes in patients with advanced and/or metastatic non-small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real-world data (KCSG LU20-11). 2021
Cancer. -
Kim HR, Lee SJ, Park S, Jung HA, Lee SH, Jeong HS, Chung MK, Ahn MJ.
A Single-Arm, Prospective, Phase II Study of Cisplatin Plus Weekly Docetaxel as First-Line Therapy in Patients with Metastatic or Recurrent Salivary Gland Cancer. 2021
Cancer Res Treat. -
Kang N, Kim KH, Jeong BH, Lee K, Kim H, Kwon OJ, Ahn MJ, Cho J, Lee HY, Um SW.
The Impact of EGFR Tyrosine Kinase Inhibitor on the Natural Course of Concurrent Subsolid Nodules in Patients with Non-Small Cell Lung Cancer. 2021
Cancer Res Treat. -
Lee YP, Jeong BH, Eun Y, Kang CI, Park S, Jung HA, Lee SH, Ahn JS, Ahn MJ, Park K, Sun JM.
Extrapulmonary tuberculosis in patients with RET fusion-positive non-small cell lung cancer treated with pralsetinib: A Korean single-centre compassionate use experience. 2021
Eur J Cancer. -
Niu J, Maurice-Dror C, Lee DH, Kim DW, Nagrial A, Voskoboynik M, Chung HC, Mileham K, Vaishampayan U, Rasco D, Golan T, Bauer TM, Jimeno A, Chung V, Chartash E, Lala M, Chen Q, Healy JA, Ahn MJ.
First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small cell lung cancer. 2021
Ann Oncol. -
Park S, Choi CM, Hwang SS, Choi YL, Kim HY, Kim YC, Kim YT, Lee HY, Song SY, Ahn MJ.
Lung Cancer in Korea. 2021
J Thorac Oncol. -
Jung HA, Jeong O, Chang DK, Park S, Sun JM, Lee SH, Ahn JS, Ahn MJ, Park K.
Real-time autOmatically updated data warehOuse in healThcare (ROOT): an innovative and automated data collection system. 2021
Transl Lung Cancer Res. -
Riely GJ, Ahn MJ, Felip E, Ramalingam SS, Smit EF, Tsao AS, Alcasid A, Usari T, Wissel PS, Wilner KD, Johnson BE.
Encorafenib plus binimetinib in patients with BRAFV600-mutant non-small cell lung cancer: phase II PHAROS study design. 2022
Future Oncol. -
John T, Taylor A, Wang H, Eichinger C, Freeman C, Ahn MJ.
Uncommon EGFR mutations in non-small-cell lung cancer: A systematic literature review of prevalence and clinical outcomes. 2022
Cancer Epidemiol. -
Cho BC, Han JY, Kim SW, Lee KH, Cho EK, Lee YG, Kim DW, Kim JH, Lee GW, Lee JS, Shim BY, Kim JS, Chun SH, Lee SS, Kim HR, Hong MH, Ahn JS, Sun JM, Lee Y, Lee DH, Kang JA, Lee N, Kwon MJ, Espenschied C, Yablonovitch A, Ahn MJ.
A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors. 2022
J Thorac Oncol. -
Ku BM, Heo JY, Kim J, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ.
ERK inhibitor ASN007 effectively overcomes acquired resistance to EGFR inhibitor in non-small cell lung cancer. 2022
Invest New Drugs. -
Im Y, Lee H, Lee HY, Baek SY, Jeong BH, Lee K, Kim H, Kwon OJ, Han J, Lee KS, Ahn MJ, Kim J, Um SW.
Prognosis of pulmonary lymphangitic carcinomatosis in patients with non-small cell lung cancer. 2021
Transl Lung Cancer Res. -
Hwang S, Hong TH, Park S, Jung HA, Sun JM, Ahn JS, Ahn MJ, Park K, Choi YL, Lee SH.
Molecular subtypes of small cell lung cancer transformed from adenocarcinoma after EGFR tyrosine kinase inhibitor treatment. 2021
Transl Lung Cancer Res. -
Lee J, Tan AC, Zhou S, Yoon S, Liu S, Masuda K, Hayashi H, Batra U, Kim DW, Goto Y, Tan SH, Wu YL, Lee DH, Tan DSW, Ahn MJ.
Clinical Characteristics and Outcomes in Advanced KRAS-Mutated NSCLC: A Multicenter Collaboration in Asia (ATORG-005). 2021
JTO Clin Res Rep. -
Jung HA, Park S, Choi YL, Lee SH, Ahn JS, Ahn MJ, Sun JM.
Continuation of Pembrolizumab with Additional Chemotherapy after Progression with PD-1/PD-L1 Inhibitor Monotherapy in Patients with Advanced NSCLC: A Randomized, Placebo-Controlled Phase II Study. 2022
Clin Cancer Res. -
Demetri GD, De Braud F, Drilon A, Siena S, Patel MR, Cho BC, Liu SV, Ahn MJ, Chiu CH, Lin JJ, Goto K, Lee J, Bazhenova L, John T, Fakih M, Chawla SP, Dziadziuszko R, Seto T, Heinzmann S, Pitcher B, Chen D, Wilson TR, Rolfo C.
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors. 2022
Clin Cancer Res. -
Kim KH, Pyo H, Lee H, Oh D, Noh JM, Ahn YC, Yoon HI, Moon H, Lee J, Park S, Jung HA, Sun JM, Lee SH, Ahn JS, Park K, Ku BM, Ahn MJ, Shin EC.
Dynamics of Circulating Immune Cells During Chemoradiotherapy in Patients with Non-Small Cell Lung Cancer Support Earlier Administration of Anti-PD-1/PD-L1 Therapy. 2022
Int J Radiat Oncol Biol Phys. -
Park S, Sun JM, Choi YL, Oh D, Kim HK, Lee T, Chi SA, Lee SH, Choi YS, Jung SH, Ahn MJ, Ahn YC, Park K, Shim YM.
Adjuvant durvalumab for esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: a placebo-controlled, randomized, double-blind, phase II study. 2022
ESMO Open. -
Lim CH, Park SB, Kim HK, Choi YS, Kim J, Ahn YC, Ahn MJ, Choi JY.
Clinical Value of Surveillance 18F-fluorodeoxyglucose PET/CT for Detecting Unsuspected Recurrence or Second Primary Cancer in Non-Small Cell Lung Cancer after Curative Therapy. 2022
Cancers (Basel). -
Passaro A, Leighl N, Blackhall F, Popat S, Kerr K, Ahn MJ, Arcila ME, Arrieta O, Planchard D, de Marinis F, Dingemans AM, Dziadziuszko R, Faivre-Finn C, Feldman J, Felip E, Curigliano G, Herbst R, Jänne PA, John T, Mitsudomi T, Mok T, Normanno N, Paz-Ares L, Ramalingam S, Sequist L, Vansteenkiste J,
ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer. 2022
Ann Oncol. -
Ahn MJ, Cho BC, Ou X, Walding A, Dymond AW, Ren S, Cantarini M, Jänne PA.
Osimertinib Plus Durvalumab in Patients With EGFR-Mutated, Advanced NSCLC: A Phase 1b, Open-Label, Multicenter Trial. 2022
J Thorac Oncol. -
Ku BM, Kim YJ, Park D, Lee SH, Ahn JS, Park K, Ahn MJ, Sun JM.
Role of Circulating Tumor DNA Profiling in Patients with Non-Small Cell Lung Cancer Treated with EGFR Inhibitor. 2022
Oncology. -
Kim BG, Jang JH, Kim JW, Shin SH, Jeong BH, Lee K, Kim H, Kwon OJ, Ahn MJ, Um SW.
Clinical Utility of Plasma Cell-Free DNA EGFR Mutation Analysis in Treatment-Naïve Stage IV Non-Small Cell Lung Cancer Patients. 2022
J Clin Med. -
Park S, Ock CY, Kim H, Pereira S, Park S, Ma M, Choi S, Kim S, Shin S, Aum BJ, Paeng K, Yoo D, Cha H, Park S, Suh KJ, Jung HA, Kim SH, Kim YJ, Sun JM, Chung JH, Ahn JS, Ahn MJ, Lee JS, Park K, Song SY, Bang YJ, Choi YL, Mok TS, Lee SH.
Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non-Small-Cell Lung Cancer. 2022
J Clin Oncol. -
Okada M, Kato K, Cho BC, Takahashi M, Lin CY, Chin K, Kadowaki S, Ahn MJ, Hamamoto Y, Doki Y, Yen CC, Kubota Y, Kim SB, Hsu CH, Holtved E, Xynos I, Matsumura Y, Takazawa A, Kitagawa Y.
Three-Year Follow-Up and Response-Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3). 2022
Clin Cancer Res. -
Park S, Oh D, Choi YL, Chi SA, Kim K, Ahn MJ, Sun JM.
Durvalumab and tremelimumab with definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma. 2022
Cancer. -
Kim HR, Jo H, Kim H, Hong J, Park S, Jung HA, Lee SH, Ahn JS, Ahn MJ.
Osimertinib Combined with Systemic Chemotherapy for EGFR Mutant, T790M-Negative, Non-Small Cell Lung Cancer Patients Who Develop Leptomeningeal Metastases with Extracranial Progression to Prior EGFR TKI. 2022
Cancer Res Treat. -
Lee J, Koh J, Kim HK, Hong S, Kim K, Park S, Jung HA, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ.
Bevacizumab Plus Atezolizumab After Progression on Atezolizumab Monotherapy in Pretreated Patients With NSCLC: An Open-Label, Two-Stage, Phase 2 Trial. 2022
J Thorac Oncol. -
Kwon M, Ku BM, Olsen S, Park S, Lefterova M, Odegaard J, Jung HA, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ.
Longitudinal monitoring by next-generation sequencing of plasma cell-free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors. 2022
Cancer Med. -
Yoo J, Lee J, Cheon M, Woo SK, Ahn MJ, Pyo HR, Choi YS, Han JH, Choi JY.
Predictive Value of 18F-FDG PET/CT Using Machine Learning for Pathological Response to Neoadjuvant Concurrent Chemoradiotherapy in Patients with Stage III Non-Small Cell Lung Cancer. 2022
Cancers (Basel). -
Park S, Noh JM, Choi YL, Chi SA, Kim K, Jung HA, Lee SH, Ahn JS, Ahn MJ, Sun JM.
Durvalumab with chemoradiotherapy for limited-stage small-cell lung cancer. 2022
Eur J Cancer. -
Yang JC, Ohe Y, Chiu CH, Ou X, Cantarini M, Jänne PA, Hartmaier RJ, Ahn MJ.
Osimertinib plus selumetinib in EGFR-mutated, non-small cell lung cancer after progression on EGFR-TKIs: A Phase 1b, open-label, multicenter trial (TATTON Part B). 2022
Clin Cancer Res. -
Drilon A, Chiu CH, Fan Y, Cho BC, Lu S, Ahn MJ, Krebs MG, Liu SV, John T, Otterson GA, Tan DSW, Patil T, Dziadziuszko R, Massarelli E, Seto T, Doebele RC, Pitcher B, Kurtsikidze N, Heinzmann S, Siena S
Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion-Positive NSCLC 2022
JTO Clin Res Rep. -
Jung HA, Lim J, Choi YL, Lee SH, Joung JG, Jeon YJ, Choi JW, Shin S, Cho JH, Kim HK, Choi YS, Zo JI, Shim YM, Park S, Sun JM, Ahn JS, Ahn MJ, Han J, Park WY, Kim J, Park K
Clinical, Pathologic, and Molecular Prognostic Factors in Patients with Early-Stage EGFR-Mutant NSCLC 2022
Clin Cancer Res. -
Kim KH, Pyo H, Lee H, Oh D, Noh JM, Ahn YC, Kim CG, Yoon HI, Lee J, Park S, Jung HA, Sun JM, Lee SH, Ahn JS, Park K, Ku BM, Shin EC, Ahn MJ
Association of T cell senescence with radiation pneumonitis in patients with non-small cell lung cancer 2022
Int J Radiat Oncol Biol Phys. -
Lee H, Kim H, Choi YS, Pyo HR, Ahn MJ, Choi JY
Prognostic Significance of Pseudotime from Texture Parameters of FDG PET/CT in Locally Advanced Non-Small-Cell Lung Cancer with Tri-Modality Therapy 2022
Cancers (Basel). -
Ahn MJ, Kim HR, Yang JCH, Han JY, Li JY, Hochmair MJ, Chang GC, Delmonte A, Lee KH, Campelo RG, Gridelli C, Spira AI, Califano R, Griesinger F, Ghosh S, Felip E, Kim DW, Liu Y, Zhang P, Popat S, Camidge DR
Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK-Inhibitor-Naive ALK+ Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study 2022
Clin Lung Cancer. -
Gettinger SN, Huber RM, Kim DW, Bazhenova L, Hansen KH, Tiseo M, Langer CJ, Paz-Ares Rodríguez LG, West HL, Reckamp KL, Weiss GJ, Smit EF, Hochmair MJ, Kim SW, Ahn MJ, Kim ES, Groen HJM, Pye J, Liu Y, Zhang P, Vranceanu F, Camidge DR
Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials 2022
JTO Clin Res Rep. -
Ou SI, Nishio M, Ahn MJ, Mok T, Barlesi F, Zhou C, Felip E, de Marinis F, Kim SW, Pérol M, Liu G, Migliorino MR, Kim DW, Novello S, Bearz A, Garrido P, Mazieres J, Morabito A, Lin HM, Yang H, Niu H, Zhang P, Kim ES
Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2) 2022
J Thorac Oncol. -
Ahn MJ, Mendoza MJL, Pavlakis N, Kato T, Soo RA, Kim DW, Liam CK, Hsia TC, Lee CK, Reungwetwattana T, Geater S, Chan OSH, Prasongsook N, Solomon BJ, Nguyen TTH, Kozuki T, Yang JC, Wu YL, Mok TSK, Tan DS, Yatabe Y
Asian Thoracic Oncology Research Group (ATORG) Expert Consensus Statement on MET Alterations in NSCLC: Diagnostic and Therapeutic Considerations 2022
Clin Lung Cancer. -
Hur JY, Ku BM, Park S, Jung HA, Lee SH, Ahn MJ
Prognostic value of FOXP3+ regulatory T cells for patients with locally advanced oropharyngeal squamous cell carcinoma 2022
PLoS One. -
Kwon HR, Cho J, Park S, Lee SH, Ahn MJ, Choi JY, Lee KH, Jung HA, Moon SH
Metabolic parameters on baseline 18F-FDG PET/CT are potential predictive biomarkers for immunotherapy in patients with head and neck squamous cell carcinoma 2022
Front Med (Lausanne). -
Kim H, Park S, Jung HA, Sun JM, Lee SH, Ahn JS, Ahn MJ
EGFR Mutation-Positive Unresectable Stage III Non-Squamous Lung Cancer is Associated with a High Incidence of Brain Metastasis 2022
Cancer Res Treat. -
Wu YL, Lu S, Yang JC, Zhou J, Seto T, Ahn MJ, Su WC, Yamamoto N, Kim DW, Paolini J, Usari T, Iadeluca L, Wilner KD, Goto K
Final Overall Survival, Safety, and Quality of Life Results From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced NSCLC 2022
JTO Clin Res Rep. -
Hartmaier RJ, Markovets AA, Ahn MJ, Sequist LV, Han JY, Cho BC, Yu HA, Kim SW, Yang JC, Lee JS, Su WC, Kowalski DM, Orlov S, Ren S, Frewer P, Ou X, Cross DA, Kurian N, Cantarini M, Janne PA
Osimertinib+Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor Mutated MET-Amplified Non-Small Cell Lung Cancer: TATTON 2022
Cancer Discov. -
Jung HA, Kim M, Kim HS, Kim JH, Choi YH, Cho J, Park JH, Park KU, Ku BM, Park S, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ
A Phase 2 Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumors (KCSG LU17-21) 2022
J Thorac Oncol. -
Jeong HO, Lee H, Kim H, Jang J, Kim S, Hwang T, Choi DW, Kim HS, Lee N, Lee YM, Park S, Jung HA, Sun JM, Ahn JS, Ahn MJ, Park K, Lee S, Lee SH
Cellular plasticity and immune microenvironment of malignant pleural effusion are associated with EGFR-TKI resistance in non-small-cell lung carcinoma 2022
iScience. -
Mitsudomi T, Tan D, Yang JC, Ahn MJ, Batra U, Cho BC, Cornelio G, Lim T, Mok T, Prabhash K, Reungwetwattana T, Ren SX, Singh N, Toyooka S, Wu YL, Yang PC, Yatabe Y
Expert Consensus Recommendations on Biomarker Testing in Metastatic and Nonmetastatic NSCLC in Asia 2022
J Thorac Oncol. -
Park S, Cha H, Kim HS, Lee B, Kim S, Kim TM, Jung HA, Sun JM, Ahn JS, Ahn MJ, Park K, Park WY, Lee SH
Transcriptional upregulation of CXCL13 is correlated with a favorable response to immune checkpoint inhibitors in lung adenocarcinoma 2022
Cancer Med. -
Psyrri A, Fayette J, Harrington K, Gillison M, Ahn MJ, Takahashi S, Weiss J, Machiels JP, Baxi S, Vasilyev A, Karpenko A, Dvorkin M, Hsieh CY, Thungappa SC, Segura PP, Vynnychenko I, Haddad R, Kasper S, Mauz PS, Baker V, He P, Evans B, Wildsmith S, Olsson RF, Yovine A, Kurland JF, Morsli N, Seiwert
Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study 2022
Ann Oncol. -
Chan ATC, Lee VHF, Hong RL, Ahn MJ, Chong WQ, Kim SB, Ho GF, Caguioa PB, Ngamphaiboon N, Ho C, Aziz MASA, Ng QS, Yen CJ, Soparattanapaisarn N, Ngan RK, Kho SK, Tiambeng MLA, Yun T, Sriuranpong V, Algazi AP, Cheng A, Massarelli E, Swaby RF, Saraf S, Yuan J, Siu LL
Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial 2022
Ann Oncol. -
Jung HA, Park S, Lee SH, Ahn JS, Ahn MJ, Sun JM
The Role of Brain Radiotherapy before First-Line Afatinib Therapy, Compared to Gefitinib or Erlotinib, in Patients with EGFR-Mutant Non-Small Cell Lung Cancer 2023
Cancer Res Treat -
Park YJ, Im Y, Kwon OJ, Han J, Ahn MJ, Kim J, Um SW, Choi JY
Prognostic value of pretherapeutic FDG PET/CT in non-small cell lung cancer with pulmonary lymphangitic carcinomatosis 2023
Sci Rep. -
Popat S, Ahn MJ, Ekman S, Leighl NB, Ramalingam SS, Reungwetwattana T, Siva S, Tsuboi M, Wu YL, Yang JC
Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies 2023
Target Oncol. -
Kim H, Park S, Han KY, Lee N, Kim H, Jung HA, Sun JM, Ahn JS, Ahn MJ, Lee SH, Park WY
Clonal expansion of resident memory T cells in peripheral blood of patients with non-small cell lung cancer during immune checkpoint inhibitor treatment 2023
J Immunother Cancer. -
Yun JM, Chung MK, Baek CH, Son YI, Ahn MJ, Oh D, Kim KW, So YK
Prognostic Significance of the Post-Treatment Neutrophil-to-Lymphocyte Ratio in Pharyngeal Cancers Treated with Concurrent Chemoradiotherapy 2023
Cancers (Basel). -
Chmielecki J, Mok T, Wu YL, Han JY, Ahn MJ, Ramalingam SS, John T, Okamoto I, Yang JC, Shepherd FA, Bulusu KC, Laus G, Collins B, Barrett JC, Hartmaier RJ, Papadimitrakopoulou V
Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial 2023
Nat Commun. -
Hong TH, Hwang S, Choi YL, Lee G, Park S, Ahn MJ, Lee Y, Jeon YJ, Lee J, Shin S, Park SY, Cho JH, Choi YS, Kim J, Shim YM, Cho J, Kim HK
Different prognostic role of EGFR mutation according to the IASLC histological grade in patients with resected early-stage lung adenocarcinoma 2023
Histopathology. -
Chi SA, Yu H, Choi YL, Park S, Sun JM, Lee SH, Ahn JS, Ahn MJ, Choi DH, Kim K, Jung HA, Park K
Trends in Survival Rates of Non-Small Cell Lung Cancer With Use of Molecular Testing and Targeted Therapy in Korea, 2010-2020 2023
JAMA Netw Open. -
Hong TH, Bang YH, Joe CY, Hwang S, Lee B, Lee N, Park S, Jung HA, Sun JM, Ahn JS, Ahn MJ, Choi YL, Lee SH
Programmed Death-Ligand 1 Copy Number Alteration as an Adjunct Biomarker of Response to Immunotherapy in Advanced NSCLC 2023
J Thorac Oncol. -
Yoo J, Lee J, Cheon M, Kim H, Choi YS, Pyo H, Ahn MJ, Choi JY
Radiomics Analysis of 18F-FDG PET/CT for Prognosis Prediction in Patients with Stage III Non-Small Cell Lung Cancer Undergoing Neoadjuvant Chemoradiation Therapy Followed by Surgery 2023
Cancers (Basel). -
Hwang S, Hong TH, Kim HK, Choi YS, Zo JI, Shim YM, Han J, Chan Ahn Y, Pyo H, Noh JM, Lee HY, Kim HJ, Park S, Ahn MJ, Park K, Lee SH, Choi YL, Kim J
Whole-Section Landscape Analysis of Molecular Subtypes in Curatively Resected Small Cell Lung Cancer: Clinicopathologic Features and Prognostic Significance 2023
Mod Pathol. -
Lee SH, Kim Y, Jeon BN, Kim G, Sohn J, Yoon Y, Kim S, Kim Y, Kim H, Cha H, Lee NE, Yang H, Chung JY, Jeong AR, Kim YY, Kim SG, Seo Y, Park S, Jung HA, Sun JM, Ahn JS, Ahn MJ, Park H, Yoon KW
Intracellular Adhesion Molecule-1 Improves Responsiveness to Immune Checkpoint Inhibitor by Activating CD8+ T Cells 2023
Adv Sci (Weinh). -
Bang OY, Kim EH, Oh MJ, Yoo J, Oh GS, Chung JW, Seo WK, Kim GM, Ahn MJ, Yang SW; Investigators of the OASIS-CANCER Study
Circulating Extracellular-Vesicle-Incorporated MicroRNAs as Potential Biomarkers for Ischemic Stroke in Patients With Cancer 2023
J Stroke. -
Galffy G, Lugowska I, Poddubskaya EV, Cho BC, Ahn MJ, Han JY, Su WC, Hauke RJ, Dyar SH, Lee DH, Serwatowski P, Estelles DL, Holden VR, Kim YJ, Vladimirov V, Horvath Z, Ghose A, Goldman A, di Pietro A, Wang J, Murphy DA, Alhadab A, Laskov M
A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-naïve, cisplatin-ineligible urothelial cancer 2023
ESMO Open. -
Kim H, Park S, Jung HA, Lee SH, Park K, Ahn YC, Oh D, Ahn MJ
Phase II Trial of Combined Durvalumab Plus Tremelimumab with Proton Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma 2023
Cancer Res Treat. -
Jeon Y, Jung HA, Park S, Sun JM, Ahn JS, Ahn MJ, Park K, Lee SH
Expanded Access Program Pralsetinib in Advanced Non-Small Cell Lung Cancer with Rearranged during Transfection (RET) Gene Rearrangement 2023
Cancer Res Treat. -
Kim SJ, Choi JY, Ahn YC, Ahn MJ, Moon SH
The prognostic value of radiomic features from pre- and post-treatment 18F-FDG PET imaging in patients with nasopharyngeal carcinoma 2023
Sci Rep. -
Lee J, Park S, Jung HA, Lee SH, Seo S, Kim SB, Kim JW, Lee KW, Kang EJ, Kim JW, Choi YJ, Shim BY, An HJ, Park LC, Shin SH, Kim JJ, Oh SY, Kim MK, Ahn MJ
A phase 2 multicenter study of docetaxel-PM and trastuzumab-pkrb combination therapy in recurrent or metastatic salivary gland carcinomas 2023
Cancer. -
Riely GJ, Smit EF, Ahn MJ, Felip E, Ramalingam SS, Tsao A, Johnson M, Gelsomino F, Esper R, Nadal E, Offin M, Provencio M, Clarke J, Hussain M, Otterson GA, Dagogo-Jack I, Goldman JW, Morgensztern D, Alcasid A, Usari T, Wissel P, Wilner K, Pathan N, Tonkovyd S, Johnson BE
Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAFV600-Mutant Metastatic Non-Small-Cell Lung Cancer 2023
J Clin Oncol. -
Tsuboi M, Herbst RS, John T, Kato T, Majem M, Grohé C, Wang J, Goldman JW, Lu S, Su WC, de Marinis F, Shepherd FA, Lee KH, Le NT, Dechaphunkul A, Kowalski D, Poole L, Bolanos A, Rukazenkov Y, Wu YL; ADAURA Investigators
Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC 2023
N Engl J Med. -
Jung HA, Ku BM, Kim YJ, Park S, Sun JM, Lee SH, Ahn JS, Cho JH, Kim HK, Choi YS, Choi YL, Shin SH, Jeong BH, Um SW, Kim H, Kim K, Ahn MJ, Kim J
Longitudinal Monitoring of Circulating Tumor DNA From Plasma in Patients With Curative Resected Stages I to IIIA EGFR-Mutant Non-Small Cell Lung Cancer 2023
J Thorac Oncol. -
Seo S, Keam B, Shin SH, Chae YS, Kim TM, Park LC, Hong SB, Ahn MJ, Kim SB
A phase Ia/Ib study of novel anti-ErbB3 monoclonal antibody, barecetamab (ISU104) in refractory solid cancers and monotherapy or in combination with cetuximab in recurrent or metastatic head and neck cancer 2023
Int J Cancer. -
Gray JE, Ahn MJ, Oxnard GR, Shepherd FA, Imamura F, Cheng Y, Okamoto I, Cho BC, Lin MC, Wu YL, Majem M, Gautschi O, Boyer M, Bulusu KC, Markovets A, Barrett JC, Hodge R, McKeown A, Hartmaier RJ, Chmielecki J, Papadimitrakopoulou VA, Ramalingam SS
Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA 2023
Clin Cancer Res. -
Cho BC, Ahn MJ, Kang JH, Soo RA, Reungwetwattana T, Yang JC, Cicin I, Kim DW, Wu YL, Lu S, Lee KH, Pang YK, Zimina A, Fong CH, Poddubskaya E, Sezer A, How SH, Danchaivijitr P, Kim Y, Lim Y, An T, Lee H, Byun HM, Zaric B
Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301 2023
J Clin Oncol. -
Wilcox JA, Chukwueke UN, Ahn MJ, Aizer AA, Bale TA, Brandsma D, Brastianos PK, Chang S, Daras M, Forsyth P, Garzia L, Glantz M, Oliva ICG, Kumthekar P, Le Rhun E, Nagpal S, O'Brien B, Pentsova E, Lee EQ, Remsik J, Rudà R, Smalley I, Taylor MD, Weller M, Wefel J, Yang JT, Young RJ, Wen PY, Boire
Leptomeningeal metastases from solid tumors: A Society for Neuro-Oncology and American Society of Clinical Oncology consensus review on clinical management and future directions 2024
Neuro Oncol -
Kim DW, Chul Cho B, Pachipala K, Kim SW, Wang CL, Chang GC, Ahn MJ, Alvarez R, Chiu CH, Trigo J, Estival A, Karam SD, O'Brien C, Gowda H, Jiang H, Bauman JE
Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III non-small-cell lung cancer: Results from the phase 1 CLOVER study 2024
Lung Cancer -
Seiwert TY, Wildsmith S, Fayette J, Harrington K, Gillison M, Ahn MJ, Takahashi S, Weiss J, Machiels JP, Baxi S, Baker V, Evans B, Morsli N, Jill Walker, Real K, L'Hernault A, Psyrri A
Outcomes in biomarker-selected subgroups from the KESTREL study of durvalumab and tremelimumab in recurrent or metastatic head and neck squamous cell carcinoma 2024
Cancer Immunol Immunother -
Kim TW, Bedard PL, LoRusso P, Gordon MS, Bendell J, Oh DY, Ahn MJ, Garralda E, D'Angelo SP, Desai J, Hodi FS, Wainberg Z, Delord JP, Cassier PA, Cervantes A, Gil-Martin M, Wu B, Patil NS, Jin Y, Hoang T, Mendus D, Wen X, Meng R, Cho BC
Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled Trial 2023
JAMA Oncol. -
Mazieres J, Paik PK, Garassino MC, Le X, Sakai H, Veillon R, Smit EF, Cortot AB, Raskin J, Viteri S, Wu YL, Yang JCH, Ahn MJ, Ma R, Zhao J, O'Brate A, Berghoff K, Bruns R, Otto G, Johne A, Felip E, Thomas M
Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial 2023
JAMA Oncol. -
Ahn MJ, Bondarenko I, Kalinka E, Cho BC, Sugawara S, Gálffy G, Shim BY, Kislov N, Nagarkar R, Demedts I, Gans SJM, Mendoza Oliva D, Stewart R, Lai Z, Mann H, Shi X, Hussein M
Durvalumab in Combination With Olaparib Versus Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: The Phase 2 ORION Study 2023
J Thorac Oncol. -
Lee KH, Cho BC, Ahn MJ, Lee YG, Lee Y, Lee JS, Kim JH, Min YJ, Lee GW, Lee SS, Lee KH, Ko YH, Shim BY, Kim SW, Shin SW, Choi JH, Kim DW, Cho EK, Park KU, Kim JS, Chun SH, Wang J, Choi S, Kang JH
Lazertinib versus Gefitinib as First-line Treatment for EGFR-mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset 2023
Cancer Res Treat. -
Gutierrez M, Lam WS, Hellmann MD, Gubens MA, Aggarwal C, Tan DSW, Felip E, Chiu JWY, Lee JS, Yang JC, Garon EB, Finocchiaro G, Ahn MJ, Luft A, Landers GA, Basso A, Ma H, Kobie J, Palcza J, Cristescu R, Fong L, Snyder A, Yuan J, Herbst RS
Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results 2023
Nat Med. -
Jeon Y, Park S, Jung HA, Sun JM, Lee SH, Ahn JS, Ahn MJ
First-Line Alectinib vs. Brigatinib in Advanced NSCLC with ALK Rearrangement: Real-World Data 2023
Cancer Res Treat. -
Lee DH, Kim HR, Keam B, Kato K, Kuboki Y, Gao H, Yovine A, Robbins SH, Ahn MJ
Safety and tolerability of first-line durvalumab with tremelimumab and chemotherapy in esophageal squamous cell carcinoma 2023
Cancer Med. -
So YK, Kim Z, Cheong TY, Chung MJ, Baek CH, Son YI, Seok J, Jung YS, Ahn MJ, Ahn YC, Oh D, Cho BH, Chung MK
Detection of Cancer Recurrence Using Systemic Inflammatory Markers and Machine Learning after Concurrent Chemoradiotherapy for Head and Neck Cancers 2023
Cancers (Basel). -
Pant S, Schuler M, Iyer G, Witt O, Doi T, Qin S, Tabernero J, Reardon DA, Massard C, Minchom A, Lugowska I, Carranza O, Arnold D, Gutierrez M, Winter H, Stuyckens K, Crow L, Najmi S, Hammond C, Thomas S, Santiago-Walker A, Triantos S, Sweiti H, Loriot Y; RAGNAR Investigators
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study 2023
Lancet Oncol. -
Yang JC, Liu G, Lu S, He J, Burotto M, Ahn MJ, Kim DW, Liu X, Zhao Y, Vincent S, Yin J, Ma X, Lin HM, Popat S
Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial 2023
J Thorac Oncol. -
Cho BC, Lee JS, Wu YL, Cicin I, Dols MC, Ahn MJ, Cuppens K, Veillon R, Nadal E, Dias JM, Martin C, Reck M, Garon EB, Felip E, Paz-Ares L, Mornex F, Vokes EE, Adjei AA, Robinson C, Sato M, Vugmeyster Y, Machl A, Audhuy F, Chaudhary S, Barlesi F
Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1-High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial 2023
J Thorac Oncol. -
Sacher A, LoRusso P, Patel MR, Miller WH Jr, Garralda E, Forster MD, Santoro A, Falcon A, Kim TW, Paz-Ares L, Bowyer S, de Miguel M, Han SW, Krebs MG, Lee JS, Cheng ML, Arbour K, Massarelli E, Choi Y, Shi Z, Mandlekar S, Lin MT, Royer-Joo S, Chang J, Dharia NV, Schutzman JL, Desai J; GO42144 Investi
Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation 2023
N Engl J Med. -
Hanna GJ, Ahn MJ, Muzaffar J, Keam B, Bowles DW, Wong DJ, Ho AL, Kim SB, Worden F, Yun T, Meng X, Van Tornout JM, Conlan MG, Kang H
A Phase 2 Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma 2023
Clin Cancer Res. -
Lim TKH, Skoulidis F, Kerr KM, Ahn MJ, Kapp JR, Soares FA, Yatabe Y
KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing 2023
Lung Cancer. -
Lee H, Choi YL, Kim HK, Choi YS, Kim H, Ahn MJ, Pyo HR, Choi JY
Prognostic Significance of Volumetric Parameters Based on FDG PET/CT in Patients with Lung Adenocarcinoma Undergoing Curative Surgery 2023
Cancers (Basel). -
Goto K, Goto Y, Kubo T, Ninomiya K, Kim SW, Planchard D, Ahn MJ, Smit EF, de Langen AJ, Pérol M, Pons-Tostivint E, Novello S, Hayashi H, Shimizu J, Kim DW, Kuo CH, Yang JC, Pereira K, Cheng FC, Taguchi A, Cheng Y, Feng W, Tsuchihashi Z, Jänne PA
Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial 2023
J Clin Oncol. -
Reungwetwattana T, Cho BC, Lee KH, Pang YK, Fong CH, Kang JH, Lee YG, Lim CS, Danchaivijitr P, Lim YN, Lee Y, How SH, Geater S, Lee SS, Min YJ, Kim JH, Lee JS, Lee GW, Soo RA, Lee SY, Choi S, Ahn MJ
Lazertinib Versus Gefitinib Tyrosine Kinase Inhibitors in Treatment-Naíve Patients With EGFR-Mutated Advanced NSCLC: Analysis of the Asian Subpopulation in LASER301 2023
J Thorac Oncol. -
Hanna GJ, Stathis A, Lopez-Miranda E, Racca F, Quon D, Leyvraz S, Hess D, Keam B, Rodon J, Ahn MJ, Kim HR, Schneeweiss A, Ribera JM, DeAngelo D, Perez Garcia JM, Cortes J, Schönborn-Kellenberger O, Weber D, Pisa P, Bauer M, Beni L, Bobadilla M, Lehal R, Vigolo M, Vogl FD, Garralda E
A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors 2023
Cancer Res Commun. -
Vokes EE, Mornex F, Sezer A, Cheng Y, Fang J, Baz DV, Cil T, Adjei AA, Ahn MJ, Barlesi F, Felip E, Garon EB, Audhuy F, Ito R, Sato M, Eggleton SP, Martin CM, Reck M, Robinson CG, Paz-Ares L
Bintrafusp Alfa With CCRT Followed by Bintrafusp Alfa Versus Placebo With CCRT Followed by Durvalumab in Patients With Unresectable Stage III NSCLC: A Phase 2 Randomized Study 2024
J Thorac Oncol. -
Seong M, Park S, Kim ST, Goo Park S, Kim Y, Cha J, Yeop Kim E, Kim HJ, Ahn MJ
Increasing discrepancy of MR imaging and CSF study in patients with leptomeningeal seeding from lung adenocarcinoma after targeted therapy using a tyrosine kinase inhibitor 2023
Medicine (Baltimore). -
Kim DH, Lim Y, Ock CY, Park G, Park S, Song H, Ma M, Mostafavi M, Kang EJ, Ahn MJ, Lee KW, Kwon JH, Yang Y, Choi YH, Kim MK, Ji JH, Yun T, Kim SB, Keam B
Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes as a predictive biomarker for axitinib in adenoid cystic carcinoma 2023
Head Neck. -
Park S, Kim YJ, Min YJ, Mortimer PGS, Kim HJ, Smith SA, Dean E, Jung HA, Sun JM, Park WY, Ahn JS, Ahn MJ, Lee SH, Park K
Biomarker-driven phase 2 umbrella trial: Clinical efficacy of olaparib monotherapy and combination with ceralasertib (AZD6738) in small cell lung cancer 2024
Cancer. -
Park S, Jung HA, Lee SH, Ahn JS, Ahn MJ, Sun JM
Real-world clinical evidence of lazertinib use in acquired EGFR T790M mutated non-small cell lung cancer 2023
Transl Lung Cancer Res. -
Ahn MJ, Cho BC, Felip E, Korantzis I, Ohashi K, Majem M, Juan-Vidal O, Handzhiev S, Izumi H, Lee JS, Dziadziuszko R, Wolf J, Blackhall F, Reck M, Bustamante Alvarez J, Hummel HD, Dingemans AC, Sands J, Akamatsu H, Owonikoko TK, Ramalingam SS, Borghaei H, Johnson ML, Huang S, Mukherjee S, Minocha M,
Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer 2023
N Engl J Med. -
Park S, Kim TM, Han JY, Lee GW, Shim BY, Lee YG, Kim SW, Kim IH, Lee S, Kim YJ, Park JH, Park SG, Lee KH, Kang EJ, Kim JW, Shin SH, Ock CY, Nam BH, Lee J, Jung HA, Sun JM, Lee SH, Ahn JS, Ahn MJ
Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Mutated Non-Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04) 2024
J Clin Oncol. -
Soo RA, Cho BC, Kim JH, Ahn MJ, Lee KH, Zimina A, Orlov S, Bondarenko I, Lee YG, Lim YN, Lee SS, Lee KH, Pang YK, Fong CH, Kang JH, Lim CS, Danchaivijitr P, Kilickap S, Yang JC, Arslan C, Lee H, Park SN, Cicin I
Central Nervous System Outcomes of Lazertinib Versus Gefitinib in EGFR-Mutated Advanced NSCLC: A LASER301 Subset Analysis 2023
J Thorac Oncol. -
Razak ARA, Wang HM, Chang JY, Ahn MJ, Munster P, Blumenschein G Jr, Solomon B, Lim DW, Hong RL, Pfister D, Saba NF, Lee SH, van Herpen C, Quadt C, Bootle D, Blumenstein L, Demanse D, Delord JP
A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma 2023
Target Oncol. -
Harrington KJ, Cohen EEW, Soulières D, Dinis J, Licitra L, Ahn MJ, Soria A, Machiels JP, Mach N, Mehra R, Burtness B, Swaby RF, Lin J, Ge J, Lerman N, Tourneau CL
Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040): Subgroup analysis by pattern of disease recurrence 2023
Oral Oncol. -
Planchard D, Jänne PA, Cheng Y, Yang JC, Yanagitani N, Kim SW, Sugawara S, Yu Y, Fan Y, Geater SL, Laktionov K, Lee CK, Valdiviezo N, Ahmed S, Maurel JM, Andrasina I, Goldman J, Ghiorghiu D, Rukazenkov Y, Todd A, Kobayashi K; FLAURA2 Investigators
Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC 2023
N Engl J Med. -
Jun S, Park S, Sun JM, Lee SH, Ahn JS, Ahn MJ, Cho J, Jung HA
Real-World Outcomes of Immunotherapy in Second- or Later-Line Non-Small Cell Lung Cancer with Actionable Genetic Alterations 2023
Cancers (Basel). -
Subbiah V, Hu MI, Mansfield AS, Taylor MH, Schuler M, Zhu VW, Hadoux J, Curigliano G, Wirth L, Gainor JF, Alonso G, Adkins D, Godbert Y, Ahn MJ, Cassier PA, Cho BC, Lin CC, Zalutskaya A, Barata T, Trask P, Scalori A, Bordogna W, Heinzmann S, Brose MS
Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study 2024
Thyroid. -
Jung HA, Park S, Lee SH, Ahn JS, Ahn MJ, Sun JM
Dacomitinib in EGFR-mutant non-small-cell lung cancer with brain metastasis: a single-arm, phase II study 2023
ESMO Open. -
Hong J, Lee J, Park S, Jung HA, Sun JM, Lee SH, Ahn JS, Sinn DH, Ahn MJ
Immune checkpoint inhibitor use and the incidence of hepatitis B virus reactivation or immune-related hepatitis in non-small cell lung cancer patients with chronic hepatitis B 2024
Cancer. -
Seo SH, Pyo H, Ahn YC, Oh D, Yang K, Kim N, Sun JM, Park S, Jung HA, Lee SH, Ahn JS, Ahn MJ, Noh JM
Pulmonary function and toxicities of proton versus photon for limited-stage small cell lung cancer 2023
Radiat Oncol J. -
Choi DH, Jung HA, Park S, Sun JM, Ahn JS, Ahn MJ, Lee SH
Effectiveness and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in non-small cell lung cancer (NSCLC) 2023
Transl Lung Cancer Res. -
Choi JH, Choi JY, Woo SK, Moon JE, Lim CH, Park SB, Seo S, Ahn YC, Ahn MJ, Moon SH, Park JM
Prognostic Value of Radiomic Analysis Using Pre- and Post-Treatment 18F-FDG-PET/CT in Patients with Laryngeal Cancer and Hypopharyngeal Cancer 2024
J Pers Med. -
Rodriguez-Abreu D, Bosch-Barrera J, Gray JE, Ahn MJ, Johnson M, Yu X, Mohammad S, Chen X, Todd T, Kim J, Reck M
STAR-121: A Phase III Randomized Study of Domvanalimab and Zimberelimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Untreated Metastatic Non-Small Cell Lung Cancer With No Actionable Gene Alterations 2024
Clin Lung Cancer. -
Riely GJ, Smit EF, Ahn MJ, Felip E, Ramalingam SS, Tsao A, Johnson M, Gelsomino F, Esper R, Nadal E, Offin M, Provencio M, Clarke J, Hussein M, Otterson GA, Dagogo-Jack I, Goldman JW, Morgensztern D, Alcasid A, Usari T, Wissel P, Wilner K, Pathan N, Tonkovyd S, Johnson BE
A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small-cell lung cancer 2024
Future Oncol. -
Shin SH, Cha S, Lee HY, Shin SH, Kim YJ, Park D, Han KY, Oh YJ, Park WY, Ahn MJ, Kim H, Won HH, Park HY
Machine learning model for circulating tumor DNA detection in chronic obstructive pulmonary disease patients with lung cancer 2024
Transl Lung Cancer Res -
Chung JW, Hwang J, Kim HJ, Seo WK, Ahn MJ, Saver JL, Bang OY
Edoxaban for the treatment of hypercoagulability and cerebral thromboembolism associated with cancer: A randomized clinical trial of biomarker targets 2024
Int J Stroke -
Chul Cho B, Han JY, Hyeong Lee K, Lee YG, Kim DW, Joo Min Y, Kim SW, Kyung Cho E, Kim JH, Lee GW, Sook Lee S, Lee N, Young Wang J, Park H, Ahn MJ
Lazertinib as a frontline treatment in patients with EGFR-mutated advanced non-small cell lung cancer: Long-term follow-up results from LASER201 2024
Lung Cancer -
Jeon Y, Park S, Lee SH, Kim TH, Kim SW, Ahn MJ, Jung HA, Chung JH
Combination of Dabrafenib and Trametinib in Patients with Metastatic BRAFV600E-Mutated Thyroid Cancer 2024
Cancer Res Treat -
Park S, Hong TH, Hwang S, Heeke S, Gay CM, Kim J, Jung HA, Sun JM, Ahn JS, Ahn MJ, Cho JH, Choi YS, Kim J, Shim YM, Kim HK, Byers LA, Heymach JV, Choi YL, Lee SH, Park K
Comprehensive analysis of transcription factor-based molecular subtypes and their correlation to clinical outcomes in small-cell lung cancer 2024
EBioMedicine -
Jung HA, Park B, Park S, Sun JM, Lee SH, Seok Ahn J, Ahn MJ
Survival benefit in EGFR-wild and ALK negative NSCLC patients who participate in clinical trials compared to standard-of-care: Propensity-matched analysis 2024
Lung Cancer -
Park S, Kang JK, Lee N, Lee SH, Kim HP, Kim SY, Kim TY, Kim H, Jung HA, Sun JM, Ahn JS, Ahn MJ, Park K
Predicting disease recurrence in limited disease small cell lung cancer using cell-free DNA-based mutation and fragmentome analyses 2024
Transl Lung Cancer Res -
Machiels JP, Tao Y, Licitra L, Burtness B, Tahara M, Rischin D, Alves G, Lima IPF, Hughes BGM, Pointreau Y, Aksoy S, Laban S, Greil R, Burian M, Hetnał M, Delord JP, Mesía R, Taberna M, Waldron JN, Simon C, Grégoire V, Harrington KJ, Swaby RF, Zhang Y, Gumuscu B, Bidadi B, Siu LL; KEYNOTE-412 Invest
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial 2024
Lancet Oncol -
Kato T, Yang JC, Ahn MJ, Sakai H, Morise M, Chen YM, Han JY, Yang JJ, Zhao J, Hsia TC, Berghoff K, Bruns R, Vioix H, Lang S, Johne A, Le X, Paik PK
Efficacy and safety of tepotinib in Asian patients with advanced NSCLC with MET exon 14 skipping enrolled in VISION 2024
Br J Cancer -
Kim Y, Keam B, Kang EJ, Kim JS, Kim HR, Lee KW, Kwon JH, Lee KE, Yang Y, Choi YH, Kim MK, Ji JH, Yun T, Choi MY, Lee KH, Kim SB, Ahn MJ
Analysis of Response and Progression Patterns of Tyrosine Kinase Inhibitors in Recurrent or Metastatic Adenoid Cystic Carcinoma: A Post Hoc Analysis of Two KCSG Phase II Trials 2024
Cancer Res Treat -
Shin J, Park S, Kim KH, Shin EC, Jung HA, Cho JH, Sun JM, Lee SH, Choi YS, Ahn JS, Kim J, Park K, Shim YM, Kim HK, Noh JM, Ahn YC, Pyo H, Ahn MJ
Adjuvant Pembrolizumab in Patients with Stage IIIA/N2 Non-Small Cell Lung Cancer Completely Resected after Neoadjuvant Concurrent Chemoradiation: A Prospective, Open-Label, Single-Arm, Phase 2 Trial 2024
Cancer Res Treat -
Prenen H, Deva S, Keam B, Lindsay CR, Lugowska I, Yang JC, Longo F, de Miguel M, Ponz-Sarvise M, Ahn MJ, Gumus M, Champiat S, Italiano A, Salas S, Perets R, Arslan C, Cho BC, Evers S, Boetsch C, Marbach D, Dejardin D, Sleiman N, Ardeshir C, Richard M, Charo J, Kraxner A, Keshelava N, Teichgräber V,
Phase II Study to Determine the Antitumor Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined with Atezolizumab in Esophageal Cancer 2024
Clin Cancer Res -
Lu S, Kato T, Dong X, Ahn MJ, Quang LV, Soparattanapaisarn N, Inoue T, Wang CL, Huang M, Yang JC, Cobo M, Özgüroğlu M, Casarini I, Khiem DV, Sriuranpong V, Cronemberger E, Takahashi T, Runglodvatana Y, Chen M, Huang X, Grainger E, Ghiorghiu D, van der Gronde T, Ramalingam SS; LAURA Trial Investigato
Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC 2024
Engl J Med -
Park S, Baldry R, Jung HA, Sun JM, Lee SH, Ahn JS, Kim YJ, Lee Y, Kim DW, Kim SW, Lee KH, Lee WJ, Choi JW, Chong K, Lee JI, Gwon SH, Son NH, Ahn MJ
Phase II Efficacy and Safety of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer (BLOSSOM) 2024
J Clin Oncol -
Spicer JD, Cascone T, Wynes MW, Ahn MJ, Dacic S, Felip E, Forde PM, Higgins KA, Kris MG, Mitsudomi T, Provencio M, Senan S, Solomon BJ, Tsao MS, Tsuboi M, Wakelee HA, Wu YL, Chih-Hsin Yang J, Zhou C, Harpole DH, Kelly KL
Neoadjuvant and Adjuvant Treatments for Early Stage Resectable NSCLC: Consensus Recommendations From the International Association for the Study of Lung Cancer 2024
Thorac Oncol -
Ou SI, Le X, Nagasaka M, Reungwetwattana T, Ahn MJ, Lim DWT, Santos ES, Shum E, Lau SCM, Lee JB, Calles A, Wu F, Lopes G, Sriuranpong V, Tanizaki J, Horinouchi H, Garassino MC, Popat S, Besse B, Rosell R, Soo RA
Top 20 EGFR+ NSCLC Clinical and Translational Science Papers That Shaped the 20 Years Since the Discovery of Activating EGFR Mutations in NSCLC. An Editor-in-Chief Expert Panel Consensus Survey 2024
Lung Cancer (Auckl) -
Jung YJ, Ahn J, Park S, Sun JM, Lee SH, Ahn JS, Ahn MJ, Cho SY, Jung HA
Machine learning prediction of the case-fatality of COVID-19 and risk factors for adverse outcomes in patients with non-small cell lung cancer 2024
Transl Cancer Res -
Murat-Onana ML, Ramalingam SS, Jänne PA, Gray JE, Ahn MJ, John T, Yatabe Y, Huang X, Rukazenkov Y, Javey M, Brown H, Li-Sucholeiki X
EGFR mutation testing across the Osimertinib clinical program 2025
Lung Cancer -
Jeong HS, Kim Y, Choi N, Kim EH, Chung MK, Son YI, Oh D, Ahn YC, Lee SH, Jung HA, Park S, Kim J, Jeong HS, Ahn MJ
Adjuvant sequential chemotherapy for salivary duct carcinomas: retrospective comparative analysis 2025
Oncology -
Zhou Q, Zhao H, Lu S, Cheng Y, Liu Y, Zhao M, Yu Z, Hu C, Zhang L, Yang F, Zhao J, Guo R, Ma R, Du Y, Dong X, Cui J, Tan DSW, Ahn MJ, Tsuboi M, Maggie Liu SY, Mok TS, Wu YL
Consensus on the lung cancer management after third-generation EGFR TKI resistance 2024
Lancet Reg Health West Pac -
Byun JM, Kim WS, Ahn MJ
Recent advances and challenges in cancer care with a focus on multiple myeloma, lymphoma and lung cancer: Key insights from the Onco Summit 2024-The APAC Chapter 2025
Asian Pac J Cancer Prev -
Ahn MJ, Cho BC, Felip E, Korantzis I, Ohashi K, Majem M, Juan-Vidal O, Handzhiev S, Izumi H, Lee JS, Dziadziuszko R, Wolf J, Blackhall F, Reck M, Alvarez JB, Hummel HD, Dingemans AC, Sands J, Akamatsu H, Owonikoko TK, Ramalingam SS, Borghaei H, Johnson ML, Huang S, Mukherjee S, Minocha M, Jiang T, M
Plain language summary: tarlatamab for patients with previously treated small cell lung cancer 2024
Future Oncol -
Kim N, Park S, Jo A, Eum HH, Kim HK, Lee K, Cho JH, Ku BM, Jung HA, Sun JM, Lee SH, Ahn JS, Lee JI, Choi JW, Jeong D, Na M, Kang H, Kim JY, Choi JK, Lee HO, Ahn MJ
Unveiling the influence of tumor and immune signatures on immune checkpoint therapy in advanced lung cancer 2024
Elife -
Kim YG, Lee B, Ha C, Lee C, Jung HA, Sun JM, Lee SH, Ahn MJ, Choi YL, Park S, Kim JW
Clinical utility of circultating tumor DNA profiling in detecting targetable fusions in non-small cell lung cancer 2024
Front Oncol -
Sands J, Ahn MJ, Lisberg A, Cho BC, Blumenschein G Jr, Shum E, Pons Tostivint E, Goto Y, Yoh K, Heist R, Shimizu J, Lee JS, Baas P, Planchard D, Pérol M, Felip E, Su WC, Zebger-Gong H, Lan L, Liu C, Howarth P, Chiaverelli R, Paz-Ares L
Datopotamab deruxtecan in advanced or metastatic non-small cell lung cancer with actionable genomic alterations: Results from the phase II TROION-Lung05 study 2025
J Clin Oncol -
Hong TH, Hwang S, Abbosh C, Dasgupta A, Jeon YJ, Lee J, Park SY, Cho JH, Choi YS, Shim YM, Hung T, Bredno J, Hodgson D, Ahn MJ, Kim HK
Association of pre-surgical circulating tumor DNA detection, use of sublobar resection with risk of recurrence in stage I non-small cell lung cancer 2025
Eur J Cancer -
Jang SY, Lee YG, Chun SH, Park JH, Park KU, Chang H, Lee KW, Kim HR, Shin SH, An HJ, Lee KE, Hwang IG, Ahn MJ, Kim SB, Keam B
Risk factors for progressive disease after immune checkpoint inhibito therapy in head and neck squamous cell carcinoma 2025
Head Neck -
Shin JE, Jung HA, Park S, Sun JM, Lee SH, Ahn JS, Ahn MJ, Shim BY
Real world data of dacomitinib as first-line treatment for patients with EGFR mutant non-small cell lung cancer 2025
Sci Rep -
Camidge DR, Sugawara S, Kondo M, Kim HR, Ahn MJ, Yang JCH, Han JY, Hochmair MJ, Lee KH, Delmonte A, Kudou K, Asato T, Hupf B, Vranceanu F, Fram RJ, Ohe Y, Popat S
Efficacy and safety of brigatinib in patients with ALK TKI-naïve advanced ALK + NSCLC: Integrated analysis of the ALTA-1L and J-ALTA trials 2025
Lung Cancer -
Hummel HD, Ahn MJ, Blackhall F, Reck M, Akamatsu H, Ramalingam SS, Borghaei H, Johnson M, Dirnberger F, Cocks K, Huang S, Mukherjee S, Paz-Ares L
Patient-reported outcomes for patients with previously treated small cell lung cancer receiving tarlatamab: results from the DeLLphi-301 phase 2 trial 2025
Adv Ther -
Hong MH, Park S, Vo T, Cho J, Jung HA, Lee SH, Kim SH, Zhou H, Chirovsky D, Koh YW, Yoon SO, Webber AL, Gumuscu B, Cho BC, Ahn MJ
Expression of PD-L1, PD-L2, and inflammatory gene expression profile in locally advanced head and neck squamous cell carcinoma 2024
ESMO Open -
Whi W, Moon SH, Oh D, Chung MK, Jeong HS, Ahn MJ, Choi JY
Diagnostic value of surveillance 18F-FDG PET/CT in head and neck squsmous cell carcinoma after curative therapy 2025
Clin Nucl Med -
Garassino MC, He Y, Ahn MJ, Orlov SV, Potter V, Kato T, Laskin J, Voon PJ, Reungwetwattana T, Ramalingam SS, Wu YL, Albayaty M, Cross SL, Huang X, Kulkarni D, Cho BC
Osimertinib long-term tolerability in patients with EGFRm NSCLC enrolled in the AURA program or FLAURA study 2025
Lung Cancer -
Herbst RS, John T, Grohé C, Goldman JW, Kato T, Laktionov K, Bonanno L, Tiseo M, Majem M, Dómine M, Ahn MJ, Kowalski DM, Pérol M, Sriuranpong V, Özgüroğlu M, Bhetariya P, Markovets A, Rukazenkov Y, Muldoon C, Robichaux J, Hartmaier R, Tsuboi M, Wu YL
Molecular residual disease analysis of adjuvant Osimertinib in resected EGFR mutated stage IB-IIIA non-small cell lung cancer 2025
Nat Med -
Kang EJ, Yang Y, Lee S, Kim YJ, Lim SM, Ahn MJ, Choi YJ, Lee Y, Kim TM, Kim I, Ahn HK, Jeung HC, Lee SI, Oh SY, Bae WK, Ryu H, Park KH, Lee KH
Corrigendum to “A phase II study of tepotinib in patients with advanced solid cancers harboring MET exon 14 skipping mutations or amplification (KCSG AL19-17) 2025
ESMO Open -
Abhyankar AV, Ahn MJ, Dy GK
Clo-25-097: Randomized phase II study of pembrolizumab 200mg q 12 weeks versus standard of care dosing in stage IV non-small cell lung cancer with prior clinical benefit to pembrolizumab monotherapy 2025
J Natl Compr Canc Netw -
Kim J, Park S, Ku BM, Ahn MJ
Updates on the treatment of epidermal growth factor non-small cell lung cancer 2025
Cancer -
Oh S, Kim Y, Kim H, Kim E, Woo SY, Choi N, Cho J, Oh D, Ahn YC, Park S, Ahn MJ, Jeong HS
The pattern of systemic metastasis in major salivary gland cancer and therapeutic implications 2025
Oral Oncol -
Heymach JV, Ruiter G, Ahn MJ, Girard N, Smit EF, Planchard D, Wu YL, Cho BC, Yamamoto N, Sabari JK, Zhao Y, Tu HY, Yoh K, Nadal E, Sadrolhefazi B, Rohrbacher M, von Wangenheim U, Eigenbrod-Giese S, Zugazagoitia J; Beamion LUNG-1 Investigators
Zongertinib in previously treated HER1 mutant non-small cell lung cancer 2025
N Engl J Med -
Fayette J, Licitra L, Harrington K, Haddad R, Siu LL, Liu YC, Tahara M, Machiels JP, Rischin D, Seiwert TY, Ferris RL, Keilholz U, Psyrri A, Keam B, Bossi P, Metcalf R, Hsieh CY, Clement PMJ, Isaev P, Mudunov A, Dinis J, Hoeben A, Kasper S, Klinghammer K, Hwang M, Blando J, Serrano O, Ruscica D, Coh
INTERLINK-1: A phase III randomized placebo-controlled study of monalizumab plus cetuximab in recurrent/metastatic head and neck squamous cell carcinoma 2025
Clin Cancer Res -
Shapira-Frommer R, Niu J, Perets R, Peters S, Shouse G, Lugowska I, Garassino MC, Sands J, Keenan T, Zhao B, Healy J, Ahn MJ
The KEYVIBE program: vibostolimab and pembrolizumab for the treatment of advanced malignancies 2024
Future Oncol -
Zhang B, Sun JM, Ahn MJ, Jung SH
Randomized phase II cancer clinical trials to validate predictive biomarkers 2024
Biomedicines -
Park GH, Park S, Kim H, Jung HA, Sun JM, Ahn JS, Ahn MJ, Lee SH
Prospective investigation of biomarker and resistance mechanism using longitudinal cell-free NGS in non-small cell lung cancer with EGFR exon 20 insertion treated with amivantamab 2025
Eur J Cancer -
Jung HA, Lee D, Park B, Lee K, Lee HY, Kim TJ, Jeon YJ, Lee J, Park SY, Cho JH, Choi YS, Park S, Sun JM, Lee SH, Ahn JS, Ahn MJ, Kim HK
Deep-learning model for real-time prediction of recurrence in early stage non-small cell lung cancer; A multimodal approach (RADAR CARE study) 2025
JCO Precis Oncol -
Jänne PA, Goto Y, Kubo T, Ninomiya K, Kim SW, Planchard D, Ahn MJ, Smit E, Johannes de Langen A, Pérol M, Pons-Tostivint E, Novello S, Hayashi H, Shimizu J, Kim DW, Pereira K, Cheng FC, Taguchi A, Cheng Y, Dunton K, Ali A, Goto K
Finaly analysis results and patient reported outcomes from DESTINY-Lung-02 A dose blinded randomized phase 2 study of trastuzumab deruxtecan in patients with HER2 mutant metastatic NSCLC 2025
J Thorac Oncol -
Choe J, Lim J, Kang N, Seo ES, Hwang M, Han KY, Lee SH, Ahn MJ, Choi YL, Kim HK, Park WY, Um SW
Novel cancer-associated secretory cells and IL-1b macrophages as key players in early lung adenocarcinoma progression in female never smokers 2025
Clin Transl Med -
Zer A, Ahn MJ, Barlesi F, Bubendorf L, De Ruysscher D, Garrido P, Gautschi O, Hendriks LE, Jänne PA, Kerr KM, Mascaux C, Mitsudomi T, Peters S, Rolfo C, Sacher A, Senan S, Ugalde P, Leighl NB; ESMO Guidelines Committee
Early and locally advanced non-small cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up 2025
Ann Oncol -
Ahn MJ, Cho BC, Ohashi K, Izumi H, Lee JS, Han JY, Chiang CL, Huang S, Hamidi A, Mukherjee S, Xu KL, Akamatsu H
Asian subgroup analysis of patients in the phase 2 DeLLphi-301 study of tarlatamab for previously treated small cell lung cancer 2025
Oncol Ther -
Paulson KG, Lau SCM, Ahn MJ, Moskovitz M, Pogorzelski M, Häfliger S, Parkes A, Zhang Y, Hamidi A, Thompson CG, Wermke M
Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive stage small-cell lung cancer (DeLLphi-303): A multicenter, non-randomized phase Ib study 2025
Lancet Oncol -
Maeng CH, Kim BJ, Ahn MJ, Choi IS, Zang DY, Kim BH, Kwon M, Heo DS, Keam B
Association between tumor size at the time of disease progression and survival outcomes 2025
Cancer Res Treat -
Hwang S, Hong MH, Shin SH, Yun T, Lee KW, Kim JH, Ahn MJ, Keam B, Lee HW, Kim MK, Yun HJ, Kim Y, Kim HJ, Cho SH, An HJ, Oh SY, Park SG, Koh YW, Ahn HK, Kwon JH, Lee YG, Park KU, Hwang IG, Kim SB, Kim S, Kim HR; KCSG TRIUMPH investigators
Identifying predictive markers of head and neck squamous cell carcinoma in an umbrella trial (KCSG HN 15-16 TRIUMPH trial) 2025
ESMO Open -
Byun JY, Kim J, Park S, Sun JM, Lee SH, Ahn JS, Ahn MJ, Kim JH, Lee EK, Jung HA
A matching-adjusted indirect comparison of first-line lorlatinib and alectinib for the treatment of ALK-rearranged advanced non-small cell lung cancer 2025
Eur J Cancer -
Yang JC, Ahn MJ, Kim JH, Lee YG, Han JY, Lee KH, Zimina A, Kim DW, Lee KH, Lee SS, Lim CS, Lim YN, Min YJ, Orlov S, Lee Y, Kim Y, Kwon MJ, Lee H, Cho H, Cho BC
Central nervous system outcomes of Lazertinib treatment in EGFR-mutated advanced NSCLC: Pooled analysis from LASER201 and LASER301 2025
Clin Lung Cancer -
Cho BC, Ahn MJ, Nishio M, Murakami H, Wan-Kim D, Kim SW, Karam SD, Estival A, Lin CC, Trigo JM, Alvarez R, Wang CL, Xie M, Iyer S, Armstrong J, Chugh P, Jiang H, Bauman JE
Durvalumab with or without tremelimumab in combination with chemoradiotherapy in patients with limited-stage SCLC: Results from the phase I CLOVER study 2025
JTO Clin Res Rep -
Rudin CM, Johnson ML, Paz-Ares L, Nishio M, Hann CL, Girard N, Rocha P, Hayashi H, Sakai T, Kim YJ, Hu H, Qian M, Singh J, Godard J, Tang M, Ahn MJ.
Ifinatamab deruxtecan in patients with extensive stage small cell lung cancer. Primary analysis of the phase II Ideate-Lung01 trial. 2026
J Clin Oncol. -
Johnson ML, Smit EF, Felip E, Ramalingam SS, Ahn MJ, Tsao A, Johnson BE, Offin M, Hussein M, Dagogo-Jack I, Goldman JW, Clarke JM, Negrao MV, Sanborn RE, Morgensztern D, Usari T, Wilner K, Alejandro L, Rifi N, Zhang X, Riely GJ.
Updated overall survival analysis from the phase II PHAROS study of encorafenib plus binimetinib in patients with BRAF V600E mutant metastatic non-small cell lung cancer. 2025
J Clin Oncol. -
Bang YH, Noh JM, Lee B, Choi YL, Yang K, Pyo H, Kim H, Kim J, Jung HA, Sun JM, Lee SH, Ahn JS, Ahn MJ, Jeon YJ, Lee J, Cho JH, Kim HK, Choi YS, Park SY, Park S.
Perioperative pembrolizumab for locally advanced thymic epithelical tumors: A single arm phase 2 trial. 2025
J Thorac Oncol. -
Mok T, Nishio M, Yoshida T, Ahn MJ, Kudou K, Asato T, Yang H, Tong X, Vincent S, Zhang P, Yamamoto N, Kim ES.
Efficacy and safety of brigatnib after alectinib in patients with ALK-positive NSCLC: Integrated analysis of the ALTA-2 and J-ALT studies. 2025
Lung Cancer. -
Shin JE, Park S, Jung HA, Sun JM, Lee SH, Ahn JS, Ahn MJ.
Combination of chemotherapy and immune checkpoint inhibitors in non-small cell lung cancer with actionable gene alterations other than EGFR, ALK, and ROS1 mutations: a retrospective observational study. 2025
BMC Cancer. -
Ahn MJ, Lin SH, Yang CT, Lee JB, Neal JW, Okishio K, Nishino K, Smith D, Rauter M, Jimenez M, Nasirova F, Kim Y.
Mutation testing, treatment patterns, and outcomes in patients with unresectable stage III EGFR mutated non-small cell lung cancer treated with chemoradiotherapy: Final analysis of a global real-world study. 2025
Lung Cancer. -
Bang YH, Park GH, Oh JW, Hwang S, Jeong JG, Lee B, Joe CY, Kim H, Kim J, Park S, Jung HA, Sun JM, Ahn JS, Ahn MJ, Choi YL, Ahn CH, Ali SM, Ock CY, Lee SH.
Artificial intelligence-powered spatial analysis of tumor microenvironment in patients with non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitor. 2025
J Immunother Cancer. -
Han M, Park S, Lee SH, Kim J, Kim JY, Sun JM, Ahn JS, Ahn MJ.
Real world efficacy and safety of first line chemo immunotherapy in extensive stage small cell lung cacner and its association with molecular subtype. 2025
Cancer Res Treat. -
Jung HA, Kim TM, Kim HR, Kim CG, Ahn HK, Lee Y, Kim YJ, Kim M, Youk J, Sun JM, Lee SH, Ahn JS, Kim DW, Ahn MJ, Keam B.
Phase II study of Lazertinib and pemetrexed in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer with leptomeningeal metastases: The KCSG LU 21-01, LAZARUS study. 2025
Lung Cancer. -
Yoon JM, Nam SW, Kim MJ, Ahn MJ, Ham DI.
Crizotinib-Associated uveitis and scleritis with abscess formation. 2025
Ocul Immunol Inflamm. -
Chiang CL, Soo RA, Mok T, Voon PJ, Thamlikitkul L, Cheng Y, Horinouchi H, Cho BC, Xu KL, Ahn MJ.
A comparison of clinical guidelines, treatment characteristics and outcomes in small cell lung cancer between East Asia and Europe/Northe America. 2025
Front Oncol. -
Aredo JV, Peled N, Arriola E, Wakelee H, Ahn MJ, Kwint MH, Taylor R, van der Gronde T, Nasirova F, Chen M.
Osimertininb before and after chemoradiotherapy for unresectable stage III EGFR mutated NSCLC: NEOLA Trial protocol. 2025
Future Oncol. -
Sands J, Ahn MJ.
Datopotamab deruxtecan versus docetaxel for non-small cell lung cancer: a plain language summary of the TROPION-Lung01 study. 2026
Future Oncol. -
Harrington KJ, Rosenberg AJ, Yang MH, Geiger JL, Oliva M, Ahn MJ, Lim SM, Ince W, Bhatia A, Sheth S, Keam B, Metcalf R, Curtin JC, Toyoizumi K, Wade M, Yilmaz E, Kim P, Verheijen RB, Shah S, Baig M, Swiecicki PL.
Subcutaneous amivantamab in recurrent/metastatic head and neck squamous cell cancer after disease progression on checkpopint inhibitor and chemotherapy: Preliminary results from the phase 1b/2 OrigAMI-4 study. 2025
Oral Oncol. -
Ahn MJ, Delmonte A, Ghosh S, Hochmair M, Yang TY, Yang JC, Han JY, Hansen KH, Wu Y, Wan Y, Lin HM, Kretz J, Hupf B, Kurec AM, Churchill EN, Fram RJ, Cabasag CJ, Goriya V, Zhao Y, Campelo MRG.
Real world treatment patterns and subsequent treatment effectiveness following frontline brigatinib in the ALTA-1L trial. 2025
Future Oncol. -
Planchard D, Kim HR, Suksombooncharoen T, Li R, Cortinovis D, Han JY, Samol J, Runglodvatana Y, Lee KY, Chang GC, Lee CH, Kowalski D, Saw SPL, Huang Y, Ruiter G, Ahn MJ, Yang TY, Yang CT, Sookprasert A, Nakajima EC, Alfon J, McEwen R, Chang YT, Yang JC.
Trastuzumab deruxtecan in patients with HER2 overexpression NSCLC: Results from part 1 of the open-label muticenter, phase 1b DESTINY-Lung-03 trial. 2025
J Thorac Oncol. -
Pundole X, Younan D, Critchlow CW, Puntis SR, Soohoo M, Anderson ES, Najdi R, Horinouchi H, Calvo V, Cobo M, Lopez-Castro R, Bernabe R, Cho J, Desai PA, Ahn MJ, Provencio M.
A multi-country study of the clinical course of extensive stage small cell lung cancer: a six-study analysis of real world treatment patterns and outcomes. 2025
Clin Epidemiol. -
Tan DS, Nadal E, Cheema P, Wu YL, Ahn MJ, Tanizaki J, Grainger E, Nizialek E, Forcina A, van der Gronde T, Yu HA.
TROPION-Lung15: a randomized phase III study of Osimertinib combined with datopotamab deruxtecan (Dato-DXd) OR Dato-DXd alone versus platinum-doublet chemotherapy in patients with EGFR mutated advanced non-small cell lung cancer and whose disease has progressed on prior osimretinib. 2025
Ther Adv Med Oncol. -
Jung HA, Lim J, Choi YL, Jeon YJ, Lee J, Cho JH, Choi YS, Park S, Sun JM, Ahn JS, Ahn MJ, Park WY, Kim HK, Lee SH.
The role of APOBEC in early stage EGFR mutant non-small cell lung cancer. 2026
Lung Cancer. -
Jung HA, Merkin R, Feng AL, Lee D, Lee K, Park S, Sun JM, Lee SH, Ahn JS, Ahn MJ, Wirth LJ, Park JC.
Artificial intelligence-powered real-time multimodal modle for predicting recurrence and survival in head and neck cancer: a multicenter, multinational study. 2026
ESMO Open. -
Chan ATC, Lee VHF, Hong RL, Ahn MJ, Chong WQ, Spreafico A, Kim SB, Ho GF, Caguioa PB, Ngamphaiboon N, Swaby RF, Wei B, Webber AL, Kang J, Gumuscu B, Yuan J, Siu LL.
Anaylsis of plasma Epstein-Barr virus DNA and clinical outcomes to pembrolizumab or chemotherapy in recurrent/metastatic nasopharyngeal cancer in KEYNOTE-122. 2026
Cancer Med. -
Tran B, Voskoboynik M, Kim SW, Lemech C, Carcereny E, Rha SY, Ahn MJ, Felip E, Lee KH, Castañón Álvarez E, Yang JC, Ascierto PA, Provencio Pulla M, Kondo S, Kuboki Y, Freeman D, Song X, Blando J, Eck S, Song FJ, Tang Z, Kuziora M, Gainer SD, Mitchell P, Asare J, Ayyoub A, Achour I, Subramaniam DS, I
Sfety, pharmacokinetics, pharmacodynamics and preliminary efficacy from a first-in-human study of volrustomig, a novel PD-1/CTLA-4 bispecific antibody. 2026
Clin Cancer Res. -
Ahn MJ, Tan DS, Windsor M, Ong BH, Ho JC, Kim HK, Lee VH, Hsu FM, Shih JY, Pham DNM, Pham CP, Chua S, Yeo SH, de Dios I.
Treatment patterns in early stage NSCLC in Asia: Findings from the ELEVATE study. 2025
JTO Clin Res Rep. -
Cha S, Shin SH, Shin SH, Lee HY, Kim YJ, Park D, Han KY, Oh YJ, Park WY, Ahn MJ, Kim H, Won HH, Park HY.
Integration of circulating tumor DNA data enhances lung cancer prediction in patients with COPD. 2026
Sci Rep. -
Piotrowska Z, Ahn MJ, Voon PJ, Pang YK, How SH, Kim SW, Cortinovis D, de Castro Carpeño J, Tiseo M, Rodríguez Abreu D, Ramalingam SS, Li J, Servidio L, Taylor R, Hartmaier R, Markovets AA, Tang KH, Cho BC.
ELIOS: a multicenter, molecular profiling study of patients with EGFR-mutant advanced non-small cell lung cancer treated with first-line Osimertinib. 2026
Cancer Discov. -
Lin SH, Kahangire DA, Nagar SP, Ahn MJ, Affi R, Agulnik J, Shih JY, Hochmair MJ, Tufman A, Debieuvre D, Chow J, Jimenez M, Davis KL, Sandelin M, Veluswamy RR.
EGFR mutation status, treatment patterns and outcomes in resectable early stage non-small cell lung cancer prior to adjuvant EGFR TKI approval: An international real-world study. 2026
Lung Cancer. -
Park S, Kang D, Lee J, Jung HA, Sun JM, Lee SH, Ahn JS, Lee H, Lim H, Pundole X, Cho J, Ahn MJ.
Treatment patterns and clinical outcomes in real-world patients with small-cell lung cancer in South Korea: A single center experience. 2026
Int J Cancer. -
Kim J, Han M, Kim J, Park S, Jung HA, Sun JM, Lee SH, Ahn JS, Shin SH, Lee K, Um SW, Ahn MJ.
Phase II efficacy and safety of pembrolizumab with platinum based chemotherapy in non-small cell lung cancer patients with untreated asymptomatic brain metastasis (PHOEBS). 2026
Cancer Res Treat. -
Tan AC, Liao BC, Li M, Lee D, Uehara Y, Thamlikitkul L, Zhang JT, Zheng M, Lee CK, Pavlakis N, John T, Soo RA, Skanderup A, Voon PJ, Ahn BC, Park S, Hayashi H, Goto Y, Horinouchi H, Yatabe Y, Reungwetwattana T, Chih-Hsin Yang J, Kim DW, Mok T, Tan DSW, Wu YL, Ahn MJ.
Consensus statement on ctDNA miminal residual disease (MRD) testing in early stage NSCLC- A Delphi study by the Asian Thoracic Oncology Research Group (ATORG). 2026
Clin Cancer Res. -
Bak M, Park H, Lee SH, Lee N, Ahn MJ, Ahn JS, Jung HA, Park S, Cho J, Kim J, Park SJ, Chang SA, Lee SC, Park SW, Kim EK
The Risk and Reversibility of Osimertinib-related Cardiotoxicity in a Real-World Population 2024
J Thorac Oncol -
Zhou Q, Yu Y, Xing L, Cheng Y, Wang Y, Pan Y, Fan Y, Shi J, Zhang G, Cui J, Zhou J, Song Y, Zhuang W, Ma Z, Hu Y, Li G, Dong X, Feng J, Lu S, Wu J, Li J, Zhang L, Wang D, Xu X, Yang TY, Yang N, Guo Y, Zhao J, Yao Y, Zhong D, Xia B, Yang CT, Zhu B, Sun P, Shim BY, Chen Y, Wang Z, Ahn MJ, Wang J, Wu Y
First-line zorifertinib for EGFR-mutant non-small cell lung cancer with central nervous system metastases: The phase 3 EVEREST trial 2024
Med -
Kang EJ, Yang Y, Lee S, Kim YJ, Lim SM, Ahn MJ, Choi YJ, Lee Y, Kim TM, Kim I, Ahn HK, Jeung HC, Lee SI, Oh SY, 배 WK, Ryu H, Park KH, Lee KH
A phase II study of tepotinib in patients with advanced solid cancers harboring MET exon 14 skipping mutations or amplification (KCSG AL19-17) 2024
ESMO Open -
Kim HI, Kim WG, Kim M, Ko NG, Jin M, Jung HA, Sun JM, Ahn JS, Ahn MJ, Choi YL, Jeon MJ, Kim TY, Kim WB, Kim SW, Lee DH, Jang SJ, Kim SW, Chung JH, Kim TH, Lee SH
Biomarker role of thyroid irAE and PD-L1 positivity in predicting PD-1 blockade efficacy in patients with non-small cell lung cancer 2024
Cancer Immunol Immunother -
Maggie Liu SY, Jin ZY, Deng JY, Zhong SM, Ahn MJ, Horinouchi H, Li Y, Wu YL
Drug development and evidence for lung cancer targeted therapy in Eastern Asia 2024
Lancet Reg Health West Pac -
Han JY, Ahn MJ, Lee KH, Lee YG, Kim DW, Min YJ, Kim SW, Cho EK, Kim JH, Lee GW, Lee SS, Lee NM, Jang HW, Han H, Park H, Lee J, Cho BC
Updated overall survival and ctDNA analysis in patients with EGFR T790M-positive advanced non-small cell lung cancer treated with lazertinib in the phase 1/2 LASER201 study 2024
BMC Med -
Kim J, Park YS, Kim JH, Hong YC, Kim YC, Oh IJ, Jee SH, Ahn MJ, Kim JW, Yim JJ, Won S
Predicting Lung Cancer in Korean Never-Smokers With Polygenic Risk Scores 2024
Genet Epidemiol -
Lu S, Ahn MJ, Reungwetwattana T, Özgüroğlu M, Kato T, Yang JC, Huang M, Fujiki F, Inoue T, Quang LV, Sriuranpong V, Vicente D, Fuentes C, Chaudhry AA, Poole L, Armenteros Monterroso E, Rukazenkov Y, van der Gronde T, Ramalingam SS
Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase III LAURA study 2024
Ann Oncol -
Jänne PA, Planchard D, Kobayashi K, Yang JC, Liu Y, Valdiviezo N, Kim TM, Jiang L, Kagamu H, Yanagitani N, Wang J, Biswas B, Poltoratskiy A, Neron Y, Rojas C, Koubkova L, Escriu C, Ezeife DA, Mann H, Armenteros-Monterroso E, Rukazenkov Y, Lee CK; FLAURA2 Investigators.
Survival of Osimertinib plus chemotherapy in EGFR-mutated advanced NSCLC. 2026
N Engl J Med. -
Ahn MJ, Tanaka K, Paz-Ares L, Cornelissen R, Girard N, Pons-Tostivint E, Vicente Baz D, Sugawara S, Cobo M, Pérol M, Mascaux C, Poddubskaya E, Kitazono S, Hayashi H, Hong MH, Felip E, Hall R, Juan-Vidal O, Brungs D, Lu S, Garassino M, Chargualaf M, Zhang Y, Howarth P, Uema D, Lisberg A, Sands J; TRO
Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study 2024
J Clin Oncol -
Weller M, Remon J, Rieken S, Vollmuth P, Ahn MJ, Minniti G, Le Rhun E, Westphal M, Brastianos PK, Soo RA, Kirkpatrick JP, Goldberg SB, Öhrling K, Hegi-Johnson F, Hendriks LEL
Central nervous system metastases in advanced non-small cell lung cancer: A review of the therapeutic landscape 2024
Cancer Treat Rev -
Sacher AG, Miller WH Jr, Patel MR, Paz-Ares L, Santoro A, Ahn MJ, Dziadziuszko R, Freres P, Luo J, Bowyer S, Desai J, Markman B, De Miguel M, Deva S, Falcon A, Alonso G, Guedes JD, Kim SH, Krebs MG, Laurie SA, Massarelli E, Medina L, Prenen H, Amatu A, Van Dongen M, Choi Y, Hou X, Qi T, Lin MT, Koli
Single-agent divarasib in patients with KRAS G12C positive non-small cell lung cancer: long term follow-up of a phase I study 2025
J Clin Oncol -
Lim CH, Um SW, Kim HK, Choi YS, Pyo HR, Ahn MJ, Choi JY
18F-Fluorodeoxyglucose Positron Emission Tomography-Based Risk Score Model for Prediction of Five-Year Survival Outcome after Curative Resection of Non-Small-Cell Lung Cancer 2024
Cancers (Basel) -
Kim BJ, Maeng CH, Keam B, Im YH, Ro J, Jung KH, Im SA, Kim TW, Lee JL, Heo DS, Kim SW, Park K, Ahn MJ, Cho BC, Kim HK, Kang YK, Cho JY, Yun HJ, Nam BH, Zang DY
The Survival and Financial Benefit of Investigator-Initiated Trials Conducted by Korean Cancer Study Group 2024
Cancer Res Treat -
Hong TH, Hwang S, Dasgupta A, Abbosh C, Hung T, Bredno J, Walker J, Shi X, Milenkova T, Horn L, Choi JY, Lee HY, Cho JH, Choi YS, Shim YM, Chai S, Rhodes K, Roychowdhury-Saha M, Hodgson D, Kim HK, Ahn MJ
Clinical Utility of Tumor-Naïve Presurgical Circulating Tumor DNA Detection in Early-Stage NSCLC 2024
J Thorac Oncol -
Bazhenova L, Hodgson JG, Camidge DR, Langer CJ, Huber RM, Kim DW, Reckamp KL, Ahn MJ, Tan DSW, Patel JD, Vincent S, Li C, Humphries MJ, Zhang P, Rivera VM, Gettinger S
Activity of brigatinib in patients with crizotinib-resistant ALK positive non-small cell lung cancer according to ALK fusion and mutation status 2025
Clin Lung Cancer -
Whi W, Lee H, Um SW, Kim HK, Pyo HR, Ahn MJ, Choi JY
Prognostic valued of 18F fluorodeoxyglucose PET/CT in the new staging system for non-small cell lung cancer 2025
Eur Radiol -
Kim J, Bang YH, Park S, Jung HA, Sun JM, Ahn JS, Ahn MJ, Jeon YJ, Lee J, Cho JH, Kim HK, Choi YS, Zo JI, Shim YM, Kang JH, Lee J, Choi YL, Han J, Hwang S, Lee HY, Lee SH
Adjuvant pembrolizumab therapy for completely resected stage I lung adenocarcinoima with micropapillary or solid histological subtypes: A single center single arm phase 2 trial 2025
EClinicalMedicine -
Ahn MJ, Lisberg A, Goto Y, Sands J, Hong MH, Paz-Ares L, Pons-Tostivint E, Pérol M, Felip E, Sugawara S, Hayashi H, Cho BC, Blumenschein G Jr, Shum E, Lee JS, Heist RS, Cornelissen R, Chang WC, Kowalski D, Zebger-Gong H, Chargualaf M, Gu W, Lan L, Howarth P, Joseph R, Okamoto I
A pooled analysis of datopotamab deruxtecan in patients with EGFR-mutated NSCLC 2025
J Thorac Oncol -
Riely GJ, Ahn MJ, Clarke JM, Dagogo-Jack I, Esper R, Felip E, Gelsomino F, Goldman JW, Hussein M, Johnson M, Marrone KA, Morgensztern D, Nadal E, Negrao MV, Offin M, Provencio M, Ramalingam SS, Roof L, Sanborn RE, Smit EF, Tsao A, Usari T, Alcasid A, Wilner K, Tonkovyd S, Zhang X, Johnson BE
Updated efficacy and safety from the phase 2 PHAROS study of encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic NSCLC- A brief report 2025
J Thorac Oncol -
de Marinis F, Kim TM, Bonanno L, Cheng S, Kim SW, Tiseo M, Chu Q, Proto C, Sacher A, Luo YH, Novello S, Hao D, Baik C, Bazhenova L, Lee JS, Cho BC, Cadranel J, Diep TB, Metro G, Narayanan P, Yoneshima Y, de Castro Carpeño J, Baldotto C, Nyhus C, Yang JC, Sequist LV, Levy B, Hartmaier R, Igwegbe I, P
Savolitinib plus Osimertinib in EGFR-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on Osimertinib: primary results from the phase II SAVANNAH study 2025
Ann Oncol -
Choi DH, Kim M, Kim YS, Park KU, Cho JH, Kim H, Lee KH, Ahn H, Kim IH, Lee KH, Lee GW, Yi SY, Ahn BC, Lee MY, Jung HA, Park S, Sun JM, Ahn JS, Lee SH, Ahn MJ
Clinical outcomes of maintenance durvalumab after definitive concurrent chemoradiotherapy in unresectable locally advanced stage III NSCLC according to EGFR and ALK status: Korean Cancer Study Group LU-22-18 2024
JTO Clin Res Rep -
Mountzios G, Sun L, Cho BC, Demirci U, Baka S, Gümüş M, Lugini A, Zhu B, Yu Y, Korantzis I, Han JY, Ciuleanu TE, Ahn MJ, Rocha P, Mazières J, Lau SCM, Schuler M, Blackhall F, Yoshida T, Owonikoko TK, Paz-Ares L, Jiang T, Hamidi A, Gauto D, Recondo G, Rudin CM; DeLLphi-304 Investigators
Tarlatamab in small-cell lung cancer after platinum-based chemotherapy 2025
N Engl J Med -
Park S, Ahn HK, Lee S, Min YJ, Kim J, Jung HA, Sun JM, Lee SH, Ahn JS, Ahn MJ, Lee JB, Lim SM, Kim HR, Cho BC, Hong MH
Lazertinib for patients with NSCLC harboring uncommon EGFR mutations: A phase II multicenter trial 2025
J Thorac Oncol -
Kim J, Kim MJ, Kim J, Park S, Jung HA, Lee SH, Ahn JS, Ahn MJ, Sun JM
Clinical relevance of staring alectinib at a reduced dose in patients with ALK positive non-small cell lung cancer 2025
Cancer Res Treat
숨 막히는 폐암 걱정? 숨통 트이는 폐암 극복! - 폐암이 궁금한 모든 분들을 위한 시민건강강좌 개최
2026-07-14
"암 연구, 환자 곁 질문에서 시작"
2026-06-26
폐암 환자가 꼭 알아야 할 개인맞춤 항암치료
2026-05-20
키트루다가 걸어온 10년, 폐암 치료의 패러다임이 바뀌었다
2026-05-18
전이성 넘어 '초기 암' 선점 경쟁…
2026-05-18
소세포폐암 신약, 고가 비급여로 장벽 높아
2026-05-11
한양대병원, '세계 폐암치료 권위자' 안명주 교수 영입…폐암센터 재편
2026-04-09
한양대병원, 원팀 체계·안명주 교수 영입 등 '폐암 치료 혁신'
2026-04-09
한양대병원, 원팀 체계로 폐암 치료 혁신
2026-04-08
한양대병원 안명주 교수 영입… 정밀의료 기반 원팀 체계로 폐암 치료 혁신
2026-04-08
8개 진료과 하나로…한양대병원, ‘다학제 원팀체계’로 폐암 정복
2026-04-08
PD-L1 음성 폐암, 여전히 '사각지대'…옵디보 급여, 해법 될까
2026-04-02
알룬브릭 기반 순차 전략, 생존 연장 기대
2026-03-18
한양대병원, 폐암·두경부암 세계적 명의 안명주 교수 영입
2026-03-13
폐암 치료 권위자 안명주 교수, 한양대병원서 진료 시작
2026-03-13
폐암·두경부암 세계적 권위자 안명주 교수, 진료 시작
2026-03-12
폐암·두경부암 세계적 귄위자 안명주 교수, 한양대병원 진료 시작
2026-03-12
"폐암분야 세계 권위자"…안명주 교수, 한양대병원 진료
2026-03-12
폐암 권위자 안명주 교수, 한양대병원 혈액종양내과 합류
2026-03-12
"삼성의 별, 한양의 태양으로"… 안명주의 '사심 없는' 승부수
2026-02-24
"절대 좌절하지 마세요" 전문가가 전하는 암 극복의 지혜
2026-07-16
폐암 검사, 왜 이렇게 많을까? '폐암 의심' 진단부터 치료까지
2026-07-16
'항암치료 너무 힘들지 않나요?' 삶의 질을 지키며 싸우는 현대 암 치료의 패러다임
2026-07-16
나에게 맞는 폐암 치료제, 어떻게 결정할까?
2026-07-16
내 몸의 면역세포를 깨운다? 면역항암제의 원리
2026-07-16
"돌연변이가 곧 열쇠입니다" 폐암 전문가가 말하는 표적치료제
2026-07-16
지난 20년간의 드라마틱한 변화.. 명의 안명주 교수가 말하는 폐암 치료의 역사
2026-07-16
클리닉정원초과